2005 - 2006 Corporate Structure

Minister for Health Queensland Government

QIMR QIMR Council Trust

Director

Chief Operating Officer Deputy Director

Assistant Directors Corporate Division

Development Infectious Cancer Population Therapeutic and Diseases and and Studies and Development Marketing Immunology Cell Biology Human and Clinical Department Division Division Genetics Research Division Division

Indigenous Health Research Program

2 Queensland Institute of Medical Research

Director Professor Michael Good

Deputy Director Professor Adèle Green

Our Vision

To be a world renowned medical research institution

Our Mission

Better health through medical research

Our Philosophy

QIMR supports scientists who perform world-class medical research aimed at improving the health and well-being of all people

Our Logo

The QIMR logo is comprised of superimposed benzene rings which symbolise one of the fundamental molecular arrangements of the chemicals which make up living things

For further copies of this report, phone 3362 0222, email [email protected] or download from www.qimr.edu.au Chairman’s Report

Since being established by QIMR has built on its reputation the Queensland Government in Queensland and Australia in 1945, QIMR has grown as a leading research services to become one of the largest provider and now provides medical research institutes in research services to the the southern hemisphere and developed and developing is an internationally recognised world. Its ability to attract centre of excellence for medical international grants makes research. QIMR a significant exporter of research services which benefits It has achieved this recognition QIMR and the flow-on effects by promoting excellence in benefit the community of the conduct and support of Queensland. Sir Bruce Watson AC its medical research projects. Chairman QIMR also portrays the In 2005-06 QIMR received essential features of innovation, $10.5 million for its exported risk taking and discovery. research services by attracting grant funding from the United The Queensland QIMR houses over 800 States, Europe and Asia. Institute of Medical scientists, students and support Research grants for research staff in four research divisions services are received from the Research (QIMR) which include 38 separate National Institutes of Health laboratories, an Indigenous (NIH), the US Department of is the State’s Health Program and a Defence, the Bill and Melinda Corporate Division. Gates Foundation and the premier health and Wellcome Foundation (UK). QIMR accommodates scientists medical research in world-class facilities with QIMR has now established itself expertise in molecular biology, as the biggest recipient of NIH institution and has population studies, gene funding within Australia with an discovery and translational annual value of $8.4 million. gained worldwide research. The international links thus recognition for its QIMR has established an created from its world- international reputation and class reputation results in research into the pursues key research areas international visitors travelling in cellular and molecular to study in Queensland who prevention and sciences, epidemiology and frequently stay for a holiday population health, cancer and as a result this benefits cures for cancer and the local purveyors of tourism biology, biotechnology, infectious diseases infectious diseases and vaccine products. QIMR and its medical development. research programs are good business for Queensland not In 2004-05, QIMR successfully just for the new therapies and used $5.5 million of grant discoveries that flow from its funding from the Queensland research but from the benefits Government to leverage $30 that flow from having a $50 million in funding for research million international business services from domestic grants and a significant exporter of and over $9 million from services to the developed and international grants. developing world.

3 Council Members

Sir Bruce Watson AC BE (Elec) as National President of the and Northern Territory of BCom (Chairman) Australian Institute of Company Medical Benefits Fund of Sir Bruce Watson was born Directors and in 1992 as Australia Limited and provided in Queensland in 1928. In President of the Australasian executive services as General 1956 he joined MIM Holdings Institute of Mining and Manager of The Brisbane Club. Limited and became General Metallurgy. In June 1985 he Paul has also been a company Manager of the Agnew Nickel was knighted in recognition of director for more than 20 years Mining Joint Venture in Western his most distinguished service and has served as Chairman/ Australia in 1975. In 1977, to Queensland industry and President of The Australian he returned to Brisbane as a in 2004 Sir Bruce was made Institute of Management and is Director and later as CEO and a Companion of the Order of now serving a second term as Chairman of MIM Holdings Australia. Chariman of The Royal Flying Limited. Mr Paul Wright AM FAIM F Doctor Service (Qld). He is Sir Bruce has been a Member Fin FAICD (Deputy Chairman) currently the Chairman of The of the Supervisory Board Paul has combined banking, CyberInstitute Pty Ltd, The of Metallgesellschaft AG, a health, hospitality and Queensland Institute of Medical Director of Boral Limited, consulting into a career which Research Trust and Phoenix ASARCO Inc, National Australia has encompassed over 25 years Eagle Company Pty Ltd. Other Bank Limited and Chairman in senior executive management current Board appointments of the Gas Corporation of with a breadth and depth in include PQ Lifestyles Pty Ltd Queensland Limited. From leadership roles. He has been and Queensland Fruit and 1992 to 1995 Sir Bruce served General Manager Queensland Vegetable Growers Limited.

QIMR Council Members From left: Back row: Mr Paul Wright AM (Deputy Chair), Sir Bruce Watson AC (Chairman), Professor Bryan Campbell AM From left: Front row: Professor Judith Clements, Professor Lyn Griffiths, Dr Paula Marlton

4 Professor Bryan Campbell AM Queensland University of Dr Marlton has a very broad MD BS FRACP FRACMA Technology and also an NHMRC experience in clinical research Professor Campbell was Principal Research Fellow. including roles as principal formerly Chief Health investigator of national trials Professor Lyn Griffiths BSc Officer Queensland and and an ongoing involvement (Hons) PhD Head of The University of in translational research in Queensland Medical School. Professor Griffiths is Director haematologic malignancies. He has been a Councillor of of the Genomics Research She was the founding Chair of the Royal Australasian College Centre at Griffith University the Australasian Leukaemia and of Physicians, the Royal Gold Coast, Head of the GU Lymphoma Group Laboratory Australian College of Medical School of Medical Science, and Science Committee and has Administrators and a member of a past Director of the Australian established and continues to the National Health and Medical Society of Medical Research direct the PWC Leukaemia Research Council. He was (ASMR) from 1999 to 2001. and Lymphoma Tissue Deputy Chair of the Australian She has authored 117 peer- Bank. Her other professional Health Ethics Committee and a reviewed publications to date in activities include serving on member of the NHMRC Embryo molecular genetics international the Board of the Leukaemia Research Licensing Committee journals, and is Chair of the Foundation, Drug Advisory until June 2006. Scientific Program Committee for the next International Boards, Government Advisory Prof Judith Clements BAppSc Congress of Human Genetics. Committees as well as a wide MAppSc PhD She was awarded the Centenary range of teaching and clinical service activities. Professor Clements has over Medal for Distinguished Service to Education and Medical 20 years experience as a Professor Peter Brooks MD Research. basic researcher in biomedical FRACP FRCP Edin FAFRM research, primarily in the Dr Paula Marlton MB BS FAFPHM MD Lund (Hon general field of molecular (Hons) FRACP FRACPA (From Causa) endocrinology. Her current February 2006) Professor Brooks was research seeks understanding of Foundation Professor of the molecular basis of hormone Paula Marlton is the Head of Rheumatology at the University dependent and urogenital Leukaemia and Lymphoma of Sydney prior to becoming cancers such as prostate, Services at the Princess Professor of Medicine at St breast, ovarian and endometrial Alexandra Hospital where she Vincent’s Hospital, Sydney carcinoma. Professor Clements has worked as the Deputy in 1992. He was appointed is currently Program Leader Director of Haematology Executive Dean of Health of the Hormone-Dependent since 1994. Her previous Sciences at the University Cancer Program within appointments included 3 years of Queensland in 1998, has the Institute of Health and at the MD Anderson Cancer extensive research experience Biomedical Innovation at the Centre in Houston Texas.

Professor Peter Brooks Mr Chris Coyne Mr Paul Fennelly Dr Jeannette Young Professor Alan Lopez

5 in basic inflammation and Registrar and subsequently Alexandra Hospital in Brisbane treatment of rheumatic diseases the Director of the Emergency for six years where she was and has been a member of the Department at Ipswich hospital responsible for the provision Fellowships Committee and for over ten years. He joined of Medical services across the Partnerships Committee of the the Queensland Ambulance Hospital and a member of the NHMRC. Services as Medical Director in Executive team. She came to 1990 and subsequently became the position following four Mr Christopher Coyne LLB Commissioner a position he held years as the Director of Medical Christopher Coyne is a solicitor for almost ten years. He has Services at the Rockhampton of the Supreme Court of held numerous positions within Base Hospital. Prior to that Queensland, specialising in the College for Emergency she spent nine years at insurance law, health law, Medicine and the Journal Westmead Hospital in Sydney corporate government and risk Emergency Medicine and as working, initially, in the area of management. He was admitted part of his current position Emergency Medicine followed as a solicitor in 1979 and was a represents the Department of by responsibility for medico- partner in the national law firm Health on numerous Councils legal issues and management of Clayton Utz from 1984 to 2002. and boards including the junior medical staff. He is an Adjunct Professor at NHMRC and ACHS. The University of Queensland One of her major areas of School of Law. He is Chair Professor Alan Lopez BSc interest has been in medical of the Mater Health Services (Hons) MS PhD workforce management and Human Research Committee Professor Lopez is Professor development. Until recently she and a member of the Australian of Medical Statistics and was the Chair of the Australian Health Ethics Committee and Population Health at the Medical Workforce Advisory the NHMRC Gene Related University of Queensland and a Council and an AHMAC Therapy Research Advisory consultant to the World Health nominee on the Australian Panel. Chris is Chairman of Organisation. He has published Medical Council. Another the Queensland Law Society’s widely on mortality analysis area of interest has been in captive insurer, Lexon and is a and causes of death, and is organ and tissue donation and director of the Heart Research co-author of the seminal Global transplantation. Until recently Institute (Queensland). He Burden of Disease Study (1996) she was the Eastern States is a sitting member of the which has greatly influenced representative on Australians Queensland Commercial and debates about priority setting Donate, the national peak Consumer Tribunal. and resource allocation in body for organ and tissue health. He has been awarded donation. In her current role Mr Paul Fennelly BA LLB major research grants in she is on the Queensland Mr Fennelly has wide population health in recognition Medical Board, the Radiation experience in financial of his research competence Advisory Council, co-chairs the management, business and and is a member of Australia’s Queensland Emergency Medical public administration. NHMRC Program Grants System Advisory Committee, Committee. chairs the Queensland Blood Dr Gerry FitzGerald MD Advisory Committee and is BS BHA FACEM FRACMA Dr Jeannette Young MB BS Queensland’s representative FACHSE (To August 2005) FRACMA MBA AFACHSE on the National Health and Dr FitzGerald was the Chief (From September 2006) Medical Research Council and Health Officer for Queensland Dr Young has been the Chief the Australian Health Protection until August 2005. He Health Officer for Queensland Committee. She has recently graduated from the University since August 2005. In her been appointed to the newly of Queensland in 1976. previous position she was established AHMAC Clinical, After two years at the Mater the Executive Director of Technical and Ethical Principal Hospital he worked as Medical Medical Services at the Princess Committee.

6 From the Director

The Institute’s research percent protection rate and capability has expanded also reduces faecal egg outputs this year, with three new by 60-70%, thus minimising laboratories becoming parasite load in the host and established. Professor Jeff in the environment, and hence Gorman heads the Protein – future transmission of the Discovery Centre which parasite. identifies proteins involved in, or affected by, physiological and The Immunovirology Laboratory disease processes and the ways developed an experimental in which these proteins function cancer treatment based on and interact. intratumoural delivery of GM- CSF by the Kunjin replikon Professor Michael Good Professor Emma Whitelaw vector and also discovered the Director relocated her team and use of PEP005 for induction laboratory from the University of anti-cancer T cells and for The Institute has of Sydney to research the role co-delivery with anti-cancer of epigentics in determinating vaccines to regress metastasis. undergone an phenotype in mammals. Dr Corinne Lendon spearheads Research in the Molecular extraordinary year of Immunology Laboratory a new direction into mental growth. The Protein health research at QIMR, demonstrated that ultra low and now leads the Molecular doses of whole inactivated Discovery Centre was Psychiatry Laboratory which malaria parasites can induce investigates factors that modify protection from malaria. opened by Deputy susceptibility to Alzheimer’s Members of the Molecular disease and related neurological Parasitology Laboratory Premier The Hon and psychiatric disorders. undertook a successful vaccination trial against Anna Bligh in May QIMR continues to gain echinococcosis in dog international recognition for definitive hosts in China using 2006, and is now its research. This year, Institute recombinant antigens expressed scientists were named on 375 by the mature adult worm. fully operational. scientific publications, with Two further new a good proportion of these The Mosquito Control Laboratory developed the Ross in high impact journals. This laboratories have represents a 25% increase on River virus Early Detection QIMR’s publications for the and Surveillance System, become established, previous year – an admirable a web-based Geographic result. Research highlights this Information System to assist a record number of year include: local government to respond to outbreaks of Ross River virus scientific publications Scientists from the Helminth with control and prevention Biology Laboratory have programs. have been published developed a prototype vaccine against schistosomes, Researchers studying Dendritic and, as always, or blood flukes, parasitic Cells (DCs) have also found worms that infect 200 million vital clues suggesting how prestigious Awards breast cancer cells evade people worldwide and are have been bestowed responsible for hundreds of recognition by the immune thousands of deaths annually. system to progress into upon QIMR scientists The vaccine gives a 50-60 tumours. Patients with breast

7 cancer were compared with doses of 200mg or more of 2006, Professor Kay Ellem was healthy women to demonstrate nonsteroidal anti-inflammatory made an Officer of the Order a higher percentage of dying drugs such as aspirin may offer of Australia for his lifetime of DCs, indicating that the body is protection against squamous achievement in cancer research. unable to effectively suppress cell carcinoma and actinic Professor Nick Martin received tumour progression because the keratoses. the Dobzhansky Award for DCs die before they can trigger lifetime contributions to Scientists studying the an immune response. behaviour genetics and three genetics of endometriosis in QIMR scientists received the Molecular and Genetic Further highlights from the research special fellowships Epidemiology Laboratories have Cancer and Cell Biology – Dr James McCarthy from identified significant linkage to Division include identification Smart State Queensland, Dr Chromosome 10 and research of low risk genes for breast David Whiteman from the US- from the Signal Transduction cancer, development of assays Australia Fulbright Commission Laboratory has uncovered to assess the functions of and Dr Nathan Subramaniam a new protein, Cep55, that variants of BRCA1 and BRCA2, from the Gastroenterological may play a critical role in the identification of several new Society of Australia. Dr Chris development of cancer. tumour suppressor genes for Schmidt won the ASMR cutaneous melanoma, and Important research from the Queensland Premier’s Senior identification of a novel damage Indigenous Health Program Postdoctoral Award, and control protein and its link with revealed the likelihood of Dr Alberto Pinzon-Charry cancer. death is significantly higher the Queensland Premier’s A link has been established for Indigenous than non- Postgraduate Student Award. Indigenous cancer patients even between the childhood Dr Stephen L Hoffman, Chief after taking into account cancer cancer Ewing’s sarcoma and Executive and Scientific Officer stage at diagnosis, place of children born with hernias in from Sanaria Inc in Bethesda, residence, cancer treatment and the Cancer and Population USA gave the Derrick- the presence of other medical Studies Laboratory. In particular, Mackerras Memorial Lecture conditions. umbilical hernias and congenital in November 2005, which hernias were associated with Awards and Achievements coincided with the Institute’s an increased risk of Ewing’s 60th Anniversary celebrations. sarcoma. Each year, QIMR scientists are recipients of highly prestigous Dr Hoffman is one of the Epidemiologists found that honours and Awards. In March world’s leading malaria vaccine aspirin may assist in reducing 2006 Professor Brian Kay was researchers. the risk of developing skin was elected to the Australian QIMR’s high achievement cancer, showing that regular Academy of Science. In June Awards were given at the

Professor Brian Kay AM FAA Professor Kay Ellem AOProfessor Nick Martin FASSA Dr Stephen Hoffman

8 same ceremony, and this year continues to provide significant This year also saw the Mr Mark Weaver received funding for the Leukaemia retirement of two long-standing the Bancroft Medal, Mr Paul Foundation Laboratory headed QIMR scientists, Professor Peter Wright and Professor John by Professor Andrew Boyd from Parsons in April 2006 and Dr Kerr were made QIMR Fellows The University of Queensland. Greg Lawrence in June 2006. and Professor Brian Kay was Professor Parsons began his awarded the Ralph Doherty The Development Department career at the Institute in 1972, Prize for Excellence in Medical continues to elicit funding and as Head of the Melanoma Research. from a range of other sources. Genomics Laboratory has made Besides receiving on-going significant contributions to the Grants and Funding Success donations and bequests from treatment of skin cancer. Dr NHMRC grants for the year a large proportion of the Lawrence also started work at included 19 new project and community, QIMR is engaged QIMR during the 1970s and one new program grant, in a three year corporate is renowned for developing bringing total NHMRC funding sponsorship contract with a vaccine to protect against to almost $20 million in total. Suncorp who this year held the Pigbel - a disease which was For the same period, Institute Bridge to Brisbane Fun Run, a common cause of child scientists received three with the Institute as beneficiary. mortality in Papua New Guinea. Research Fellowships, four A special Christmas campaign QIMR is grateful to these two Career Development Awards, during this year featured Rupert valuable scientists for their one Training Fellowship and McCall’s Green and Gold contributions to the Institute four Postgraduate Scholarships. Malaria poem. over the years, and wishes both a happy and fulfilling Six NIH grants were received The Development Department retirement. from the United States, totalling also performs the important more than $US8 million, two function of disseminating As always, the Institute remains for parasitology research, three QIMR research to the wider inordinately grateful to our for genetic epidemiology and community, and does so visionary sponsors, Altantic one for breast cancer research. through external speaking Philanthropies and Mr Clive The Queensland Cancer Fund engagements and tours of Berghofer, and the many other provided seven grants for Institute facilities and This year, donors, both small and large research covering a range of more than 9,000 people learned who continue to contribute different cancer-related areas, about QIMR through these to the very worthy cause of and the Australian Research avenues. The Department also medical research in Queensland. Council funded four different mails over 20,000 copies of Life projects. Lab magazine each quarter. Michael Good Director The Leukaemia Foundation

Mr Mark Weaver Dr Chris Schmidt Dr Alberto Pinzon-Charry

9 Research

Research is conducted in 40 separate laboratories under four separate Divisions, each with a major focus. Important research collaborations take place within and between the laboratories, as well as with external entitities.

The Infectious Diseases and Immunology Division focuses on improved understanding of viruses, bacteria and parasites, and how they interact with the immune system with the aim of developing new tools to diagnose, treat and prevent infection.

The Cancer and Cell Biology Division integrates research on the cellular, molecular and genetic basis of a wide range of cancers, including melanoma, leukaemia, breast, ovarian, endometrial and colorectal cancer, to develop screening tools for early detection and devise strategies for the treatment and prevention of disease.

The Population and Human Genetics Division utilises a wide range of contemporary epidemiological, genetic and molecular techniques to investigate a spectrum of diseases relevant to the Australian population, aimed at understanding the mechanisms of disease and identifying potential therapeutic targets. The Division includes the Indigenous Health Research Program which carries out collaborative research projects for the improvement of the health and well-being of Aboriginal and Torres Strait Islander people.

The Therapeutic Development and Clinical Research Division develops and tests immunotherapeutics manufactured within the Q-Gen laboratory at QIMR. Currently, it oversees clinical research and trials using cell-based therapeutics that target post-transplant lymphoma, malignant melanoma, prostate cancer and cytomegalovirus infection.

10 Infectious Diseases and Immunology Division

The focus of the Infectious Diseases and Immunology Division is improved understanding of viruses, bacteria and parasites and how they interact with the immune system, as well as the role of the immune system in the control of cancer. Through such increases in knowledge, it will then be possible to develop:

• New tools to diagnose infection • New treatments for infection Division Chair Associate • New vaccines to prevent infection Professor James McCarthy • New methods to control cancer

Work undertaken by the Division ranges from detailed studies of how the immune system operates, including how it responds to challenge by a variety of infectious agents and tumours, to study of the biology of a number of pathogens ranging from viruses to worms – to the development and testing of vaccines.

Highlights of the year include: The laboratory of Dr Geoff Hill has defined the role of NK T cells in graft-versus-leukaemia effects after transplantation. Dr Scott Burrow’s laboratory has highlighted the importance of epitopes of over 10 amino acids in length as CTL epitopes from viral and tumour antigens for vaccine development. Work in the laboratory of Dr Christian Engwerda has led to the development of several cysteine proteases from pineapple stems as novel anti-cancer and immunosuppressive drugs. Work in the laboratory of Dr Andreas Suhrbier that has resulted in the development and patenting of a new cancer treatment based on intratumoural delivery of GM-CSF by the Kunjin replikon vector system. Demonstration in the laboratory of Professor Michael Good that ultra low doses of whole inactivated malaria parasites can induce protection from malaria.

11 Bacterial Pathogenesis HIGHLIGHTS Associate Professor Kadaba Sriprakash Demonstrated that genetic transfers between GAS and GGS occur more frequently This laboratory undertakes research into groups A (GAS), B (GBS) in areas of endemic infection and G (GGS) streptococcus, a group of bacteria that cause a wide range of potentially fatal diseases in humans Produced the first complete nucleotide sequence for a GAS, GGS and GBS cause a genetic transfer that occurs GGS bacteriophage wide range of human disease, between GAS and GGS. Demonstrated that different some of which are fatal. This transfer occurs more GAS strains have different Genetic, epidemiological and frequently in regions where capacities to form biofilms pathogenic studies of these the GAS and GGS infection is organisms were undertaken endemic. Such transfers have during the year. SIC and the capacity to significantly the closely related DRS are alter the pathogenicity of Symposium on Streptococci proteins secreted from GAS individual strains and may and Streptococcal Diseases that have the capacity to bind account for the increase in which brought together multiple host factors, including pathogenicity of GGS. As part internationally renowned components of the immune of this study, this laboratory was experts to discuss the latest system. the first to provide a complete developments in streptococcal nucleotide sequence for a GGS research. The success of this The Bacterial Pathogenesis bacteriophage. Laboratory continued to dissect conference continued to build the interaction of SIC/DRS with Projects investigating the devel- the international reputation of various host proteins, including opment of a two-component QIMR. the complement proteins C6 vaccine, and the role of biofilms and C7, as well as the beta- in the pathogenesis of GAS defensins. In collaboration are yielding good results. A with Dr Natkuman Ketheesan, fruitful collaboration with the the contribution of these WuChopperen Health Service proteins to post-streptococcal investigating skin sores in glomerulonephritis is also being Indigenous communities in investigated. Northern Queensland was also established and new projects GGS, a close genetic relative in the field of streptococcal of GAS traditionally recognised diagnostics have begun. as a commensal organism, has emerged as significant Along with the Molecular human pathogens in it’s own Immunology Laboratory, this right. Research continues to laboratory co-hosted the emphasise the continuing XVIth Lancefield International Group A streptococcus biofilm

Bacterial Pathogenesis Laboratory Staff: From left: Back row: Sri Sriprakash (Head), Mark Davies, Josephine Shera, David McMillan. Front row: Meru Sheel, Therese Vu, Michael Binks

12 Bone Marrow Transplantation HIGHLIGHTS Dr Geoff Hill Analysed new cytokines to mobilise stem cells for allogeneic transplantation in The Bone Marrow Transplantation Laboratory works towards the clinic understanding the pathophysiology of the complications of bone marrow transplantation, particularly Graft-versus-Host disease Defined the role of NKT cells in graft-versus-leukaemia The Bone Marrow This high productivity reflects in effects after transplantation Transplantation team studies large part the stable and highly Defined the effect of the pathophysiology of Bone experienced members within recipient B cells in Graft- Marrow Transplantation the group. versus-Host disease after complications, particularly The laboratory continues to transplantation Graft-versus-Host disease and be funded by a program grant the mechanisms by which from the NH&MRC and both leukaemia is eradicated during Dr Geoffrey Hill and Dr Kelli the procedure. MacDonald received NH&MRC The ultimate aim is to develop fellowships in the past year. The more effective preventative laboratory continued to excel and treatment therapeutics to at the Transplantation Society translate to the clinical setting. of Australia and NZ annual meeting with Helen Bofinger In the last year the laboratory winning the Presidents prize has continued to make for best original work this year. progress in the understanding This is the third year in a row of GVHD and Graft-versus- that the laboratory has won this Leukaemia (GVL) effects after award. transplantation. This work has lead to multiple publications in the last year, culminating in a Journal of Clinical Investigation publication outlining the effects of cytokines on donor NKT Cells and subsequent GVL effects.

Bone Marrow Transplantation Laboratory Staff: From left: Back row: Geoff Hill (Head), Tatjana Banovic, Naomi Odorico, Kate Markey, Alistair Don. Front row: Rachel Kuns, Renae Skoczylas, Angela Burman, Helen Bofinger, Kelli MacDonald

13 Cellular Immunology HIGHLIGHTS Associate Professor Scott Burrows Provided evidence and proposed the theory that international efforts to The main focus of the Cellular Immunology Laboratory is the identify CTL epitopes from cytotoxic T lymphocyte (CTL) and factors controlling its primary viral and tumour antigens function in recognising and killing virus-infected cells for vaccine development have underestimated the Mammalian cells have Since long viral peptides have importance of epitopes developed complex mechanisms not been studied in detail of over 10 amino acids in to alert the body’s immune previously, a major aim of length defense mechanisms of virus the lab during the year was infection. After a virus enters to determine how TCRs bind Discovered that HLA- a cell, short peptide epitopes to these extraordinary target restricted T cell recognition of viral origin are processed by structures. sometimes involved very the infected cell and presented few contacts between the on the cell surface to flag a Although TCR-peptide-HLA TCR and HLA molecules population of white blood binding usually involves Identified new CTL cells called CTLs to kill the extensive contact between the epitopes from human virus-infected cells. Critical TCR and the HLA molecule, cytomegalovirus and molecules in this process are it was demonstrated that the showed the dramatic the cell surface molecules that TCR sometimes make very little influence of minor HLA bind the viral peptides and contact with the HLA molecule differences on their present them for recognition if the peptide being presented immunogenicity by CTLs. These are called class is unusually long, bulging I histocompatibility antigens beyond the surface of the Demonstrated that highly (HLAs) in humans. HLA molecule. This work has mobile HLA-bound peptides provided surprising new insights can be targeted by T cells Other critical molecules in this into how the body’s immune process are T cell receptors system recognises virus-infected Crystal structure of a T cell receptor (TCRs) that are expressed on cells – information that could be molecule (blue and red) bound to the surface of CTLs and are exploited in vaccine and drug a class I human leukocyte antigen responsible for specifically design for a range of human (green) presenting a 13-mer viral recognising viral peptides infections. peptide (yellow). Note the minimal contact between the T cell receptor bound to HLA molecules. In and the human leukocyte antigen. collaboration with researchers in Melbourne, this laboratory recently showed that unusually long viral peptides are presented on the cell surface with an irregular bulging conformation.

Cellular Immunology Laboratory Staff From left: Jacqueline Burrows, Melissa Bell, John Miles, Scott Burrows (Head), Rebekah Brennan

14 Clinical Tropical Medicine HIGHLIGHTS Associate Professor James McCarthy - Joint appointment Demonstrated that a with the Royal Brisbane and Women’s Hospital number of HIV protease inhibitors in clinical use possess antimalarial activity This laboratory researches how malaria and other parasites cause in a murine model disease, and to develop new and improved tests both to diagnose these parasite infections as well as to detect drug resistance Identified a genetic mutation in the scabies mite that likely causes drug resistance Identification in the laboratory In collaboration with Dr Qin that a number of Antiretroviral Cheng of the Australian Army Identified the antimalarial Protease Inhibitors (ARPI) Malaria Institute why so-called properties of PI-88, a already in clinical use for rapid diagnostic tests for malaria heparin-like drug currently treatment of HIV infection sometimes do not work is being undergoing clinical trial as show activity against the explored. This study has led to an anti-cancer agent malaria parasite in vitro has led the identification of significant to recent in vivo studies both polymorphism in the HRP-II Improved understanding of in a rodent model of malaria, protein, the target of rapid why rapid diagnostic tests and using sera from patients diagnostic tests, which helps for malaria may sometimes taking these antiretrovirals explain why these tests are be inaccurate for treatment of HIV. This sometimes unreliable. Epitope work has indicated that mapping to identify which these observations may have parts of the HRPII protein are prescription policy. significant clinical relevance in recognised in these diagnostic regions where malaria and HIV tests has recently been occur together, regions where completed. The laboratory is researching antiretrovirals are being more the interactions between widely used. Following a series of severe malaria-infected erythrocytes A joint project with Dr infections due to a virulent and host receptors, developing Shelley Walton and other drug-resistant strain of new models for studying Investigators from the Menzies Staphylococcus aureus in cytoadhesion in malaria, and School of Health Research a southeast Queensland identifying novel anti-disease on drug resistance in human Indigenous community, a therapeutics to target this scabies has resulted in the collaborative project was identification of a mutation in undertaken with external a drug-resistant strain of the researchers to investigate the scabies mite. This will assist in epidemiology of this important combating this growing threat pathogen. The work resulted to community-based control in the finding of high rates programs currently underway in of carriage of this pathogen, Indigenous communities across particularly on skin sores, and northern Australia. has led to change in antibiotic

Clinical Tropical Medicine Laboratory Staff From left: Back row: James McCarthy (Head), Ranbir Sarai, Lewis Melville, Kathy Andrews. Front Row: Thanh Tran, Cielo Pasay, Liza Fernandez, Mei-Fong Ho, Nelson Lee

15 EBV Biology HIGHLIGHTS Professor Denis Moss Investigated the potential of a vaccine formulation consisting of all of the This laboratory is committed to understanding the biology and possible epitopes within immunology of two clinically important human pathogens, Epstein- the proteins present in Barr virus (EBV) and vaccinia virus. EBV laboratory findings are used nasopharyngeal carcinoma in human clinical trials (referred to as SAVINE vaccine) Evaluating a formulation Mapping immune responses to designed to control vaccinia virus Defined the immune response in healthy nasopharyngeal carcinoma The laboratory has been individuals and naso- A vaccine formulation has involved in collaborative pharyngeal carcinoma been designed that consists projects to map and characterise patients using tis SAVINE of a series of minimal EBV- the CD8+ T cell responses vaccine encoded within specific CTL epitopes encoded to vaccinia virus VACV in adenovirus in a replication-deficient form humans and mice. This work is of adenovirus. Preliminary important for our understanding Initiated clinical trial results indicate that this of VACV as a vaccine vector on adoptive transfer of formulation can protect and also for our understanding EBV-specific T cells as immunocompromised mice in of immunity to poxviruses such a treatment option for which human nasopharyngeal as monkeypox and smallpox, nasopharyngeal carcinoma carcinoma cells are growing. the emergence or re-emergence of which is a current cause for Gained an understanding A peptide-based protocol for concern. The main achievement of the protective capacity activating an immune response was mapping of the CD8+ T of a polyepitope vaccine in human cells suitable for cell epitopes of VACV in mice formulation delivered adoptive transfer and using this new information in adenovirus to protect Conditions required to stimulate to show that the route of against growth of human components of the EBV-specific vaccination can affect the parts nasopharyngeal carcinoma cytotoxic T cell response that of a virus or vaccine to which will be used in adoptive transfer the immune system directs its into patients with end-stage response. have been defined. This formulation has become the Nasopharyngeal carcinoma basis of activating cytotoxic is caused by Epstein-Barr T cells from nasopharyngeal virus in association with a carcinoma patients and range of co-factors. While the subsequently adoptively virus is always present in this transferring these cells back into malignancy, the individual co-factor varies depending on these patients. geographical location

EBV Biology Laboratory Staff From left: Back row: David Tscharke, Denis Moss (Head), Natasha Stevens, Simone Cross. Front row: Viviana Lutzky, Leanne Morrison, Michelle Martinez, Pauline Crooks

16 EBV Molecular Biology HIGHLIGHTS Dr Tom Sculley Identified an additional five functional nuclear localisation signals in the The major area of research in the EBV Molecular Biology Laboratory EBNA3A protein is how the Epstein-Barr virus (EBV) is able to transform normal cells into cancer cells

The Epstein-Barr nuclear in the presence of EBNA3A. antigen 3A (EBNA3A) is one of Under these circumstances only six viral proteins essential it is possible that interaction for Epstein-Barr virus (EBV)- with cytoplasmic proteins may induced transformation of mask one or more of the NLS primary human B-cells in vitro. in the EBNA3A protein and Viral proteins, such as EBNA3A, multiple NLS would then be are able to interact with cellular required to ensure that EBNA3A proteins, manipulating various is efficiently targeted to the biochemical and signalling nucleus. pathways to initiate and Sub-cellular localisation of an EGFP- maintain the transformed state Human Sin1 (SAPK-interacting protein 1) was originally EBNA3A fusion construct following of infected cells. EBNA3A has mutation of nuclear localisation signals been reported to have one identified as a partial cDNA nuclear localisation signal that inhibited signalling and is targeted to the nucleus by constitutively activated during transformation, where it RAS2G19V in yeast. Searches of associates with components of online databases demonstrated the nuclear matrix. the presence of both a Raf- like Ras-binding domain (RBD) Using EGFP-tagged deletion and a pleckstrin homology mutants of EBNA3A, in (PH) domain in the human combination with site directed Sin1 protein and most of its mutagenesis, the laboratory orthologues. The RBD was has identified an additional five shown to be able to bind to functional nuclear localisation Ras while recombinant Sin1 signals in the EBNA3A protein. interacted with GST-Ras in It is not understood why a a GTP-dependent fashion single protein contains multiple in vitro, suggesting that the NLS, however, EBNA3A has RBD is functional. Sin1 co- multiple binding partners with immunoprecipitated and co- many of these partner proteins localised with Ras in vivo and being present in the cytoplasm inhibited activation of the PI3K and recruited to the nucleus signalling pathways by Ras. Sin 1 colocalises with activated RAS

EBV Molecular Biology Laboratory Staff From left: Back row: Tom Sculley (Head), Ihor Misko. Front row: Marion Buck, Anita Burgess

17 Helminth Biology HIGHLIGHTS Dr Alex Loukas Development of a recombinant vaccine for schistosomiasis which The Helminth Biology Laboratory explores the molecular basis of married data from animal host-parasite interactions, with a particular emphasis on the proteins models and human secreted by parasitic helminths and their efficacy as vaccines immunoepidemiology to identify a highly efficacious Efficacious recombinant Two new projects, both funded target antigen vaccines have been identified by NIH have gotten underway. for the two major blood- One explores the roles of liver Development of a feeding helminth parasites of fluke secretions in causing recombinant vaccine for humans – schistosomes and cancer of the bile ducts in hookworm infection that hookworms. Southeast Asia. In the other, interrupts blood-feeding in immunomodulatory proteins the parasite’s gut Funding has been secured secreted by hookworm parasites First use of laser from the Gates Foundation are being studied to determine microdissection microscopy to develop the hookworm how these might be developed to identify tissue-specific vaccine and it is undergoing as therapeutics for autoimmune mRNAs from multicellular process development for clinical disorders. trials. Funds are currently parasites with a focus on being sought to develop the vaccine antigen discovery schistosomiasis vaccine and take it into clinical trials. This laboratory continues to discover hookworm vaccine antigens from the gut of the parasite using Laser Detection of the integral membrane protein, Sm-TSP-2 on Microdissection Microscopy the outer tegument of Schistosoma mansoni parasites. and was the first to apply this technique to a parasitic helminth. Hookworm genes that are associated with the transition from a free-living to a parasitic state are also being identified.

Helminth Biology Laboratory Staff From left: Back row: Alex Loukas (Head), Darren Pickering, Michael Smout. Front row: Mark Pearson, Soraya Gaze, Tegan Don, Danielle Smyth

18 HIV Molecular Virology HIGHLIGHTS Dr David Harrich Revealed that an HIV protein called Tat directly stimulates reverse The principal focus in this laboratory is detailed analysis of a step in transcriptase activity HIV replication called reverse transcription. During this process, HIV is able to convert its genetic material composed of RNA into a form Recent experiments compatible with human DNA suggested TAR forms a unique ribonucleoprotein Over the last several years, into DNA so that the genomic complex, and additional our research and that of others material is compatible with the critical RNA elements world wide has revealed cell. Studies by other labs and regulating reverse complex interactions between confirmed by this laboratory transcription have been viral proteins, unexpected roles show that virions contain very identified for virus RNA, and requirements little, if any, DNA. Given that Showed for the first time for cell factors to support virus the virus machinery is designed that protein kinase C growth. to convert RNA to DNA using regulated an early event reverse transcriptase, it has HIV is, in most respects, a during HIV-1 but not been puzzling why reverse through cellular receptors typical retrovirus. The virus transcription is repressed in particle is 100 nm in diameter virions. Research supported the and surrounded by a cell- hypothesis that reverse derived lipid membrane. Within A clear understanding of transcription must initiate the virus are the structural how HIV regulates reverse in a core, but requires proteins including reverse transcription, and how cellular unknown factors to transcriptase, and the genomic factors impact this process complete the process RNA. Reverse transcriptase is a have potential to identify novel viral enzyme and its role is to antiviral strategies. Demonstrated that protein convert the viral genomic RNA methylation is critical for HIV-1 infectivity

HIV Molecular Virology Laboratory Staff From left: Back row: Nicole Willemsen, David Harrich (Head), Luke Meredith. Front row: David Warrilow, Ann Apolloni, Haran Sivakumaran

19 Immunology and Infection HIGHLIGHTS Dr Christian Engwerda Successfully cloned and expressed several distinct cysteine proteases from This laboratory studies the host immune response during malaria pineapple stems in yeast and leishmaniasis, and aims to distinguish host immune responses to parasites that lead to control of disease and those that contribute to A Biotechnology company tissue pathology listed on the Australian stock exchange in May 2006 to Work on experimental models cell mediated immunity at a develop novel anti-cancer of cerebral malaria caused critical stage in infection. and immunosuppressive by Plasmodium berghei and drugs derived from visceral leishmaniasis caused by Work on visceral leishmaniasis pineapple stems, based Leishmania donovani aims to revealed important, but distinct, on intellectual property identify the key molecules and roles for lymphotoxin alpha developed in this laboratory and tumour necrosis factor cells that cause tissue pathology Discovered a novel role associated with infection. in the host immune response during experimental visceral for regulatory T cells Many of the molecules and in the pathogenesis of cells identified to date also play leishmaniasis. These studies were extended to find that experimental cerebral important roles in protection malaria against infection, indicating VCAM-1, a cell adhesion they are either produced molecule that is expressed in in excessive amounts or in the liver following lymphotoxin inappropriate tissue locations. alpha and tumour necrosis factor production during Research on experimental visceral leishmaniasis, plays Dendritic cells produce IL-12 (red) in cerebral malaria has identified a an important role in the the spleen after Leishmania donovani key role for regulatory T cells in recruitment of cells into the infection. These dendritic cells capture parasite antigens in the marginal zone the pathogenesis of this disease. liver during infection, as well as (bright green region) prior to migrating These cells play an important the generation of cell mediated into lymphocyte compartments to role in balancing immune immune responses in the liver activate parasite-specific T cells. This responses to prevent pathology. very early after infection. is a critical event in the generation of effective immunity during visceral However, they can sometimes leishmaniasis exert too much influence and The laboratory has also been prevent effective control of involved in a research program parasite growth. Results to to identify cysteine proteases date indicate that regulatory from pineapple stems with T cells promote an early burst immunomodulatory properties of pro-inflammatory cytokine and has now successfully production that contributes cloned several distinct to the induction of cerebral cysteine proteases into yeast pathology, but also restrict the and produced recombinant development of anti-parasitic enzymes.

Immunology and Infection Laboratory Staff From left: Back row: Louise Randall, Christian Engwerda (Head), Amanda Stanley, Ashraful Haque. Front row: Yonghong Zhou, Fiona Amante, Karli McSweeney, Saskia de Walick

20 Immunoregulation HIGHLIGHTS Professor Anne Kelso Showed in a second tumour model that IL-4 secretion by tumours increases the This laboratory researches how CD8+ T lymphocytes acquire the frequency of secondary ability to kill infected cells and tumours so that these processes can tumours that are poorly be controlled through improved vaccine design or immunotherapy immunogenic Found that the IL-4-induced low When CD8+ cytolytic T Effects of the cytokine CD8 T cells persist long lymphocytes (CTL) interact with interleukin-4 (IL-4) on tumour term in vivo and do not pathogen-infected or tumour growth control and the tumour- re-acquire cytolytic function low cells, they release regulatory induced CD8 T cell response when CD8 expression is and cytolytic proteins, such were explored in two mouse restored ectopically as cytokines, perforin and models. When the tumour cells Established a new project enzymes known as granzymes. secreted IL-4, their clearance to assess the functional This laboratory is investigating was impaired and they induced flexibility of memory CD8+ ways to control activation and markedly higher expression of T cells inhibition of CTL so that they granzyme A and IL-4 mRNAs express functions needed for in the responding T cells than host protection. did control tumour cells. These CD8 expression and cytolytic in vivo data are consistent with function. When transferred A new project is investigating the finding in vitro that IL-4 the functional flexibility of into congenic mice, in vitro enhanced granzyme A mRNA low memory CD8+ T cells generated generated OT-I CD8 T cells levels and functional enzymic persisted for up to 3 months. in various priming conditions activity. using transgenic OT-I CD8+ T However, some cells re-acquired cells and OT-II CD4+ T cells that Following an earlier CD8 expression after injection recognise defined sequences demonstration that IL-4 induced of OVA-expressing tumour cells. in the protein ovalbumin CD8α down-regulation and Current work is investigating the conditions that maintain (OVA). Conditions have been impaired CTL function in low established for induction of activated primary CD8+ T the CD8 phenotype long effector and memory CD8+ cells, the laboratory examined term and their implications for T cells following adoptive whether re-expression of CD8α tumour control in vivo. transfer of the transgenic cDNA restores CTL function. cells into congenic mice and Recombinant expression of the immunisation with OVA. Lyt2.1 CD8low allele in Lyt2.2 Experiments are in progress CD8low T cells did not increase to assess the functions and CTL activity or perforin and expression of effector genes in granzyme mRNA levels, arguing the transferred cells. against a causal link between

Immunoregulation Laboratory Staff From left: Back row: Norbert Kienzle, Simon Apte, Anne Kelso (Head), Penny Groves. Front row: Regina Gary, Kathy Buttigieg, Adriana Baz, Stuart Olver

21 Immunovirology HIGHLIGHTS Associate Professor Andreas Suhrbier Developed and patented a new cancer treatment based on intratumoural delivery The Immunovirology Laboratory is exploiting new knowledge about of GM-CSF by the Kunjin interactions between viruses and the immune system to develop replikon vector system novel anti-viral and anti-cancer strategies Discovered and patented Patents have been the main vaccines to eradicate distant the use of PEP005 for focus of work in the past year. secondary tumours. PEP005 induction of anti-cancer A novel intratumoural gene may thus emerge as a unique T cells and for co-delivery therapy system was developed chemotherapeutic drug that with anti-cancer vaccines to that uses the Kunjin replicon can be readily used together regress metastases system (developed by Dr with immune-based anti-cancer Discovered that HIV-1 Khromykh, UQ) to deliver the therapies to reduce the rate induces SerpinB2 and that immunostimulatory cytokine of cancer relapse. This work SerpinB2 enhances HIV-1 GM-CSF into a growing tumour. was assigned to Peplin Ltd and transcription and replication The self replicating Kunjin RNA patented. vector combines with GM-CSF to stimulate the immune system CBio Ltd has developed a novel infection of macrophages and to generate anti-cancer T cells anti-inflammatory compound, that SerpinB2 then enhances that then destroy the tumour Cpn10 which has shown some HIV-1 transcription and cells. The system was patented extraordinary success in recent replication raises the question of and assigned to Replikun Ltd clinical trials, particularly for whether polymorphisms in the who was awarded an AU$1 rheumatoid arthritis. Under a SerpinB2 gene play a role in the million Commercial Ready contract R&D agreement the progression to AIDS. grant to develop this system for Immunovirology Laboratory human trials. was involved in establishing SerpinB2 is nearly always expressed how this biological agent during inflammation and infection and The novel topical chemo- mediates its activity. Cpn10 has affects gene expression via its effect therapeutic agent PEP005 being anti-inflammatory properties on Rb developed by Peplin Ltd has and inhibits the production of shown considerable promise inflammatory mediators by Toll- in recent clinical trials of non- like receptor agonists. This work melanoma skin cancer. Much was assigned to C-Bio Ltd and of the preclinical work for this patented. compound was performed at QIMR and ongoing research Work on SerpinB2, a serine has illustrated that PEP005 can protease inhibitor induced be used to stimulate anti-cancer during most inflammatory T cells. Treatment of primary processes continued. The tumours with PEP005 has been discovery that SerpinB2 is shown to synergise with cancer potently induced by HIV-1

Immunovirology Laboratory Staff From left: Back row: Wayne Schroder, Lee Major, Grant Darnell, Eleanor Lambley, Andreas Suhrbier (Head). Front row: Itaru Anraku, Paweena Rattanasena, Joy Gardner, Diem Hoang-Le

22 Malaria and Scabies HIGHLIGHTS Professor David Kemp Showed that scabies mite inactivated proteases (SMIPPS) can be expressed Work in this laboratory concentrates on the control of diseases in proper conformation, bind caused by the scabies mite Sarcoptes Scabiei and on malaria, which peptides and competitively is transmitted by mosquitos of the Plasmodium genus inhibit proteases

Scabies, caused by the mite transmitted by the bite of an Demonstrated that Sarcoptes scabiei which burrows infected Anopheles mosquito. Plasmodium falciparum through the skin, is a major parasites show enhanced problem in northern Australia. Gametocytogenesis is a invasion into Rh null It facilitates infection by group poorly understood stage of erythrocytes A streptococci, which cause the parasite lifecycle that is rheumatic fever and heart essential for transmission of disease. the parasite from the human to the mosquito host. This stage Research this year has focused is being explored as a potential on the unexpected family focus for intervention strategies. of scabies mite inactivated protease paralogues (SMIPPs) Aminopeptidases are being Below: Transfected Plasmodium falciparum expressing the Maurer’s previously discovered in this evaluated as potential drug targets. There are four cleft protein, REX2, fused to green laboratory, and thought to fluorescent protein. Maurer’s clefts play some important role in aminopeptidases involved in are parasite-derived structures evading host defences. It has haemoglobin degradation and within the host cell cytoplasm that been demonstrated that they each enzyme represents a are thought to function as a sorting potential target at which novel compartment between the parasite are secreted into the gut and and the erythrocyte membrane. excreted in faeces; hence they antimalarial drugs that disrupt A series of confocal images was could interact with the host parasite protein turnover and generated from a single infected red both internally and externally. synthesis could be developed. blood cell and reconstructed to give a 3-dimensional representation with Colleagues at Monash A number of Ring Exported volumetric rendering. The images correspond to the 00 and 900 different University have demonstrated Proteins (REX) have been localised to a unique trafficking rotation frames. Images collected by by X-ray crystallography that P. L. Hawthorne, Queensland Institute these molecules, produced in organelle in the host red blood of Medical Research and N. Klonis, La Pichia pastoris, are in proper cell which is used to transport Trobe University. conformation and so their virulence genes involved in functions can now be examined. severe disease to surface of the RBC. GFP fusions and Malaria is caused by infection photo-bleaching studies have with parasitic protozoa of the been used to investigate the genus Plasmodium, and is properties of these proteins.

Malaria and Scabies Laboratory Staff From left: Back row: Cassandra Lane, Katja Fischer, Dave Kemp (Laboratory Head), Katharine Trenholme. Front row: Karen Anderson, Mei-Fong Ho, Simone Beckham, Simone Smith

23 Malaria Biology HIGHLIGHTS Dr Don Gardiner Development of a technique in which transgenic parasites overexpress a target enzyme To combat multi-drug resistant (MDR) malaria, transgenic in order to validate its approaches are used in this laboratory to investigate novel genes as potential as a rational drug possible targets for intervention therapy target

Antiretroviral Protease Inhibitors Additional studies currently the right arm of chromosome (ARPIs) as antimalarials being performed include those 9 is being investigated. This laboratory has shown aimed at identifying the malarial Genes located in this region that antiretroviral drugs of the target of these drugs. are known to be involved protease inhibitor class can in cytoadherence, protein Evaluation of aminopeptidases inhibit the growth of malaria trafficking and agglutination, as potential drug targets parasites in vitro. Recent data all of which are associated with from the laboratory now In conjunction with collaborator, virulence in P. falciparum.Genes confirms that this in vitro Professor John Dalton, other involved in gametocytogenesis activity has in vivo relevance. potential targets for new are also located in this region. Not only has the group shown antimalarial drugs are also Understanding the molecular that these agents can kill being investigated. There are and cellular processes involved malaria parasite in a rodent 4 aminopeptidases involved in in these critical phases of the model, but has now shown that haemoglobin degradation and parasite life cycle, may indicate sera taken from HIV patients they each represent a target novel targets for intervention. treated with the antiretroviral at which novel anti-malaria agents can also inhibit parasite drugs could be directed. The growth. Antimalarial and HIV laboratory has developed a drug interactions are now technique in which transgenic being investigated in an effort parasites overexpress a target to improve the treatment enzyme in order to validate of co-infected malaria and its potential as a rational HIV individuals, reduce drug target and will use this Plasmodium falciparum expressing aspartyl aminopeptidase, fused to treatment costs and prevent methodology to assess other candidate targets. green fluorescent protein. A – Bright the development of drug Field. B – GFP. resistance. Preliminary studies Characterisation of a are very exciting, demonstrating transmission and virulence locus that in addition to their own on Chromosome 9 antimalarial activity, these In collaboration with the protease inhibitors “boost” Malaria and Scabies Laboratory, the antimalarial effects of the role of a 55kb region on other commonly used drugs.

Malaria Biology Laboratory Staff From left: Back row: Elin Ljunggren, Don Gardiner (Head), Chris Peatey. Front row: Franka Teuscher, Sonja Zacherl, Tina Skinner-Adams

24 Malaria Drug Resistance HIGHLIGHTS Demonstrated that a and Chemotherapy physical linkage with drug Dr Qin Cheng - Australian Army Malaria Institute resistant gene resulted in the conservation of otherwise highly diverse var genes in This laboratory studies the mechanisms and processes leading to the parasites from the Western development of drug resistance in malaria parasites, and also the Pacific region factors influencing the survival and spread of resistant parasites Established that clinical relapses of vivax malaria Antigenic variation in genes result from their physical are caused by the release Plasmodium falciparum linkage with drug resistant of individual hypnozoites resulting from varying the genes and drug selections. and are generally clonal surface protein PfEMP1 helps infections parasites avoid the host immune We expressed fusion proteins response. Transcription from of several var genes to examine In vitro cultivation genes encoding PfEMP1 has the characteristics of antibodies of patient-derived P. been quantified using real- in volunteers and patients falciparum parasites for time RT-PCR and conventional who were infected with P. less than 2 weeks causes a RT-PCR, to find that in vitro falciparum. The results suggest significant reduction in the cultivation significantly that a parasitemia above ~20 transcription of the multi- decreases transcription. Not parasites/μl is required to gene var family, but not all all genes are equally affected trigger an immune response to genes within the family are which complicates investigation PfEMP1, and once triggered, affected equally of malaria pathology and the response is rapidly boosted transcription of the virulence following re-exposure. Mapped target epitopes of genes since some in vitro Antibodies generally last longer 3 HRP2 MABs and found cultivation is usually required than 100 days and show both significant variability in the to expand parasite material cross-reactivity, and specificity. frequency of these epitopes obtained from patients. The specific antibodies in parasite isolates agglutinate parasites and Var genes encoding PfEMP1 are the cross-reactive antibodies there may be several clones highly diverse with little overlap disrupted the rosettes. infecting the liver, as shown by between P. falciparum isolates. the later release of a different Five var genes shared at a high Vivax malaria differs from falciparum malaria in its ability clone. These findings suggest frequency have been identified remarkable regulation of among P. falciparum isolates in to cause clinical relapses, initiated by the release of relapse intervals in vivax malaria the West Pacific region, mapped and highlight the importance to chromosomes 4 and 7, hypnozoites from the liver. Studies suggest that clonal of reducing the number of approximately 100kb to drug infective mosquito bites in resistance determinants (pfdhfr hypnozoites are released at pre-determined periods minimising the number of and pfcrt), demonstrating that relapses. the conservation of these var causing a relapse, even though Malaria Drug Resistance and Chemotherapy Laboratory Staff From left: Back row: Michelle Gatton, Jenny Peters, Karryn Gresty. Front row: Marina Tchavtchitch, Qin Cheng (Head), Darren Krause

25 Molecular Genetics HIGHLIGHTS Associate Professor Peter Upcroft Discovered that the antiretrovial protease inhibitors Kaletra is effective This laboratory works on the two most common protozoan parasites against both Trichomonas of medical importance, the sexually transmitted Trichomonas vaginalis and also the gut vaginalis and the intestinal parasite Giardia duodenalis protozoan parasite Giardia duodenalis The anaerobic protozoan identified, the spread of drug- parasite Trichomonas vaginalis resistant strains of the parasite Demonstrated that a specific is the most prevalent sexually in a community can now be component of Kaletra was transmitted infection. It is followed. The identification responsible for a blockage associated with preterm of such drug-resistant strains in the final stages of cell delivery, low birthweight is also being targeted by in division of G. duodenalis and predisposes women to situ DNA hybridisation of Demonstrated that one HIV/AIDS. The focus in this metaphase arrested parasite readily synthesized novel laboratory is on following chromosomes. This technique drug is effective against virulent and drug resistant will identify markers for drug metronidazole-resistant T. infections in a community, and resistance and allow physical vaginalis and G. duodenalis on developing new drugs and mapping of the large T. vaginalis treatment for infections caused genome partitioned across 6 Found that the mechanism by this organism. chromosomes. of clinical metronidazole Researchers from the Molecular Five new drugs have been resistance in T. vaginalis is Genetics Laboratory have used identified, of the same class of likely to be via a transport the genotyping method that compounds as metronidazole, mechanism the treatment of choice for T. they developed in collaboration Found that the similarly vaginalis infections, which are with Professor Patricia Johnson sized 6 chromosomes of T. effective against metronidazole- at UCLA to show that T. vaginalis can be identified resistant parasites. One in vaginalis parasites from each using one probe which has particular, which is readily infection can be specifically a specific but very different synthesized in large quantities, identified and that within a number of sites on each is being focused upon and remote community such as chromosome the Highlands of Papua New preclinical trials of this drug are Guinea, the parasite genotypes being planned. are more similar than in the The laboratory has found the worldwide community. antiretroviral protease inhibitor In combination with earlier Kaletra is effective against T. studies on metronidazole vaginalis parasites in vitro and resistance in the same are planning to study the T. community where 4 of 20 vaginalis prevalence in patients isolates displaying unexpectedly from HIV endemic areas who high levels of resistance were are prescribed these drugs.

Molecular Genetics Laboratory Staff From left: Janelle Wright, Rebecca Dunne, Jacqui Upcroft, Peter Upcroft (Head)

26 Molecular Immunology HIGHLIGHTS Professor Michael Good Demonstrated that ultra low doses of whole inactivated malaria parasites can induce The Molecular Immunology Laboratory studies the immune response protection from malaria to pathogens with the goal of understanding pathogenesis and developing vaccines Demonstrated that malaria infection can cause Malaria research is involved with support from QIMR apoptosis of memory B cells in developing a novel malaria scientists, produced five 10L and plasma cells vaccine and understanding why scale processes for development Demonstrated that lipidated current vaccine candidates do and consistency purposes, the peptides can induce mucosal not work. In the last year, data product recovery improved immunity to group A has been published showing through the series of runs with streptococci that in mice the malaria the last run producing good parasites induce the death of product yield. QIMR provided memory B cells and long-lived analytical support to CSIRO plasma cells that mediate long by developing appropriate memory B-cells are crucial for term protection. assays to monitor the quality long-term protection following and quantity of protein present immunisation with their lead Most vaccines, including throughout the process. The GAS vaccine candidate. This malaria vaccines, are required QIMR team submitted their highlights the importance of a to generate these cells to report to MVI for review at the recent observation that J8- protect the individual, years end of June 2006. antisera is protective in passive after vaccination. If death of transfer experiments and that these cells occurs in humans, It is with deep sadness that these antibodies are the likely as suggested by circumstantial the Laboratory notes that Dr effector molecules in protection evidence, then this could Michael Hocart passed away in against GAS. In preparation for explain in part why current January 2006. a phase I human clinical trial malaria vaccines have not been with J8-Diptheria Toxoid/alum, effective. The laboratory has Streptococcal research has focused on four key aspects: Q-Gen has been assisting also focused on development in the GMP manufacture of Defining the mechanism of of a vaccine using an ultra low the vaccine candidate and immunity induced by the dose of whole killed parasites development of associated leading group A streptococcus that protect primarily via T cells, assays. work which will proceed into (GAS) vaccine candidate J8 or clinical trial in the near future. its derivatives, The laboratory is also interested Investigating the immune in developing novel mucosal With the continued support memory responses following adjuvants such as lipopeptides of the PATH Malaria Vaccine immunisation with J8 or its which can stimulate a local Initiative (MVI) and in derivatives, immune response at the primary collaboration with the Evaluating novel mucosal point of GAS infection and have Molecular Science Division demonstrated that the induction of CSIRO Clayton, work has delivery strategies for peptide based vaccines, and of a local immune response continued on the production by GAS lipopeptides not only Finalisation of the J8-Diptheria and purification of the protects against GAS but also Toxoid formulation to be used recombinant malarial vaccine reduces GAS colonisation of the in phase I human clinical trials. candidate antigen RAP2. In throat. July 2005, Dr Michael Hocart Recent research has demon- resigned from the project and strated that immunisation with Ms Katia Potter was appointed J8-Diptheria Toxoid can induce Project Leader. Subsequently memory B-cells that are present a decision was made to for a minimum of 19 weeks relocate the RAP2 project post-primary immunisation. team to Q-Gen, QIMR’s GMP Researchers are convinced that manufacturing facility. CSIRO,

27 Molecular Parasitology HIGHLIGHTS Professor Don McManus Validated a microarray comprising the majority of the schistosome This laboratory researches the biology and epidemiology of parasitic transcriptome worms of humans and on developing new interventions and diagnostic procedures that will lead to their elimination Identified unique family clustering of human Schistosomiasis and stages of the schistosome echinococcosis cases in a echinococcosis are two major lifecycle, strain variation and the Chinese community diseases caused by parasitic effect of drugs and vaccines on Demonstrated a genetic worms. Work on schistosomiasis schistosome worms. component linked to human is focused predominantly in infection with Schistosoma China and is aimed at: Work on echinococcosis includes major field and japonicum in China – providing new insights into epidemiological studies the prophylactic effects of the in China, and the further Characterised a surface- drug artemether against acute development of a highly associated pathway for iron S. japonicum infection and to sensitive and specific blood absorption in schistosomes determine the effectiveness test (based on a recombinant Undertook successful vacc- of combined artemether and antigen, EpC1) for diagnosis of praziquantel treatment as an ine trials undertaken against patients infected with hydatid canine echinococcosis adjunct to control, disease and its application for – increasing knowledge detection of the disease in Defined a contributory role of the environmental and sheep and marsupials. for hepatic stellate cells genetic factors involved in in the dynamics of egg- predisposition to infection, and Successful vaccination trials induced fibrosis in schisto- analysing the molecular and have been underataken in somiasis cellular mechanisms leading to China against echinococcosis formation of fibrotic hepatic in dog definitive hosts using Demonstrated the effective- lesions, recombinant antigens expressed ness of artemether in preventing acute human – determining the importance by the mature adult worm. This schistosomiasis infection of buffalo reservoirs in work is important because it provides proof of principle that the persistence of human Completed a drug-based vaccination of the dog host schistosomiasis transmission, intervention study to against E. granulosus is feasible demonstrate the importance – pursuing genomics and using recombinantly-derived of buffaloes in human post-genomics research on proteins. existing and newly discovered Schistosoma japonicum S. japonicum molecules that infection are candidate vaccine and Microarray analysis of the adult worm and schistosomulum of Schistosoma diagnostic targets, and japonicum – developing a validated mathematical model for improved and sustainable schistosomiasis morbidity control. Along with a commercial partner Agilent Technologies, a microarray has been constructed that contains the majority of the schistosome transcriptome which, along with proteomics analysis, is being used to investigate differential gene expression during different

28 Molecular Immunology Staff From left: Back row: John Hartas, Michael Batzloff, Graham Magor, Lieke Berger, Kirsten Hanks, Michael Good (Head) Alberto Pinzon-Charry. Front row: Manisha Pandey, Meru Sheel, Michelle Wykes, Virginia McPhun, Yawalak Panpisuthchai, Xueqin Liu, Suhua Jiang

Molecular Parasitology Laboratory Staff From left: Back row: Don McManus (Head), Luke Moertel, Wenbao Zhang, Malcolm Jones, Geoffrey Gobert, Amber Glanfield, Tracey Laing. Front row: Yurong Yang, Wei Hu, Mary Duke, Yeusheng Li, Magda Ellis, Giovanna Raso, Melissa Burke

Mosquito Control Laboratory Staff From left: Back row: Jason Jeffery, Brian Kay, Tanya Russell, Katie Lee, Tessa Knox. Front row: Anna Guerney, Hau Tran, Le Nguyen, Kay Marshall, Peter Ryan (Head)

29 Mosquito Control HIGHLIGHTS Dr Peter Ryan Established broad inter- sectoral collaboration to devise, trial and refine new Research in the Mosquito Control Laboratory focuses on the biology approaches to dengue and control of mosquito-borne viruses such as dengue, Ross River control in three provinces in virus and Barmah Forest virus southern Vietnam

The World Health Organization This will incorporate health Incorporated health impact recognises that water resource impact assessments to monitor assessments to monitor development and management the impact of water supply the impact of water supply contributes to the proliferation infrastructure on dengue infrastructure on dengue of dengue and other water transmission risk, and if transmission risk related vector borne diseases by necessary, develop interventions Developed a web-based, increasing mosquito breeding at different stages of water GIS to provide timely data sites in infrastructure such as infrastructure development to on Ross River virus disease water storage jars, water tanks mitigate water-related dengue incidence throughout and wells. The contribution of risk. This project will maximise Queensland new water infrastructure to the benefits of water supply dengue risk was demonstrated programs by ensuring the water Determined the suitability of in Khanh Hoa Province in they provide is safe from water cuticular hydrocarbon (CH) central Vietnam, where 92% of related vector borne diseases. and gene expression (GE) dengue mosquito production analyses for age grading The laboratory continues was occurring in 2000-litre a range of Australian collaborative research with UNICEF jars. This laboratory’s mosquito vector species. community based control the Mosquito and Arbovirus Research Committee – an programs, incorporating The Ross River virus Early Mesocyclops as a biological independent organisation made up of representatives Detection and Surveillance control agent against Aedes (RREDS) System is described aegypti, mitigated this risk by from local governments from Queensland, New South Wales in more detail in the ACITHN eliminating dengue mosquitoes report on page 61. from these and other water and Victoria, and Queensland storage containers. Health and industry. To assist local governments and The Mosquito Control facilitate responsive mosquito Below: Mrs Nguyen Thi Yen (National Laboratory is now involved in a control and disease prevention Institute of Hygiene and Epidemiology, new five-year AusAID funded interventions, a web-based, Hanoi) and Mrs Luu Le Loan (Pasteur project which aims to reduce geographic information system Institute, Ho Chi Minh City) inspect water storage tanks for dengue dengue risk in rural areas in has been developed to provide mosquito larvae, Long An Province, southern Vietnam that are data on Ross River virus disease southern Vietnam. Photograph receiving new water supply incidence in Queensland. courtesy of Prof Vu Sinh Nam. infrastructure as part of the Cuu Long Delta Rural Water Supply and Sanitation Project. This project, in collaboration with the Centre for Water Supply and Sanitation (CERWASS) and the Administration of Preventive Medicine in Vietnam, and the Australian Foundation for the Peoples of Asia and the Pacific Ltd, will establish broad inter- sectoral collaboration to devise, trial and refine new approaches to dengue control.

30 Protein Discovery Centre HIGHLIGHTS Professor Jeff Gorman Commissioned a MALDI- TOF/TOF tandem mass spectrometer The Protein Discovery Centre aims to discover the identities of and benchmarked its proteins involved in or affected by physiological and disease performance by analysis processes and the ways in which these proteins function and interact of post-translational modifications of murine A variety of milestones have The staging of the assessment dioxin receptor been achieved towards the and acquisition process has establishment of the QIMR enabled the most up to date Determined a site of Protein Discovery Centre (PDC). equipment to be purchased. asparagines hydroxylation As a consequence the Centre The package includes the first of the Notch protein by an has a range of equipment ESI-Linear Ion Trap-Fourier asparaginyl hydroxylase that and commissioned relevant Transform-Tandem Mass regulates the activity of this staff employed in core roles Spectrometer (a.k.a. Orbitrap). transcription factor’s role in to deliver outcomes to QIMR stem cell differentiation investigators, both through In addition, the Centre has Commissioned a MALDI- services and collaborative work. acquired one of only two ESI-ETD-3D Ion Trap-Tandem TOF mass spectrometer Visits to the USA and Germany Mass Spectrometers in Australia for open access by were undertaken during 2005 capable of the revolutionary QIMR investigators to to evaluate latest equipment, new fragmentation process of accommodate requirements particularly mass spectrometry, Electron Transfer Dissociation to identify novel proteins for proteomics operations. (ETD). ETD is particularly This was timed so that the suitable for the process of most mature emerging identification of phosphorylation technologies could be selected sites in proteins which serve and delivered in a timeframe as critical switches in various to coincide with occupation of biological processes. the newly constructed QIMR laboratory space for the Protein Delivery of capability has Discovery Centre. These visits already commenced with those also provided opportunities pieces of equipment that have to evaluate ancillary been fully commissioned. The equipment. Specifications were fully commissioned equipment subsequently written for a has been benchmarked range of equipment and tender against exacting performance responses evaluated and orders expectations. written for selected instruments.

Protein Discovery Centre Staff From left: Back row: Brett Hamilton, Keyur Dave, Jeffrey Gorman (Head), Marcus Hastie. Front row: Una Cuffe, Madeleine Headlam, Jason Mulvenna, Tristan Wallis

31 Tumour Immunology HIGHLIGHTS Associate Professor Rajiv Khanna Small panel of viral epitopes that activate protective killer T cells for use in This laboratory seeks a deeper understanding of the mechanisms by HCMV vaccine selected for which an immune response to tumors may be generated, augmented immunology testing in a and applied to the inhibition of tumor growth mouse model

Although both irradiation and Congenital human International patent multi-agent chemotherapy cytomegalovirus (HCMV) describing these epitopes are efficient therapies for infection remains one of the filed Hodkin’s Disease (HD), the major health problems and it Discussions initiated with non-specific nature of these is estimated that more than 1 biotechnology companies treatments often results in million infants are born every for licensing the epitopes for severe side effects. Moreover, year with HCMV infection. diagnostic application a significant proportion of It is estimated that each year HD patients relapse following US$1billion dollars are spent by chemo- and radio-therapy, who the US government alone, for fail to respond to conventional the management of congenital extensive population-based therapeutic strategies. Recently, HCMV-related complications. analysis of these epitopes has there has been an increasing According to a report published been conducted with a smaller emphasis to develop novel by the Institute of Medicine panel selected to be tested for therapeutic strategies which (IOM, USA), vaccination immunogenecity studies in a are specifically designed to provides the most practical mouse model. prime patient’s own immune modality of achieving a long- system to recognise and destroy term protection from congenital A final international patent cancer cells with minimal or HCMV infection. According to describing these epitopes, no associated toxicities. One a market analysis published by along with population-based such approach involves killer IOM, an HCMV vaccine can analysis, has been filed and it T cells which can be specially potentially have a worldwide is anticipated that the epitopes trained in vitro to recognise market of US$500 million per identified in this project will cancer cells and adoptive annum. form an important basis for transfer of these cells often the future design of an HCMV results in therapeutic benefit. The primary aim of this project vaccine for human use. Over This laboratory intends to is to develop such a vaccine. A the last months, preliminary develop a killer T cell epitope- large number of viral epitopes discussions have been initiated based therapeutic vaccine that activate protective killer with two biotechnology which specifically recognise T cells were identified. These companies (one Australian and viral antigens in cancer cells epitopes provide an important one US-based) for licensing the from HD, ultimately to use this platform for the development HCMV epitopes for diagnostic vaccine as a therapeutic tool for of a vaccine formulation. application. the treatment of relapsed HD. Over the last 12 months, an

Tumour Immunology Laboratory Staff From left: Back row: Katherine Wynn, Corey Smith, Rajiv Khanna (Head). Front Row: Tom Yoshizaki, Jie Zhong, Natalie Rosenzweig, Ujjwal Dua

32 Cancer and Cell Biology Division

The Cancer and Cell Biology Division consists of 13 laboratories located in both the Bancroft Centre and the Clive Berghofer Cancer Research Centre. Research carried out in the Division covers a variety of topics to integrate investigations of the cellular, molecular and genetic basis of a wide range of cancers, including melanoma, leukaemia, breast, ovarian, endometrial and colorectal cancer. Research themes include the normal mechanisms that control cell growth and stable inheritance of genetic information, identification of cancer Division Chair susceptibility genes, development of mouse models to study Dr Kum Kum Khanna in vitro functions of cancer genes, developing screening tools for early detection and devising normal strategies for the treatment and prevention of cancer.

The Division collaborates in an important program with QIMR’s Population Studies and Human Genetics Division aimed at understanding environmental and lifestyle factors that contribute to cancer susceptibility. In addition, there are research interactions with the University of Queensland and various hospitals that have helped translation of research findings into patient care.

Highlights of the year include: Identification of low risk genes for breast cancer Development of assays to assess functions of variants of BRCA1 and BRCA2 Identification of several new tumor suppressor genes for cutaneous melanoma Identification of a novel damage control protein and its link with cancer Encouraging data from treatment of a patient with recurrent glioblastoma using Dendritic cell based immunotherapy in combination with chemotherapy Demonstration of the use of antibodies and antagonists of Eph and Epherin proteins as cancer therapeutics Demonstration of protective effect of a novel nitroxide antioxidant on tumor latency in ATM mutant mice Appointment of Dr Corinne Lendon as Head of the Molecular Psychiatry Laboratory at QIMR

33 Cancer Genetics HIGHLIGHTS Dr Georgia Chenevix-Trench Established three international consortia to study the genetics of breast This laboratory investigates why some people get cancer, and how and ovarian cancer these cancers develop from a normal cell, particularly breast and ovarian cancer which are often found together in the same families Confirmed that a promoter and share many similar characteristics variant of the progesterone receptor gene protects Most of the research in the XRCC3 genes are associated against the risk of Cancer Genetics laboratory with breast cancer risk. In endometrioid and clear cell is focused around two contrast, in a similarly powered ovarian cancer major Australian resources, study, compelling evidence Found two convincing ‘low- the Kathleen Cuningham has been found that two other risk’ genes for breast cancer Foundation for Research polymorphisms do affect into Familial Breast Cancer breast cancer risk. Through Further established that the (kConFab) and the Australian OCAC, and using ~4500 ATM 7271T>G mutation Ovarian Cancer Study. In the cases and 7000 controls, is a rare breast cancer last year the laboratory has the laboratory has validated mutation, that confers also been heavily involved their previous finding that a moderate risk of the disease with three new international promoter polymorphism in the consortia, the Breast Cancer progesterone receptor reduces Association Consortium (BCAC), the risk of endometrioid ovarian the Ovarian Cancer Association cancer. Consortium (OCAC), Consortium of Investigators of Further analysis of the rare Modifiers of BRCA1/2 (CIMBA), mutation in the ATM gene that which aim to have sufficient predisposes to breast cancer, power to find convincing 7271T>G (V2424G) has evidence of low risk genes for shown that it occurs in 7/3743 breast and ovarian cancer, and population-based cases (0.2%) for genetic modifiers of the and 0/1268 controls (P = 0.1) major breast cancer genes, from the US and Australia, BRCA1 and BRCA2. and confers a hazard ratio of 8.6 (95% CI 3.1-23.6; P < BCAC has collated data from 0.001). The laboratory has 10,000 – 30,000 breast now identified this mutation cancer cases and controls and in three multiple-case breast refuted previous suggestions cancer families in Australia, that commonly studied nine and shown that it acts as a polymorphisms in the ADH1C, dominant negative in terms AURKA, BRCA2, ERCC2, LIG4, of the expression profile in TP53, XRCC1, XRCC2 and lymphoblastoid cell lines.

Cancer Genetics Laboratory Staff From left: Back row: Nicci Wayte, Julie Johnson, Anna Marsh, Jonathan Beesley, Jeremy Arnold. Front row: Soori Manu, Nicola Waddell, Jean Fleming, Sue Healey, Sharon Johnatty, Xiao Qing Chen, Georgia Chenevix-Trench (Head)

34 Cancer Immunotherapy HIGHLIGHTS Dr Chris Schmidt Current Phase III trial for patients with early metastatic melanoma (Stage Understanding how the immune system succeeds in its fight IIIB/C) reached 40% of against malignancies is central to the future development of cancer planned accrual immunotherapies, and the focus of research in this laboratory Dendritic cell-based In two recent studies, it of recurrent glioblastoma, in immunotherapy, in was found that patients a recently completed trial in conjunction with with advanced, metastatic collaboration with Dr David chemotherapy, proved melanoma who responded to Walker (Royal Brisbane and capable of inducing a an irradiated tumour/dendritic Women’s Hospital). A new trial complete clinical response cell immunotherapy all had with a modified dendritic cell in a patient with recurrent lower volume disease. This therapy is planned. The core glioblastoma encouraged researchers to test research focus in this laboratory Analysed ex-vivo anti- the therapy in patients with remains the characteristics of tumour T cell responses resected, regional metastatic a successful anti-tumour T cell at the level of individual melanoma. In conjunction with response. tumour epitopes using Professor Michael O’Rourke The Depot Cytokine Group multi-colour flow cytometry (Mater Hospital), Professor (KE, MH, XH) successfully Mark Smithers (Princess developed novel technologies Alexandra Hospital), and Dr Ian for the encapsulation in an Hermans (Malaghan Institute), a inert, biocompatible matrix, Phase III clinical trial has begun, of a highly selected subline with the aim of enrolling 200 of HEK293 cells capable of patients. Manufacture under resisting the intratumoural GMP is performed by QGen. environment. Once transfected The success of the Phase I with any of several relevant studies led to trials for prostate cytokines, the encapsulated cancer (with Professor Frank cells can be injected into Gardiner, the Royal Brisbane tumours, initiating combined and Women’s Hospital, the anti-angiogenic and cell University of Queensland, and mediated immune responses. the Northern section of the Encapsulation confines the Urological Society of Australia) cytokines to the tumour, thus (LOC). These trials are nearing avoiding the toxic effects of completion. The efficacy of many cytokines when they Melanoma cell line the treatment in combination enter the systemic circulation. with chemotherapy was The first clinical trial of this Cancer Immunology demonstrated in one patient approach with canine patients Laboratory and who had complete remission will commence next year. Dendritic cells and Cancer Laboratory Staff From left: Back row: Michael Lai, Guillaume Bach, Michelle Neller, Tammy Maxwell, Chris Schmidt (Head, Cancer Immunology). Middle row: Ming Lin, Melanie Reiter, Alejandro López (Head, Dendritic Cells and Cancer), Cathy Lanagan. Front row: Nathan Martinez, Kalpana Patel, Xiang Quan Huang, Kay Ellem

35 Dendritic cells and Cancer HIGHLIGHTS Associate Professor J Alejandro López Established that CD40L may recover functionality of immature DR+ cells Dendritic cells (DC) are potent initiators of the immune response accumulating in patients currently used in novel therapies for melanoma, prostate and with advanced cancer glioblastoma at QIMR. This laboratory explores the function of DC in patients with breast cancer and in healthy donors and studies the Discovered a high level of role of DC in the response to cancer as the basis for optimised DC- apoptosis in circulating DC based immunotherapy clinical trials in the blood of patients with breast cancer The characterisation of DR+IC, The laboratory investigated Discovered that CD40L an immature population interactions between DC and prevents tumour induced of antigen presenting cells tumour cells (melanoma) apoptosis of blood DC in accumulating in patients leading to antigen presentation patients with advanced with advanced cancer was and established that they breast cancer completed. Interestingly, it efficiently form into conjugates was demonstrated that their incapable of eliciting recognition functional defects may be by melanoma specific CTL when recovered by the treatment melanoma cells were either with ligand (CD40L). These intact or irradiated. However, observations in patients when early apoptotic melanoma with advanced cancer were cells were used, specific replicated in the smaller recognition was observed. proportion of DR+IC also present in healthy individuals. In addition to the beneficial effect of CD40L on DR+IC, it Below: Contrast phase microscopy was demonstrated that CD40L studying the interaction between DC also prevents the induction of (green) and melanoma cells (red) in a apoptosis in circulating DC. vaccine preparation for immunotherapy A higher proportion of blood DC undergo apoptosis in patients with breast cancer. It was shown that this process is induced by tumour products and efficiently prevented by the treatment with CD40L.

Left: Effect of breast cancer on DC. A. Shows apoptosis induced in circulating DC from a patient with advanced disease. B. Accumulation of immature cells (DC+IC) replacing bona fide DC shown here under light and electron microscopy

36 Human Genetics HIGHLIGHTS Dr Nicholas Hayward Identified a gene expression profile associated with mutation of the ARF gene This laboratory identifies novel cancer genes and studies the way in which defects in these genes are associated with cancer Identified several novel predisposition or development tumour suppressor genes in cutaneous melanoma using Gene expression profiling was no association between the array-based comparative used to identify a molecular protein levels of either FN1 or genomic hybridization signature characteristic of ARF AKAP12, and patient survival Carried out extensive mutation status in a panel of in a panel of 62 archival gene expression profiling 63 melanoma cell lines. Using tumours. Comparative genome of oesophageal cancers, siRNA knockdown and gene hybridisation arrays applied to precancerous oesophageal induction we confirmed a a pilot sample of oesophageal tissue and normal number of the differentially tumours and cell lines has oesophagus expressed genes as downstream demonstrated evidence of effectors of ARF. homozygous deletion targeting Confirmed localization of the genes CDKN2A (9p21.3) the congenital microcoria Mouse models for melanoma and FHIT (3p14.2). We are locus to chromosomal locus development have shown that currently working on combining 13q31-q32 activation of the Ras/MAPK similar DNA copy number pathway alone can increase methods and expression susceptibility to UVR-induced profiling to generate a whole- Through continued melanoma. Furthermore, with genome view of oesophageal collaboration with the lab of the introduction of a Cdk4 adenocarcinoma in a large panel Dr Rick Sturm at IMB, the mutation that is involved in of biopsies taken from tumours Neural Crest Cell Biology Group susceptibility to melanoma in and precancerous conditions. are now able to grow human humans, the animals develop These data will be use to melanoblasts (the precursors UVR-induced tumours very select novel cancer-related of melanocytes), the pigment rapidly. The mutant Cdk4 genes for confirmation and producing cells in the skin. Work both enhances initiation, characterisation. In collaboration continues into determining and contributes to tumour with Professor David Beer at the the molecular pathways which progression, producing University Of Michigan Medical control the differentiation aggressive metastatic School, humoral response process into a mature melanomas. arrays have been used to assess melanin producing terminally Using mRNA expression the presence of circulating differentiated melanocyte and profiles from oesophageal antibodies to tumour antigens how these pathways might be adenocarcinomas, a number in a combined sample of over reversed during tumorigenesis of genes have been identified 350 plasma samples, taken from when unrestricted growth which may be involved in control subjects and patients of melanocytes leads to patient survival, although with oesophageal cancer or melanoma. immunohistochemistry revealed precancerous lesions. Human Genetics Laboratory Staff From left: Back row: Magdalena Auret, Leisl Packer, Jill Larsen, Mitchell Stark, Peter Johansson, Arne Mould. Middle row: Heather Smith, Elke Hacker, Graeme Walker, Cheryl Filippich, Derek Nancarrow. Front row: Nick Matigian, Nick Hayward (Head), Jane Palmer, Lauren Aoude, Herlina Handoko

37 Leukaemia Foundation HIGHLIGHTS Professor Andrew Boyd – In collaboration with Used antibodies and The University of Queensland inhibitors of Eph and ephrin proteins in cancer The Leukaemia Foundation of Queensland laboratory is seeking to Used inhibitors of EphA4 as understand the role of critical cellular proteins in the causation and potential therapeutics for evolution of leukaemia and other cancers spinal cord injury Expressed the Fat Eph and ephrin membrane EphA4 in spinal cord injury protocadherin in early proteins in cancer A mouse knockout of the vertebrate development When Eph and ephrin proteins EphA4 gene was developed on adjacent cells bind together, earlier in this laboratory and they initiate bi-directional showed to have a defect in signals which affect the spinal cord development. It has of proteins which inhibit cytoskeleton and adhesion now been shown that these programmed cell death. One proteins generally resulting mice, unlike normal animals, example is the causative role of in de-adhesion and contact recover completely after spinal increased expression of Bcl-2 repulsion. These interactions injury. Inhibitors of EphA4 have in follicular lymphoma. A novel have critical roles during been used to show that these anti-Bcl-2 drug has been shown embryonic development and in can promote healing in normal to induce cell death in tumours. pathological states, notably in mice after spinal cord injury. Another project explores ways cancer. Fat protocadherin of circumventing resistance to Glivec, a therapeutic molecule Studies in this laboratory Fat is an adhesion molecule targeted against the Bcr-Abl have paved the way for the which is involved in normal oncoprotein in chronic myeloid development of antibodies development and in kidney leukaemia. and antagonists of Eph and function. An abnormal form of ephrin proteins. Antibodies and this protein is expressed in some antagonists of EphA3, a protein forms of T cell leukaemia and expressed on a high proportion lymphoma. This abnormal form of metastatic melanomas and inhibits the normal Fat protein other human tumours including and may thus contribute to leukaemias, have been tested as tumour spread. potential cancer therapeutics. In a leukaemic model an EphA3 Apoptosis inhibitors antibody has been shown to The group headed by Dr be very effective in preventing Lickliter studies the over- spread of leukaemic cells. expression in tumours

Leukaemia Foundation Laboratory Staff From left: Back row: Brett Stringer, Ke Chen, Mark Coulthard, Bryan Day, Mark Spanevello. Front row: Fiona Smith, Lucy Wilkinson, Con Stylianou, Nirmitha Herath, Jacinta Carter, Trina Yeadon.

38 Membrane Transport HIGHLIGHTS Dr Nathan Subramaniam Generated and characterised the first complete Transferrin Receptor 2 knockout mouse, This laboratory studies how the liver regulates iron metabolism. a model of type 3 hereditary The identification of the molecules involved and defining the way haemochromatosis they work has major implications for iron related disorders such as hereditary haemochromatosis and anaemia Demonstrated that regulation of the iron Many of the proteins implicated accumulates in the Golgi regulatory peptide hepcidin in iron metabolism are compartment of hepatocytes is lost in the Transferrin expressed at very high levels in and that this could be another Receptor 2 knockout mouse potential level of its regulation. the liver. Alterations in many Described prohepcidin of these proteins have been expression in hepatocytes shown to lead to the iron The laboratory is identifying the molecular basis of atypical overload disorder, hereditary Identified the first case of iron overload or hereditary haemochromatosis. The study the A77D mutation of the haemochromatosis in the of these molecules has been ferroportin gene in the Australian population, and has imperative in defining the Australian population various processes involved in been at the forefront of studies maintaining the appropriate in this field. In collaboration Established that iron-related levels of this essential element. with Professor Darrell Crawford, fibrosis in C282Y HFE from the Princess Alexandria subjects can be reversed In the past year, the first Hospital in Brisbane, several by iron removal therapy if complete knockout animal mutations in the iron exporter diagnosed early model for type 3 hereditary ferroportin have been studied and identified to show that haemochromatosis has been Top Image: Perls’ staining showing iron generated in this laboratory. this leads to iron overload or deposits in livers of normal (left) and The Transferrin Receptor 2 gene ferroportin disease. Transferrin Receptor 2 knockout mice knockout mice develop iron (right) Bottom Image: Prohepcidin overload in a similar fashion to In a collaborative study from expression in livers of mice with iron overload (left) and anaemia (right) humans with mutations in the QIMR with Professor Powell, transferrin receptor 2 gene. and Associate Professors Analysis of these mice showed Ramm and Anderson, it has that they had an inappropriately been shown that unidentified low level of expression of asymptomatic individuals the iron regulatory hormone homozygous for the C282Y hepcidin, indicating that mutation of HFE were at a risk transferrin receptor 2 is a of iron overload-related hepatic regulator of this peptide. Using fibrosis and cirrhosis, and if specific reagents for prohepcidin diagnosed early, fibrosis could researchers showed, for the be reversed by iron removal first time, that this peptide therapy.

Membrane Transport Laboratory Staff From left: Nathan Subramaniam (Head), Elizabeth Leddy, Lesa Summerville, Daniel Wallace

39 Molecular Cancer Epidemiology HIGHLIGHTS Dr Amanda Spurdle Showed that tumour protein markers improve clinical classification of variants of In some families, genes are inherited that predispose members to BRCA1 and BRCA2 develop cancer. This laboratory works on identifying the genes which contribute to endometrial, breast, ovarian and colorectal cancer Developed RNA expression assays of blood cell lines to In collaboration with Dr Webb, Work led by Dr Joanne Young assess function of variants of many resources have been continues to characterise BRCA1 and BRCA2 spent establishing a national the genetic predisposition to Further characterised a novel endometrial cancer case- develop serrated neoplasia in syndrome of colorectal control-family study, involving the colorectum. A model has cancer showing widespread set up of collaboration and been developed describing methylation in normal tissue recruitment at more than 25 three settings in which sites across Australia. This serrated neoplasia gives rise Developed a genetic model NHMRC-funded project will to cancer of the colorectum; for serrated neoplasia in the create a data and biospecimen hyperplastic polyposis colon repository to allow investigation as a recessive condition, of the environmental and serrated pathway syndrome Identified features of young- genetic causes of this disease, as an autosomal dominant onset endometrial tumours and the molecular features of condition and sporadic MSI- which indicate an inherited tumours in relation to patient H colorectal cancer as a mild predisposition outcome. Work assessing the gene environment interaction. cancer-causing potential of It has been shown that in showed distinct gene expression subtle variants of the breast hyperplastic polyposis, the profiles when compared to cancer predisposition genes extensive DNA methylation that that of normal controls. We BRCA1 and BRCA2 continues, occurs in serrated neoplasms have also demonstrated that and preliminary data indicate also occurs in the normal approximately 25% of women that use of tumour protein bowel tissue, supporting aged 50 or younger have a expression assays will aid the evidence for a genetic field strong familial predisposition to clinical classification of these defect in the normal colon in develop not only endometrial variants. It has also been shown this disorder. Further, studies but also colorectal cancer, a that RNA expression in long- of blood cells in patients with condition known as Lynch lived cells from blood of patients familial serrated neoplasia Syndrome. with known mutations in these genes can distinguish mutation- Lymphoblastoid cell line RNA expression carriers from individuals without profiles discriminate such mutations. Data indicates BRCA1 and BRCA2 that this methodology will be a mutation carriers useful tool to assess the clinical from breast cancer cases without significance of variants in mutations. BRCA1 and BRCA2.

Molecular Cancer Epidemiology Laboratory Staff From left: Back row: Michael Walsh, Kaltin Ferguson, Sven Arnold, Daniel Buchanan. Middle row: Lesley Jaskowski, Amanda Spurdle (Head), Felicity Lose, Joanne Young. Front row: Diane McKeone, Sue Healey

40 Molecular Pathology HIGHLIGHTS Professor Sunil Lakhani – In collaboration with Established QIMR-RBWH The University of Queensland Cancer Tissue Bank, an Australasian Biospecimen Network (ABN) funded The focus in this laboratory is the genetics and cell biology of breast resource which will provide cancer with the goal of improving the classification and diagnosis of tissue for local and national this disease research groups.

During the year this laboratory validation of the cohort, and Approximately 100 fresh established the QIMR-RBWH for molecules of interest to the normal and/or breast tissue bank for the collection laboratory. Data analysis and tumour specimens collected of normal breast tissue and further immunohistochemistry from consenting patients. breast cancer specimens from is ongoing. consenting patients. A large cohort of metastatic The resource now contains brain tumours have also been samples from approximately collected and their matched 100 patients being used by primary breast tumours researchers in this laboratory through local and international and collaborators within QIMR collaborations in Brazil and the (Georgia Chenevix-Trench Czech Republic. A TMA has and Alejandro Lopez) and at been created for this study the University of Queensland and analysis is underway (Brent Reynolds). Studies investigating the mechanisms of include investigating familial metastasis to the brain. breast cancer, and the use of mammospheres for dendritic Techniques have been cell immunotherapy and in the established in the laboratory isolation of breast tumour stem for molecular genetic cells. analysis – comparative genomic hybridisation, loss In collaboration with Dr Glenn of heterozygosity, E-cadherin Francis, tissue microarrays gene sequencing and gene (TMA) of over 600 sporadic methylation. These are being tumours have been created used to study the mechanism and the matched in situ of development of lobular components from patients carcinomas and for cell biology with comprehensive clinical and immunofluorescence which follow up. The TMAs have is being applied in the study been stained with a large panel of normal breast cells from of antibodies for molecules sporadic and BRCA1 mutation used in diagnostic practice, as patients.

Molecular Pathology Laboratory Staff From left: Kelvin Lim, Peter Simpson, Leonard Da Silva, Sunil Lakhani (Head), Suzanne Parry, Catherine Clarke

41 Molecular Psychiatry HIGHLIGHTS Dr Corinne Lendon Established the Molecular Psychiatry Laboratory at This Group investigates factors that modify susceptibility to QIMR dementia, especially Alzheimer’s disease and related neurological Developed a model and psychiatric disorders, including psychosis and depression to investigate gene- environment interactions Staff and equipment for this A two pronged approach is used laboratory arrived from the of hunting for novel genes and University of Birmingham, UK mechanisms that incur risk for influence the presence and in March 2006. Since then the the dementias using association severity of symptoms. lab has become operational and strategies and in vitro modelling ethics approvals secured. of their effects and interactions. The laboratory’s in vitro models This laboratory’s case-control incorporate expression systems One arm of the work involves a cohorts, together with their as well as human brain cells, study of the carers of dementia European collaborators, extend and patient lymphoblasts patients. Some carers cope cases to over 4000. are used to investigate the well with their role but others molecular mechanisms of become overburdened and The novel and candidate interaction between gene- develop depressive symptoms genes arising from this work environment factors known to themselves. So far, it has been are further investigated using be involved in predisposition to revealed that carer burden is genotype-phenotype studies dementia, and those discovered heightened by carers feelings that incorporate variables by the laboratory and its of role captivity, a diminished including neuropathological collaborators. confidence in their role and measures, response to poor patient relationship quality. treatment and patient and It is envisaged that the carer well-being, memory and combination of such The molecular investigations of neuropsychological measures. studies could stimulate the the lab are aimed at discovering development of novel treatment factors that predispose to The behavioural and strategies aimed at the majority or protect individuals from psychological symptoms of of clinical dementia cases, dementia and Alzheimer’s AD occur in some but not as well as an adaptation of disease. Much of the current all patients. When they do those existing therapies and drug discovery programs in occur, they cause both patient possible recommendations Alzheimer’s disease are aimed and carers considerable for acceptable levels of some at mechanisms inspired by the distress. Genes are studied agents in the environment. rare familial forms caused by that have been implicated single-gene mutations. This in psychosis and depression, laboratory focuses on the including neuregulin 1 and most common forms that are those of the serotinergic and inherited in a non-Mendelian catecholaminergic system, Molecular Psychiatry Laboratory complex/sporadic manner. to determine whether they Staff From left: Corinne Lendon (Head), Antonia Pritchard

Pathology of Alzheimer’s Disease – A: Diffuse amyloid deposits in brain parenchyma B: Neurofibrillary tangles, tau deposits inside neurones C: Dense cored amyloid plaque with surrounding reactive neurites and D: Amyloid deposits in cerebrovascularature

42 QCF Transgenics HIGHLIGHTS Dr Graham Kay Found that the inactive X chromosome can be reactivated by siRNA- The research focus in the QCF Transgenics Laboratory is on cell and mediated knockdown of developmental biology with particular emphasis on using transgenic SmcHD1 indicating that the and knockout mice as model systems SmcHD1 protein is involved in the maintenance of X Epigenetic modulation of protein product appears to inactivation gene expression results from be involved in maintaining structural modifications to the the inactive state throughout Identified the prophylactic genome that do not involve development. effect of anti-Vegf-B changes in the DNA sequence. monoclonal antibody Such epigenetic changes ensure In another area of study, administration on arthritic that the information encoded research in this laboratory has disease in mice within the genome is used previously established a role for Discovered that the correctly during development Vegf-B in the pathogenesis of combined loss of Rb1 and and in the maintenance of arthritis using gene knockout p130, or Rb1 and p53 adult tissues. Gene expression mice. A prophylactic effect in mouse melanocytes is also epigenetically modulated of anti-Vegf-B antibody does not have deleterious in diseases, like cancer, where administration on arthritic consequences for the expression of genes which disease in mice has now been melanocyte homeostasis in favour disease progression, or confirmed. This data further vivo our body’s response to disease, endorses the therapeutic are modulated. potential of blocking Vegf-B signaling as a treatment for To effectively treat disease it arthritis. is essential that we gain a full Blastocyst stage female mouse embryo understanding of this level of The pocket protein family (Rb1, p130 and p107) in conjunction with the inactive X chromosome gene expression control. This stained (red) for presence of histone laboratory studies the Xist, with p53 act to regulate cell H3 trimethylated at lysine 27 Tsix and SmcHD1 genes that cycle progression and prevent are involved in epigenetically tumour formation. Various modifying chromatin to silence combinations of these proteins one of the two X chromosomes are being deleted in mouse in female cells thereby melanocytes to determine which achieving dosage equivalence combination is acting to prevent for expressed X-linked genes melanoma. Loss of Rb1, alone, between males and females. does not cause melanoma but when the melanocytes are The Xist and Tsix genes cultured they display some are involved in initiating X properties of cancer cells. inactivation while SmcHD1

QCF Transgenics Laboratory Staff From left: Back row: Ian Tonks, Graham Kay (Head), Arne Mould. Front row: Sonia Greco, Anna Zournazi

43 Radiation Biology and Oncology HIGHLIGHTS Professor Martin Lavin – In collaboration with Provided new insight into The University of Queensland the activation of ATM Described the protective DNA damage response and its role in maintaining the integrity of effect of a novel nitroxide DNA to minimize the risk of cancer and neurodegeneration is the antioxidant on tumour major focus of research activity in this laboratory latency in ATM mutant mice Showed that the same The gene defective in the downstream substrate for ATM antioxidant could correct human genetic disorder ataxia- called Mre11 which also plays neurological abnormalities in telangiectasia (A-T), ATM, a key role in maintaining the ATM mutant mice plays a key role in recognizing integrity of the genome. The double strand breaks in DNA functional consequences of Identified new activities for and signaling these breaks to the phosphorylation reaction Aprataxin mutated in AOA1 the cell cycle checkpoints and involved are being delineated. the DNA repair machinery. Previous data from this Cloned and expressed Failure to recognize and repair laboratory showed that a novel genes for novel toxins from this damage in A-T patients isoindoline nitroxide (CTMIO) Australian elapid snakes results in increased frequency was capable of preventing of cancer and progressive some of the neurological different forms of damage in neurodegeneration. Being able features in ATM mutant mice. DNA. A role for the protein to slow or halt the progress of These studies have been Aprataxin, defective in ataxia this neurodegeneration would extended to demonstrate that with oculomotor apraxia type be of great benefit to A-T CTMIO increases dramatically 1 (AOA1), has been shown in patients. the latency period for the the recognition and repair of appearance of thymomas single strand breaks in DNA. Recent data demonstrate in ATM mutant mice. This Research is currently under way that autophosphorylation antioxidant also corrected on the gene product Senataxin, and activation of ATM neurobehavioural defects in defective in a related syndrome involves several separate these mice. AOA2, and preliminary data phosphorylation sites on reveal that this protein too is the molecule. These sites Since A-T is one of several involved in the DNA damage have been mapped and their related syndromes characterized response. Other novel forms functional significance in cell by ataxia, investigations are of AOA are being investigated cycle control and protecting underway on whether other with a view to determining against radiation damage related human ataxias might whether the proteins involved established. Investigations also be characterized by a participate in the DNA damage are continuing on a novel reduced capacity to deal with response and protection of the nervous system. Radiation Biology and Oncology Laboratory Staff From left: Back row: Kelly Landers, John Luff, James Brown, Janelle Hancock, Rick Woods, Cheng Peng. Middle row: Magtouf Gatei, Philip Chen, Aine Farrell, Yi Chieh Lim, Michelle Burger, Sergei Kozlov. Front row: Amila Suraweera, Oliver Becherel, Geoff Birrell, Renee Stirling, Kerry Roper, Martin Lavin (Head)

44 RBWH Gastroenterology HIGHLIGHTS Professor Barbara Leggett – In collaboration with The Royal Showed that 9% of Brisbane and Women’s Hospital Foundation colorectal polyps are sessile serrated adenomas, which are highly correlated with This laboratory identifies genetic changes which define distinct BRAF mutation, proximal subtypes of colon cancers with differing clinical features with the aim location, female gender and of predicting which of these will most likely to progress to cancer polyp multiplicity

Colorectal cancer (CRC) is and is therefore currently Established methylation a heterogeneous disorder being investigated for gene microarray technology for in which clinically relevant deletion and/or mutation. It has clustering CIMP status subgroups may be identified also been shown that THBS4 and candidate gene based on shared molecular expression is down-regulated identification alterations. Frequent target in the majority of CRCs Began a study of early gene inactivation via through aberrant promoter methylation in histologically promoter hypermethylation hypermethylation, and the normal colon for the future defines a subgroup of CRCs protein has been localised to development of molecular displaying the CpG Island epithelial cells. The functional stool, serum and/or biopsy Methylator Phenotype (CIMP). consequences of re-expressing screening tests Approximately half of all this protein in CRC cell lines are CIMP+ tumours show a high currently being investigated. novel model system in which level of microsatellite instability Increased transcript expression to study the complex functions (MSI-H) due to methylation of IL24 is common in sporadic of this important suppressor of of the mismatch repair gene (81%) and familial (70%) TGFß signalling. Mutation of MLH1. Over the past year MSI-H tumours compared with the BRAF oncogene is highly significant advances have been 44% of remaining cancers correlated with CIMP+ cancers. made towards identifying (P<0.02). Intriguingly, protein A conditional intestine-specific genes which may be relevant expression does not always BRAF V600E mouse model to the progression of CRC, in mimic the transcript pattern, is being generated to further particular, those which define which may be a consequence probe the function of this gene the CIMP+ and MSI subtypes. of disrupted secretion (see in colorectal tumorigenesis. Research has demonstrated figure). ID4 methylation has that BMP3 is dramatically been correlated with decreased down-regulated in most CRCs, expression to show that this commonly due to aberrant occurs most frequently in promoter hypermethylation in CIMP+ tumours. Research also both polyps and cancers. KLF4 shows that SnoN expression is a transcription factor down- is specifically down-regulated regulated in 86% of CRCs. in MSI-H tumours, and the Despite a typical CpG island, laboratory now proposes that it is not commonly methylated these tumours represent a

RBWH Gastroenterology Laboratory Staff From left: Back row: Ron Buttenshaw, Sarah-Jane Cozzi, Kevin Spring, Barbara Leggett (Head) Front row: Vicki Whitehall, June Chia, Gagori Bandopadhyay, Kim Loh

45 Signal Transduction HIGHLIGHTS Dr Kum Kum Khanna Gained an improved understanding of the biological and biochemical This laboratory seeks to understand signal transduction pathways functions of novel single involved in the detection, signalling, or repair of DNA damage, an strand binding protein and area of critical importance to cancer research its link with cancer

A novel ssDNA binding protein Taken together, our results Identified redox-dependent (hSSB1), which is more closely indicate that hSSB1 is regulation of SBP2 as a related to both the bacterial and dispensable for induction of mechanism to regulate the archaeal SSB proteins has been cell cycle checkpoints but is expression of selenoproteins characterised. Single stranded required for repair of double in cells DNA (ssDNA) binding proteins strand breaks by homologous are ubiquitous to life. They bind recombination. The laboratory has found that to ssDNA regions protecting SBP2 shuttles between the them from further damage and In collaboration with Dr Grant nucleus and the cytoplasm. are involved in the recruitment McArthur from the Peter Oxidative stress induces of other repair proteins to MacCallum Institute, evidence nuclear accumulation of SBP2 sites of DNA damage. The has been provided for a novel via oxidation of cysteine laboratory has found that hSSB1 role of cyclin dependent kinases residues within a redox- is stabilised after treatment in the activation of DNA sensitive cysteine rich domain of cells with various DNA damage response pathway, (CRD). These modifications damaging agents and ionising which can be used to selectively are efficiently reversed in vitro (IR) and UV irradiation-induced enhance responses of cancer by human thioredoxin and stabilisation is dependent on cells to DNA-damaging agents glutaredoxin, suggesting that the presence of functional ATM like cytotoxic chemotherapy and these antioxidant systems might and ATR kinases, respectively. radiotherapy application. regulate redox status of SBP2 in vivo. Depletion of SBP2 in In response to IR, hSSB1 rapidly Evidence for redox-dependent cell lines using siRNA results in relocalises to nuclear foci regulation of SBP2, a key a decrease in Sec incorporation, that also contain other repair regulator of selenoproteins providing direct evidence for its proteins. Downregulation of synthesis in cells, has also requirement for selenoprotein hSSB1 expression by small been provided. Incorporation synthesis. Furthermore, Sec interfering RNA yields a of selenocysteine (Sec) into incorporation is reduced radiosensitive phenotype and selenoproteins employs a substantially after treatment prevents IR-induced repair unique mechanism to decode of cells with agents that cause focus formation and ssDNA the UGA stop codon. The oxidative stress suggesting formation at the site of DNA process requires the Sec that nuclear sequestration of damage. Depletion of hSSB1 in insertion sequence (SECIS) SBP2 under such condition normal cells results in cell cycle element, the tRNASec and may represent a mechanism arrest due to chronic activation protein factors including the to regulate the expression of of the DNA damage response SECIS binding protein 2 (SBP2). pathway. selenoproteins.

Signal Transduction Laboratory Staff From left: Back row: Julia Pagan, Aaron Urqhart, Kienan Savage, Derek Richard, Mathew Jones, Chris Jekimovs.Front row: Karen Hobson, Emma Bolderson, Kum Kum Khanna (Head), Laura Papp, Seema Khan

46 Population Studies and Human Genetics Division

The Population Studies and Human Genetics Division utilises a wide range of contemporary epidemiological, genetic and molecular techniques to investigate a spectrum of diseases relevant to the Australian population. The Division has a particular strength in cancer research with broad programs in skin, ovarian, endometrial, oesophageal, head and neck and liver cancer. Scientists in the Division also make extensive use of twins to analyse the relative importance of genes and environment in a variety of important health problems and Division Chair Associate traits including endometriosis, drug and alcohol dependence, Professor Greg Anderson asthma, pigmentation, fertility and cognitive ability. Another long term research initiative has been in the area of gastrointestinal disease, with studies on liver fibrosis, paediatric cholestasis, alcoholic liver disease and disorders associated with body iron overload such as hemochromatosis. This year the Division welcomed a significant new group with the arrival of Emma Whitelaw and her epigenetics team. The role of epigenetic changes in the biology of complex disease has received increasing interest in recent years.

Many of the Division’s projects make extensive use of large population studies to investigate patterns of disease and we are indebted to the public for their continued goodwill in helping to make so much of this research possible. A particular landmark this year has been the Nambour skin cancer study reaching its twentieth, and final year of followup. The collection of epidemiological and clinical data from studies such as these allows researchers to correlate patterns of disease with environmental factors, and blood and tissue samples enable a variety of genetic and basic molecular analyses to be carried out. The need to conduct large-scale studies means that the Division possesses extensive resources for high throughput genotyping and gene expression analysis. These population and genetic approaches are complemented by detailed biochemical and cellular studies to investigate mechanisms of disease and identify potential therapeutic targets.

47 Cancer and Population Studies HIGHLIGHTS Professor Adèle Green Nambour (skin cancer) cohort study reaches its 20th and final year of The Cancer and Population Studies Group investigates the causes of follow-up cancer and other chronic diseases and avenues for their prevention Obtained evidence that Three of the main projects To assess causality, researchers melanomas on the face being conducted by the ascertain cancer-free people of are associated with chronic Cancer and Population Studies the same sex and similar ages high-level sun exposure, Group are nationwide studies with whom to compare the whereas those on the trunk of cancers of the ovary, affected individuals in regard are associated with lower oesophagus and more recently, to their environmental and levels of sunlight endometrium. personal exposures (ranging, Developed a novel risk for example, from dietary On the one hand, the group prediction algorithm for intake to medication history aims to identify their causes, cutaneous melanoma to reproductive history and and on the other, the prognostic related factors in women); and life-courses followed by Completed participant in regard to the expression of patients after diagnosis of such recruitment and both data various relevant genes. cancers. The work combines and sample collection for epidemiological methodology Follow-up of the occurrence national studies of ovarian and clinical follow-up data with of skin cancers in a cohort and oesophageal cancer. collaborative genetic analyses of of some 1,000 residents of Commenced recruitment blood and tumour tissue. This the Queensland township of for the national study of involves working with clinical Nambour, originally ascertained endometrial cancer in and research collaborators, not in 1986, who were participants collaboration with the only locally but across Australia, in the Nambour Skin Cancer Molecular Epidemiology to recruit several thousands of Prevention Trial (1992-1996), Laboratory people with these cancers and is now in its twentieth and final related conditions. year.

Cancer and Population Studies Laboratory Staff: From left: Back Row: Valerie Logan, James Doecke, Susan Jordan, Kylie Smith, Catherine Baxter, Barbara Ranieri, Paula Moser, Naomi Richmond, Jolieke Van Der Pols. 3rd row: Suzanne Moore, Colleen Loos, Nirmala Pandeya, Barbara Alexander, Kiri Ibiebele, Maricel Hughes, Fariba Kolahdooz, Ann Ward. 2nd row: Jeanette Mayhew, Lea Jackman, Lynn Green, Penny Webb, Adèle Green (Head), Patricia Valery, Christina Nagle, Catherine Olsen. Front row: Philippe Carriere, Penny McBride, Justin Scott, Shahram Sadeghi, Andrea McMurtrie, Sonya Webb

46

48 The group is collecting ongoing information relevant to sun Indigenous Health Research Program exposure, general lifestyle, Ms Janelle Stirling other sun-related disease, and occurrence of other cancers and This Program covers work across QIMR Divisions with a research serious diseases as well. A major agenda which includes projects on cancer, childhood respiratory focus is to clarify the role of diseases, scabies, Group A Streptococcus and type 2 diabetes diet alongside sun exposure in causation of skin cancer through The Indigenous Health Research Program covers a range of this cohort. Researchers are research projects which include: also collaborating with a Asthma Education Intervention Study in the Torres Strait: European consortium to study This is a collaborative project with Associate Professor Anne the links between skin cancer Chang and Dr Brent Masters of the Royal Children’s Hospital, and Human Papilloma Virus skin Brisbane and the Queensland Asthma Foundation. Four specialist infections. clinics have now been conducted with a total of 305 children and Collaborative research into young people seen by the team with no adverse events. At this Indigenous Health and related stage there are 70 children enrolled in the study. Future clinics are training and education, planned for July and October 2006. continues to increase and During the March 2006 clinic, the 12 month Doctor Reviews diversify. Topics include asthma, for the 1st cohort were completed with 11 children seen. A bronchiectasis, diabetes in Participant’s Manual and three day workshop course has been youth, and health service care developed and, to date, has been delivered on three occasions of adult Aboriginal and Torres on Thursday Island. In addition to the workshops, children’s Strait Islander cancer patients educational booklets have been developed and are currently after diagnosis in Queensland. being used by health care workers to reinforce information to This group is also the base for the children. In order to fully evaluate the educational materials, the newly-established QIMR- an education intervention study which commenced in 2005 is RBWH Statistics Unit and currently underway and data collection for this evaluation will be will assist them in facilitating completed in October 2007. biostatistical collaborative research and support within the During the project, three health worker trainer courses have Institute. been conducted on 11th-13th April 2005, 18th-20th July 2005 and 13th-15th March 2006. During the April, July and March workshops a total of 29 health staff (one nurse and 28 health workers) have completed the training course. The first training workshop was delivered to 10 Torres Strait Islander health workers and one nurse and the second workshop was delivered to ten health workers from the outer island communities. The Wuchopperen Skin Study Data collection has been completed and analysis of the results is currently underway. This collaborative study with the

Indigenous Health Research Program Staff From left: Ms Suzanne Moore, Mrs Val Logan, Dr Patricia Valery, Ms Janelle Stirling

49 Wuchopperen Health Service in Cairns, aims to assist the health HIGHLIGHTS service find out more about the Awarded two NHMRC types of skin sores presenting grants and a Royal at the clinic and researchers Children’s Hospital at QIMR will use the Group Foundation grant A Streptococcus (GAS) strains Published a paper in the found to further their research Lancet (Valery PC, Coory towards developing a vaccine M, Stirling J, Green A). for GAS. Cancer diagnosis, treatment The Multi Centre and survival in Indigenous Bronchiectasis Study compared with non- Indigenous Australians Part of the observational treated in public hospitals) component of this study (a collaborative and international Vanessa Clements joined the study of bronchiectasis in program as a QIMR based Indigenous children) has ANU Master of Applied commenced in some sites. Epidemiology student The intervention component Held the third Spotlighting is currently being organised. Careers in Indigenous Because of the international and Health and Science Program multi-site nature of this project, there is an enormous amount Hosted the Cooperative of regulatory requirements Research Centre for that have to be met before this Aboriginal Health Brisbane component can start. Showcase Top: Vanessa Clements – Master Sue Moore awarded an of Applied Epidemiology Student. NHMRC scholarship to Centre: Dr Sue Vlack and Alzira Conlon presenting at the Brisbane Aboriginal further investigate findings Health CRC Showcase in June 2006, from the Program’s recently Bottom: Bayley Wilson, a student from published cancer study (to the Spotlighting Careers in Indigenous commence July 2006) Health Program in May 2006

50 Epigenetics HIGHLIGHTS Professor Emma Whitelaw Established a maternal ethanol exposure regime in mice, to model foetal The Epigenetics Laboratory became established at QIMR in February alcohol syndrome (FAS) 2006 with the main aim of understanding the role of epigenetics in the determination of phenotype in mammals Identified the underlying mutation in another ENU This laboratory investigates Staff in the QIMR Animal House mutant mouse the role of epigenetics in the also helped to make this difficult Produced a new mouse establishment of phenotype transition happen with relatively model of Turner’s syndrome, in mammals, both mice and little pain. where the female is XO, humans. The ultimate aim rather than XX of the research is to test the The laboratory is now hypothesis that epimutation functioning well with many plays a role in complex disease of the personnel collaborating and sporadic disease. with other scientists in the Institute and learning new skills. All the members of the old For example, protein gels are Whitelaw laboratory at the being run for the first time! University of Sydney moved Microarray hybridizations have to Brisbane and into the Clive also been initiated to study Berghofer Cancer Research genome-wide changes both Centre in February this year, in DNA copy number and in accompanied by a large methylation state. truckload of equipment and many mice. In collaboration with Professor Nick Martin from the Genetic The mice are now settled into Epidemiology Laboratory, their new facility and breeding investigations have begun into well. Grateful thanks are the epigenetic state of the expressed to the senior postdoc genome in identical twins and in the lab, Suyinn Chong, in individuals with idiopathic whose embryonic skills enabled disease. the group to rederive the majority of their mouse strains so that their health status would Monozygotic twins may share identical comply with QIMR Animal genetic information, but whether they differ in epigenetic state is currently House standards. being investigated

Epigenetics Laboratory Staff From left: Back row: Emma Whitelaw (Head), Alyson Ashe, Kylie-Ann Mallitt, Tim Bruxner, Daniel Morgan. Front row: Nikki Vickaryous, Nadia Whitelaw, Nathan Oates, Jane van Vliet, Suyinn Chong

51 Genetic Epidemiology HIGHLIGHTS Professor Nick Martin Undertook first application of genome-wide IBD sharing to estimate heritability The Genetic Epidemiology Group investigates the pattern of disease – confirms Fisher’s 1918 in families, particularly identical and nonidentical twins, to assess theory of polygenic the relative importance of genes and environment in a variety of inheritance important health problems and to locate the genes responsible using genetic linkage and association analysis Identified association of PLNX2A with anxious Alcohol consumption is been obtained from these depression – supports role associated with many medical twins with a view to identifying of adult neurogenesis in and social variables. With particular genes predisposing depression support from both NHMRC to drinking problems. A and four large new grants from major interest is the alcohol Identified association of the U.S. National Institute of metabolising enzymes; the GDF9 with DZ twinning Alcoholism and Alcohol Abuse, alcohol dehydrogenase gene supports role of ovarian 5,000 pairs of twins plus their complex on chromosome 4 signalling pathway in relatives, 23,000 subjects in has a significant effect on risk multiple follicular release all, have been surveyed, and of alcoholism and detailed fine Linkage and association telephone interviews with over mapping of this region is being analysis suggest role of 11,000 twins and 4,000 of their undertaken to identify causal CD28 in asthma spouses have been conducted. variants. Genetic factors account Major projects are also for about two thirds of the underway to find major genes latter being a major risk factor susceptibility to alcoholism influencing several important for infertility. The laboratory is in both women and men in women’s health problems also interested in the genetics of Australia. Blood samples have including endometriosis, the super-fertility, as manifested in

Genetic Epidemiology and Molecular Epidemiology Laboratories Staff From left - Back row: Pam Barton, Fran Husband, Adele Somerville, Olivia Zheng, Carol Pretsel, Monica de Noyer, Amanda Toivanen, Thanuja Gunasekera, Michelle Luciano, Rita Middelberg. Fourth row: Brendan Zietsch, Harry Beeby, David Smyth, Marisa Grimmer, Scott Gordon, Kerrie McAloney, Amanda Baxter, Jonathan Hansen, Gu Zhu, Troy Dumenil. Third row: Anthony Caracella, Peter Hatemi (visiting student), Narelle Hansell, Stuart MacGregor, Allan McRae, Carl Anderson, Beben Benyamin, Sri Shekar, Katherine Morley, Coral Pink. Second row: Dixie Statham, Andrew Birley, Sue Treloar, John Whitfield, Grant Montgomery (Head - Molecular Epidemiology), Nick Martin (Head - Genetic Epidemiology), Peter Visscher, Margaret Wright, David Duffy. Front row: Steven Crooks, Leanne McNeill, Lisa Bardsley, Ali Abdirahman, Shane Thomas, Anjali Henders, Megan Campbell, Zhen Zhen Zhou, Will Coventry.

52 familial dizygotic twinning and have genotyped over 400 pairs of sisters who each have DZ twins in order to find the genes responsible and are currently expanding this sample to 500 affected sister pairs. A further focus is the way melanoma runs in families. All familial cases and twins with melanoma diagnosed in Queensland and NSW from 1982-1990 have been identified and are now being followed up in a major NIH funded project. By obtaining detailed information on sun exposure, natural coloration and moliness in index cases and their relatives, a much better perspective of the role of genetic factors in melanoma is being gained. Much of the year Different screens has been spent investigating from the ViewPoint program created by the role of the OCA2 gene as a Harry Beeby and Sarah melanoma risk factor. Medland to assist researchers to visualise It is clear that moles the outputs of genetic (melanocytic naevi) are a major analyses. From top: risk factor for melanoma. It is ViewPoint Combined therefore important that more Chromosomes is known about the factors Univariate plot responsible for development showing two variables in separate plot panels and change of moles. In an for each. NHMRC/QCF-funded study, ViewPoint Multivariate moles in over 1000 pairs of plot for Chromosome Brisbane 12 year old twins are 1 showing active being counted and mapped, points, and two pinned and then followed up at panels displaying sub- factors contributing to their fourteenth birthday. the point score. The research has shown that individual differences in ViewPoint Multivariate all-chromosome moliness in this sample are summary display. largely genetic and a genome ViewPoint Univariate scan that indicates a number plot for Chromosome of chromosomal regions of 5, showing active major effect has recently been points on X axis and completed. two pinned marker flags.

53 Hepatic Fibrosis HIGHLIGHTS Associate Professor Grant Ramm Demonstrated that in haemochromatosis, significant liver fibrosis is This laboratory investigates the role of liver cells called hepatic frequent in asymptomatic stellate cells, in the fibrosis and cirrhosis (liver scar tissue formation), subjects and, except when which accompanies serious liver diseases of children cirrhosis is present, this liver fibrosis is reversed by iron In a project which investigates the development of liver removal from the liver the mechanisms of cellular scarring. and tissue injury in the liver Demonstrated a role for in the iron overload disease The laboratory is also actively neutrophils in the liver haemochromatosis, this group involved in researching potential and liver matrix degrading has shown that a population mechanisms responsible for enzymes expressed by these of liver cells called hepatic paediatric cholestatic liver neutrophils in repairing stellate cells, are activated in diseases, such as cystic fibrosis the liver following liver haemochromatosis and are and extrahepatic biliary atresia. injury caused by bile duct responsible for excess collagen The work is currently funded obstruction deposition causing scarring of by a National Institutes of the liver, or fibrosis. In recent Health (NIH) grant, under a the extent of hepatic stellate research, the laboratory has clinical research consortium cell activation is pivotal in this identified a number of signalling with Professor Ross Shepherd, prediction. These studies are molecules within these stellate Director of Paediatrics at being extended to identify cells, which are themselves Washington University, St Louis. disease-specific markers in the activated in the presence of This year, the collaboration liver and blood to make a much an iron-binding/transport has shown that the degree earlier diagnosis in infants with protein called ferritin. The of liver fibrosis at the time of biliary atresia so that they may group has also demonstrated diagnostic liver biopsy in infants progress to surgical correction that signalling events elicited with biliary atresia predicts the rather than be subject to liver through ferritin binding to its likelihood of progression to transplantation in future years. cell surface receptor on hepatic liver transplantation and that stellate cells appear to be Paracrine interaction responsible for activating genes between liver cells in iron overload-induced activation involved in inflammation and of hepatic stellate cells fibrosis. New gene “knockout” (HSC). Iron overload technologies are now being initially in hepatocytes and utilised in the laboratory to subsequently in Kupffer silence the genes involved cells leads to the production of a variety of molecules in ferritin-induced signalling capable of activating hepatic within hepatic stellate cells in an stellate cells to produce attempt to halt these cells from fibrosis. (Ramm GA and transforming into a fibrogenic Ruddell RG, Semin. Liver Dis., 2005;25(4):433-449). phenotype and thus inhibiting

Hepatic Fibrosis Laboratory Staff From Left: Back row: Richard Ruddell, Jeffrey Smith, Grant Ramm (Head), Louise Ramm. Front row: Pengcheng Li, Tamara Pereira, Lynn Reid, Chunxia Xu, Marie Bertrand-Philippe

54 Iron Metabolism HIGHLIGHTS Associate Professor Greg Anderson Identified HCP1, a candidate intestinal haem iron transporter The Iron Metabolism Laboratory focuses on understanding how the essential trace element iron is transported into and out of cells and Demonstrated that the how disruption of these processes can lead to human diseases such diferric transferrin in the as haemochromatosis plasma is a major factor regulating hepcidin Iron is essential for a large The relationship between expression number of critical cellular various liver diseases (notably Showed that subclinical processes but its concentration alcoholic liver disease and liver disease is common in the body must be kept within fatty liver disease) and iron in patients with defined limits. Too little iron homeostasis has also been haemochromatosis and can result in anaemia while investigated. Research has that it can be successfully too much can cause damage helped define the mechanism ameliorated by phlebotomy to vital organs such as the liver by which the liver-derived therapy and heart. A central goal of the regulatory peptide hepcidin Iron Metabolism Laboratory is alters the expression of key Determined that hepatic to understand the mechanisms iron transport molecules in steatosis (fatty liver) of cellular iron transport the intestine, and thus iron is an important co- and the way in which these absorption, and also how the factor in patients with processes are regulated. A body directs hepcidin to bring haemochromatosis particular theme is to describe about these effects. the pathways of intestinal iron absorption and to understand A major collaborative study has In addition, this group how absorption is altered in led to the identification of a maintains a strong interest in disorders of iron metabolism putative haem transporter in the the pathogenesis, penetrance such as haemochromatosis and small intestine. Haem is a major and genetics of the iron loading thalassaemia. source of dietary iron but how disorder haemochromatosis. it is absorbed is very poorly Recent efforts in the laboratory understood at present. have been directed towards understanding physiological The laboratory continues variations in iron absorption at to generate evidence the molecular level. Situations that the level of differric studied include the modulation transferrin in the plasma, of body iron stores, changes in the major blood iron the rate of red cell production, transport protein, is an the acute phase response important determinant (which is associated with of hepcidin expression infection) and pregnancy. and thus of body iron Pathways by which the expression of homeostasis. the iron regulatory hormone hepcidin is regulated Iron Metabolism Laboratory Staff From left: Back row: David Raffelt, Deepak Darshan, Cameron McDonald, Melanie Beaton, Lawrie Powell. Middle row: Emily Hay, Paula Hawthorne, Jeanette Dixon, Greg Anderson (Laboratory Head). Front row: Priya Shah, Sarah Wilkins

55 Melanoma Genomics HIGHLIGHTS Professor Peter Parsons Discovered that expression of the melanoma-associated MIC-1 cytokine is regulated This laboratory combines expertise in cancer biology with genomics by the PI3 kinase and MAP and drug discovery. Cell communication networks in sun-induced kinase signalling pathways cancers, cancers of the head and neck and ovarian cancer reveal responses that address important issues of prevention and treatment Identified a candidate gene in the Wnt pathway The overall theme is to identify Such information might well for the progression of and study the function of establish gene expression ovarian cancer, from gene genes that are important in the pathways of fundamental expression profiling of development and treatment of significance in tumor tumors and normal tissue certain cancers, with the longer development. Similarly, the Found that loss of term aim of discovering agents role of a novel cytokine this expression of the HRev107 that can be aimed at specific laboratory found to be highly gene is associated with high targets. Several such genes expressed in melanoma sensitivity to protein kinase have been identified in ovarian progression has been further C activators and consequent cancer, squamous cell carcinoma elucidated and shown to be senescence in human breast, of the head and neck, and necessary for tumorigenicity in a melanoma and colon cancer breast cancer, to being followed mouse model. cells up at the functional level. Drug discovery has involved The above approaches applied screening large numbers of within a collaborative NHMRC novel compounds on selected program have led to siRNA tumor cell lines chosen for reagents being developed their particular signalling and applied to several gene pathway characteristics. These candidates for the progression compounds were sourced from of ovarian cancer and head and a variety of natural products. neck cancer. This followed on This group conducted the from extensive genomic and primary screening, purification immunohistochemical analysis and subsequent development of tumors, followed by data for several Australian analysis in order to establish companies. correlations between molecular markers and clinical responses. One of the lead genes found Right: Expression profiling reveals novel progression markers of ovarian cancer subtypes. A hierarchal in ovarian cancer has been clustering dendrogram grouping of over 3,000 successfully overexpressed genes selected using a non-parametric ANOVA and is now being functionally test (p<0.05) and multiple testing correction. evaluated in a mouse model. Blue, normal ovarian tissue; Yellow, benign ovarian tumors; Green, ovarian tumors of low malignant potential; Red, malignant ovarian tumors.

Melanoma Genomics Laboratory Staff From left: Back row: Adam Martyn, Glen Boyle, Peter Parsons (Head) Front row: Sharon Mason, Jenny Johns, Melissa Merritt

56 Molecular Epidemiology HIGHLIGHTS Dr Grant Montgomery Published the first genome wide linkage scan with evidence for significant The Molecular Epidemiology Group investigates patterns of disease linkage to endometriosis in families using high throughput genomics platforms to identify on chromosome 10 and genes and pathways contributing to disease risk suggestive linkage on chromosome 20 The overall theme of the fertility and may have practical laboratory is to identify variation implications for controlling Identified additional loss in genes and gene pathways fertility and infertility. Five of function mutations in contributing to risk for common hundred pairs of sisters from GDF9 in mothers of twins human diseases. The laboratory Australia and five hundred pairs and demonstrated that rare has a focus on women’s of sisters from the Netherlands mutations in the ovarian health with projects on the are being recruited for gene pathway controlling follicle genetics of endometriosis and discovery in these families. growth contribute to dizygotic twinning. Work is also twinning frequency The laboratory supports a undertaken on a range of other Developed improved diseases including migraine, range of studies in the Genetic Epidemiology Laboratory by analysis methods for data melanoma, asthma, alcohol and from DNA pools generated drug dependence. maintaining the large biobank of samples held by the Genetic from genome wide One aim is to identify Epidemiology and Molecular single nucleotide marker genes that influence risk for Epidemiology Laboratories for genotyping chips. Typing endometriosis in collaboration twin and family studies. DNA pools can significantly with Dr Sue Treloar and decrease the cost of genome Prof Nick Martin, who have This laboratory processes blood wide association studies assembled the largest collection samples, extracts DNA and of affected sister pair families prepares samples for large throughput genotyping and and triad families (a case scale genotyping projects. It gene expression analyses. and two parents), including is located with the QIMR SNP Genotyping services (zygosity 3,900 women with clinically genotyping facility. This facility testing, microsatellite and SNP diagnosed endometriosis. The has Sequenom MassARRAY genotyping) are provided for a first genome wide scan and and Illumina Bead Station range of projects. identified significant linkage to genomics platforms for high chromosomal 10 was published during the year. The Illumina Bead Station is being used to genotype markers under the linkage peak to find the gene or genes predisposing to endometriosis. Another project is trying to understand why twins run in some families. The tendency to conceive spontaneous dizygotic twins is complex and influenced by genetic and environmental factors. Finding the gene(s) responsible for twinning is likely to provide insights into mechanisms of female

Molecular Epidemiology Laboratory Staff Photograph – Included with Genetic Epidemiology Staff on page 52

57 Therapeutic Development and Clinical Research Division

The Therapeutic Development and Clinical Research Division is committed to the development and testing of immunotherapeutics manufactured within QGen. Laboratories included in the Division are the EBV Biology, Cancer Immunotherapy, Tumour Immunology and Cancer Therapy laboratories.

Five cell-based clinical trials have been sponsored Division Chair by QIMR. These trials are aimed at testing cell- Professor Denis Moss based therapeutics associated with prostate cancer, melanoma, glioma and cytomegalovirus. The success of these trials is dependent on the production of clinical material within the QGen to a standard approved by the Therapeutic Goods Administration (TGA) (referred to as GMP standard).

During the past year, Atlantic Philanthropies have announced that they will continue funding cell-based projects within the Division. This is extremely important in that it will provide support for the shortfall currently available from other funding agencies.

58 Translational Research HIGHLIGHTS Dr Geoff Beadle The Cognition in Breast Cancer Project continued to accrue large numbers of The goal of the Translational Research Laboratory is to foster participants research collaborations between scientists and clinicians for the benefit of patients and society Early results suggest that there is a measurable Breast cancer is a major public indicate that a measurable change in memory after health problem in Australia. change in memory can be treatment for early breast This year, well over 11,000 identified after treatment. cancer but there is also women in Australia will be However, further recruitment evidence of recovery of diagnosed with breast cancer and longer follow-up are memory after treatment. and there will be more than necessary to identify the full 2,500 deaths. The focus of range of cognitive changes as the Translational Research a result of treatment, and to As our understanding of both Laboratory is to develop assess patterns of recovery. The the nature of breast cancer research programs around an final results of this study will and the explosion of emerging understanding of the biology of provide important information therapeutic agents increases, breast cancer, the consequences about the long term functional more opportunities will of survivorship, and the and social outcomes for women become available for women engagement of women with with breast cancer. to participate in clinical trials breast cancer in research. and research projects such as An understanding of the the Cognition in Breast Cancer Significant improvements of biology of breast cancer is Study. Consequently there is survival after a diagnosis of an increasingly important an increasing need to address breast cancer have been the imperative in research in order ethical issues for women in result of early detection and to better understand both participation of such studies. more intensive treatments. prognosis and predictors of Cognitive impairment has response to the ever increasing The Translational Research been reported by women after array of therapeutic options Laboratory is currently treatment for breast cancer for women with early breast undertaking two research and the Cognition in Breast cancer. The Translational projects to evaluate the Cancer Study is setting out Research Laboratory continues understanding of women with a to evaluate the nature and to accumulate a large number diagnosis of breast cancer of the extent of cognitive change of breast cancer pathology ethics of participation in clinical after chemotherapy for breast specimens in order to trials and molecular research. In cancer, as well as the impact of provide a database for future addition, an important project is cognitive change on daily living. development and application currently underway to evaluate To date, more than 150 women of biomarker assays to predict the perception of cancer nurses have agreed to participate in outcome and response to about patient participation in this project and early results treatments. cancer clinical trials.

Translational Research Laboratory Staff From left: Sandra Stein, Geoff Beadle (Head), Katharine Kennedy

59 QIMR Sponsored Clinical Trials 2005-2006

Clinical Trial Investigators Funding Prostate cancer: An internal Investigators: Prof Kay Ellem, Royal Brisbane and Women’s solid-malignancy model for Dr Christopher Schmidt, Dr Bev Hospital Research Foundation vaccine therapy (NUQM00J1) Kerr, Mrs Linda O’Connor, Mrs $46,500 Cathy Davern (QIMR), Prof Frank Gardiner, Mrs Betty Scells, Ms Liz Hamlyn (University of Queensland, Royal Brisbane Hospital), Prof Greg Seymour (University of Queensland), Prof Derek Hart (Mater Medical Research Institute), Dr David Yaxley, Dr David Nicol (Urological Society of Australasia)

Phase III trial of an Investigators: Prof Kay Ellem, Dr Atlantic Philanthropies immunotherapy for Stage III Christopher Schmidt (QIMR), $350,000 (AJCC) melanoma based on Prof Michael O’Rourke (Mater cultured autologous dendritic Adult Hospital), Dr Barry cells presenting autologous O’Loughlin (Royal Brisbane and tumor cell antigens Women’s Hospital), A/Prof Mark (MRPQ0161) Smithers (Princess Alexandra Hospital), Dr Ian Hermans (Malaghan Institute, New Zealand)

Dendritic cell vaccination Investigators: Prof Kay Ellem, Royal Brisbane and Women’s trial for hormone refractory Dr Christopher Schmidt, Prof Hospital Research Foundation prostate cancer with Martin Lavin, Dr Michelle $46,500 autologous tumour as the Burger, Ms Linda O’Connor antigen (NRQ03J1) (QIMR), Prof Frank Gardiner (University of Queensland, Royal Brisbane and Women’s Hospital)

Adoptive immunotherapy Investigators: Dr Rajiv Khanna Leukaemia Foundation for the prevention of human (QIMR), Dr Geoff Hill (QIMR, $200,000 cytomegalovirus (HVMV) Royal Brisbane Hospital), Drs reactivation and disease Simon Durant, James Morton after allogeneic stem cell (Royal Brisbane Hospital), transplantation (QR-2002- Dr Leanne Lockwood (Royal CMV1) Children’s Hospital), Dr Suzanne Elliott (Q-Pharm)

60 Joint Research Programs

Australian Centre for International Tropical Health

The Australian Centre for International Tropical Health and Nutrition (ACITHN) changed its name to the Australian Centre for International Tropical Health (ACITH) in January 2006. This year saw the fourth renewal of the Public Health Education and Research Program of the Australian Government Department of Health and Ageing, and of ACITH. This core funding until 31 December 2010 will take our tropical health education, training and research activities to its twentieth year. In July 2005, Professor Brian Kay stepped down as Director, ACITH by a rotational arrangement with University colleagues and Professor Richard Taylor is wished every success in maintaining ACITH as one of Australia’s two national flagship centres for regional public health. Professor Kay has agreed to be Deputy Director, ACITH and to effectively represent QIMR. ACITH expects to further develop national leadership in international and tropical health, addressing emerging national priorities in indigenous public health and workforce development. It will respond to emerging and existing infectious disease threats that have bearing on national and regional biosecurity and disaster response, while recognising that lifestyle (chronic) diseases have assumed great importance to the overall burden of disease. The Centre is expected to take a lead role in improving the quality of research and its academic impact on population health. Because the new contract is more output driven, with payment conditional on achievement of designated milestones, it will be important for all QIMR ACITH members to assess how they can best contribute to these goals. Whereas research and research training are important at the individual level, the growing of collaborative relationships with other bodies involved in public health is also seen as important. In 2005, ACITHN and the Australian Biosecurity CRC signed an agreement to foster collaboration and greater effectiveness, and in 2006, Dr Kathy Andrews was nominated to enhance joint activities between QIMR (and ACITH) with Griffith University and the new Griffith Medical Research College. Collaborative linkages to the Pacific Asia Travel Association were enhanced by Professors Kay and Jeff Wilks (UQ Centre for Tourism and Risk Management) who agreed to be keynote discussants at their Macau conference during April 2005. During the summer months, Drs Peter Ryan and Michelle Gatton launched a trial to evaluate the usefulness of their Ross River virus Early Detection and Surveillance System (RREDS), facilitated through the collaboration of local governments in Queensland, Queensland Health and the QIMR IT department to develop the web base for access. ACITH has a proud record at QIMR, facilitated in part through these collegial collaborations. The Centre thanks its partners for their effort and looks forward to the future. The Ross River virus Early Detection and Surveillance (RREDS) System was developed in an effort to assist Local Governments and facilitate responsive mosquito control and disease prevention interventions. A web-based, geographic information system, it provides timely data on Ross River virus disease incidence throughout Queensland.

The system was trialed by 15 Queensland Local Governments during the year, and allowed users to actively track disease patterns during the most recent transmission season, providing seasonal data on unusually high disease occurrence in South East Queensland during February and March 2006. The success of the system during the initial trial period provided a robust platform for the statewide release of the system.

61 Joint Research Programs

CRC for Vaccine Technology This year saw the closure of the CRC for Vaccine Technology which has been located at QIMR, as host partner, since its inception in 1993.

From the beginning, the CRC has had excellent leadership with Sir Bruce Watson AC as the initial Chairman and Professor Michael Good as Director, assisted by a committed Board of Management. Researchers from partner institutions addressed the challenges implicit in the Mission and Objectives of the Centre – to develop and improve vaccines for medical and veterinary purposes.

In 1999, funding was achieved for a second term with new partners, staff and Board. Professor Anne Kelso was appointed Director and led the Centre admirably through the last six years of its existence, with a number of Committees to assist with the Centre’s executive, commercial and education aspects.

A lasting legacy of the CRC-VT is the students who have been able to progress their careers under quality supervision of some of the nation’s best medical researchers. Presentations made by the Above: Mr Ian Goddard, second students have been one of the highlights of the Centre’s Annual Chairman of the CRC-VT, and Professor Conferences, functions through which they were able to interact Anne Kelso, Director of the Centre with contacts that will be of inestimable value in their futures. during its second round of funding

The year just finished has been very intense, with considerable involvement in legal agreements associated with the closure. Much effort was needed to ensure that the Intellectual Property which has been developed will find a “champion” to continue the good work into the future. In this context, QIMR is gratefully acknowledged for the role it has undertaken to be the Trustee for the other Parties in many areas. A number of inventions and discoveries have led to commercial arrangements. Major international companies and research funding organisations have recognised the value of the research conducted through the CRC-VT. The spin-off company, VacTX Pty Ltd, is in the early stages of its development.

A decision was made by the Board not to seek third term funding or to create a modified CRC for consideration in the last round of funding. The emphasis on commercial outcomes and the need for all parties to commit to a seven year programme were significant issues.

The last event for the CRC-VT was the extremely successful Symposium – Capturing Value from Biomedical Research – held in Melbourne in May. Dame Bridget Ogilvie headed a most impressive list of speakers, who together helped to make it a memorable occasion and a fitting legacy for the CRC.

Ian Goddard Above: Sir Bruce Watson - first Chairman Chairman of the CRC-VT and Below: Professor Michael Good - first Director

62 Spin-Off Companies

Q-Pharm Pty Ltd Q-Pharm Pty Ltd is a clinical trials company specialising in Phase I and II trials and bioequivalence and bioavailability studies. The company conducts trials on pharmaceutical, biotechnology and complementary medicine products spanning the areas of therapeutic, diagnostic and prophylactic agents. Q-Pharm Pty Ltd offers the best appointed early phase clinical trials facilities in Australasia, with facilities including a specialised 12-bed clinic for the conduct of the most medically demanding trials and an open plan 36 bed facility for larger healthy volunteer trials. The company concluded its fourth full year of trading as a private company on 30 June 2006 and has continued the very satisfactory growth shown in the previous year. Highlights include: Gross revenue from operations has increased in line with forecasts as profitable trade continues. Continued growth in all areas of the business with Phase I/II clinical trials now accounting for approximately fifty percent of revenue. Bioequivalence Studies remain a very strong contributor to the company’s operation. Broadening of the client base has continued in accordance with the business plan with sixty percent of Q-Pharm’s dealings now with international clients. Q-Pharm played a leading role in the establishment of the Queensland Clinical Trials Network and has been actively involved in promoting both the company’s and Queensland’s capabilities at various national and international conferences. Healthy employment growth continued in the company which now supports around 50 full-time- equivalent positions.

Q-Gen Pty Ltd Q-Gen Pty Ltd, established as a commercial spin-off company for contract manufacture of investigational therapeutics, is now in its second year of trading. This year has seen substantial structural reorganisation and expansion to ensure that operations are carried out with a customer satisfaction focused marketing strategy. A number of contracts have been successfully completed or are in progress in the facility including: Mater Medical Research Institute – Development of a bioprocess for the cGMP manufacture of a human/ chimeric IgG4 antibody to an antigen expressed on human blood dendritic cells and the subsequent cGMP manufacture of the antibody for clinical use; Phoenix Eagle Company Pty Ltd – Translational development and GMP manufacture of an investigational therapeutic in the treatment and preventation of ulcers; Murdoch Children’s Research Institute – Bioprocess Development of attenuated live Rotavirus Vaccine; Incitive Pty Ltd – Production of Native and Recombinant ICV-0019 for preclinical studies in autoimmune disease targets; Herdvac Pty Ltd – GMP compliant masterbanking of vaccine organism and Implicit Biosciences Pty Ltd – GMP storage, clinical release and recall or materials for a clinical trial in an infectious disease indication (HepC). Q-Gen is presently qualifying a new aseptic vialing suite so that Q-Gen’s customers will be able not only to produce their recombinant actives at the facility, but also have these actives formulated and filled, labelled and packaged for clinical trials.

63 Vaccine Solutions Pty Ltd Vaccine Solutions is a joint venture between the Queensland Institute of Medical Research (QIMR) and CSL each of whom have equal shares. Vaccine Solutions was established by the CRC for Vaccine Technology. Its purpose is to commercialise the intellectual property developed in CRC programs. During 2005-6 the operations of Vaccine Solutions was wound down and the company was prepared for the transition to a wholly owned company of CSL which will occur in late 2006. Many of the licenses and contracts that were held by Vaccines Solutions have been assigned to QIMR who is the trustee for the CRC-VT with a few specific contracts being maintained in Vaccine Solutions under the management of CSL Limited.

Replikun Biotech Pty Ltd Replikun Biotech (a biotechnology company formed by QIMR in March 2005) took great strides in the last year, achieving some significant milestones in its development. The company is commercialising the Kunjin Replicon, a novel delivery system for vaccine and immunotherapy design. The company was awarded a $1 million Commercial Ready grant in January 2006, which will assist the development of its lead oncology product, KUN-GMCSF.

An important part of that project is the manufacture of GMP master and working cell banks, being done by Cobra Biomanufacturing in the UK. The cell line will be an important asset for Replikun as it seeks to create value by partnering its technology with biopharmaceutical companies.

Adipogen Pty Ltd

Adipogen is a company that was established by the University of Queensland using intellectual property that was developed by staff of the University of Queensland and the Queensland Department of Health. The Queensland Institute of Medical Research manages the interests of Queensland Health in the commercialisation of the intellectual property and is a minor shareholder in Adipogen.

64 Corporate Division

The Corporate Division provides support to almost 800 QIMR scientists through groups covering finance and administration, human resources, scientific services, information technology, building services, regulatory affairs, business development and safety.

This year, the Finance team has further developed strategies to enhance and support the integration of financial information and reporting both for internal users and external stakeholders. This has included development of a grant management system which integrates the grant register with receivables to ensure that grant revenue inflows are monitored and received on a timely basis. The team has also responded to a significant increase in compliance requirements, particularly in the area of audit of project grants, and has successfully completed a comprehensive internal audit program conducted on an ongoing basis throughout the year.

From left: Back row: Joy Black, Nerida Fox, Mark Weaver, Simon Jaremzsuk, Damian James, Mark Feodoroff, Margaret Stromberg, Karen Moran, Catherine Baldwin. Third row: Melanie Anderson, Lorna Lane, Famena Khaya, Tracey Laing, Kathy Laza, Christine McNally, Pauline Donnelly, Xiaping Lin, Peter Kaim. Second row: Lachlan Ward, Chris Ward, Nicole Green, Michael Staley (COO), Michael Good (Director), Marlene Cornell, Helen Leonard, Juan Cooper, Gerald Haaima. Front row: Agnes Nutley, Donalee O’Brien, Madeleine Kersting, Roxanne Gray, Mandie Quince, Jann O’Keefe, Jennifer Ho, Tracey Checkley, Janet Fox

65 Human Resources has been Core scientific support for gene expression analysis: largely involved in the ongoing QIMR researchers is provided Illumina Beadstation funded process of developing, by a dedicated team of by the NHMRC, live cell implementing and evaluating professionals in stores and imaging funded by the NHMRC progress of new HR systems purchasing, glassware, animal and automated scanning of and procedures, and also holding and culture media. pathology slides funded by the formalising and reviewing A range of state-of-the-art Golden Casket Foundation. existing practices. Significant biotechnological services such progress was made towards as DNA sequencing, flow Building Services have formalising and updating the cytometry, confocal microscopy successfully brought on line regulatory framework governing and histotechnology are also both level C of the CBCRC employment of QIMR staff, offered. building and the fully re- including the introduction of fitted animal facility within new employment contracts for A highlight this year was the the Bancroft Centre with all all categories of staff. refurbishment of the Animal redundant animal containment Facility, completed in 2005 equipment disposed of by either Negotiations for a replacement with all animal operations recycling or being reused by Certified Agreement and successfully transferred in other facilities. The auditorium salary increases for staff were October. The cleaner, more audio visual equipment upgrade commenced in conjunction with environmentally enriched has been successfully completed the Department of Industrial animal holding areas together with optimum performance Relations and the implications with the higher level of being achieved using digital of the Federal Government’s containment have been well control technology. All major WorkChoices legislation for received by researchers and items of plant and equipment QIMR are being monitored on facility staff. QIMR researchers have been successfully tested an ongoing basis, pending the also benefited from several and overhauled as required State Government’s strategy for major equipment purchases to without any disruption to the statutory authorities covered by support technology platforms facilty. the legislation. providing genotyping and

From left: Back row: Gordon Madders, Jean-Paul Fahrner, Andrew McKee, Alan Stockman, Robert Tyrell, Dave Patrick, Merrick Bugden. Middle row: Andrea O’Regan, Nadja Felder, Marcia McInnes, Sarah James, Ruth Lee, Valmai Mathews, Sam Watkins Front row: Heather Matthews, Paula Hall, Grace Chojnowski, Juan Cooper, Macky Edmunson, Sandra Woods, Paul Collins, Linda Jones

66 Information Technology this Committee on behalf of the Safety Services provided audit year began the adoption of HREC regarding the second and review to ensure that ITIL (IT Infrastructure Library, round of the revision of the QIMR’s operations and facilities an internationally accepted National Statement on Ethical comply with the appropriate standard for best practice in Conduct Involving Humans. regulations. In March 2006, IT). This has already realised An external audit of QIMR doors were added to the ends benefits in the areas of change animal facilities, animal of the corridors on all lab floors management and process research activities, and AEC in Bancroft Centre to enable control. QIMR’s network operations was conducted by QIMR to apply for certification has seen an expansion of the Queensland Department under OGTR guidelines for active and passive network of Primary Industries and these floors to be classed as infrastructure providing Fisheries on October 2005 to PC2 containment rather then additional capacity and greater assess compliance with the individual labs being certified. network resilience. Additional Queensland Animal Care and OGTR certification was also servers and disk storage have Protection Act, 2001. obtained for new facilities on C been added to cope with the floor CBCRC and the expanded data and processing demands The Business Development G floor facility in Bancroft. of modern medical research. Office has a number of QIMR now has 25 OGTR A significant collaborative strategies in place to facilitate certified facilities. The Institute scientific project with the the identification, protection was audited under the Radiation Mosquito Control laboratory and commercialisation of novel Safety Act by Radiation Health has received major IT support, research carried out by QIMR and was found to be compliant resulting in the development scientists. These include the with good radiation practice. of the web-based RREDS formation of collaborative This is the first QIMR radiation (Ross River Early Detection relationships with medical practice audit since the new Surveillance) system which institutes and universities, Act commenced in 2000. Over has been very well received by both at home and abroad, the year, the Safety Committee Local Government Authorities the out licensing of patented either approved or returned throughout Queensland. There technology and the formation for amendment 378 safety is considerable interest in of start-up companies. QIMR protocols, 309 risk management expanding the system to include now have business relationships forms and 445 OGTR forms. other notifiable diseases. with over thirty two commercial companies, such arrangements In Regulatory Affairs, the include licensing of QIMR QIMR Human Research Ethics patented technology as well as Committee (HREC) and the contract research arrangements. QIMR Animal Ethics Committee QIMR has a proven track record (AEC) reviewed 311 and as a contract research and 284 research applications development facility. QIMR respectively. To keep abreast recognise companies’ need of the changes in the ethical to protect their intellectual and regulatory framework, property, and their need to HREC members attended the develop products. An example 5th Annual Health and Medical of this during 2005-2006 was Research Conference and the signing of a research and the 3rd Annual Australasian development agreement with Biospecimen Network Meeting, Incitive Limited to develop both in Brisbane in November Incitive’s lead compound, 2005. The HREC Chairman ICV-0019 (formerly CCS), for provided a written submission the treatment of inflammation to Australian Health Ethics and autoimmune disease.

67 Development and Marketing

The Development and Science cannot be conducted with individuals including Clive by stealth. Therefore scientists Berghofer and companies such Marketing Department collaborate with colleagues as Suncorp, as well as many from state to state and around others whose names are listed was established in 1994 the world in a common search on pages 107-112 of this for cures to hitherto incurable report. It is their contribution to to raise awareness and diseases. This is vital if we are the most noble of goals which funds for QIMR. The to play a meaningful role in the is outstanding and enhances the effort to eliminate cancer and quality of our research, inspiring Department is responsible many diseases and the fear that our scientists to greater goals. they engender. for many activities We must also pay tribute to the Equally as important is the many people who attend the including fund raising involvement of the wider Development and Marketing community. To this end, the Department’s various fund- events, bequests, media role of the Development and raising events or participate Marketing Department is to through donations, gifts-in- releases and liaison, share the research progress kind, sponsorship, spread the and breakthroughs with the word about QIMR through their newsletters, brochures, community at large and inform networks and leave provisions powerpoint presentations them of advances in health and in their wills. Quite simply, medical research. One of the our research would not exist and public awareness fundamental activities of the and would certainly not be Department is to disseminate propelled forward without their campaigns. research findings to numerous unwavering support. community groups and associations and, as QIMR has As QIMR celebrates 60 years no budget for advertising, this is of research & results, being done through external speaking prepared for the possibilities presentations and providing that lie in research is not simply Rupert McCall launches the Green and just a matter of applying talent, Gold Malaria poem campaign in support tours of QIMR’s laboratories of QIMR research in November 2005 and facilities. time and collaborative effort. Since 1995, more than 9,000 The ongoing relationship people learned more about between medical research and vital medical research and its supporters is crucial and how this impacts on health, most definitely one of mutual life and longevity directly via benefit, as funding is essential these community initiatives. for research and research is Furthermore, our quarterly essential for solving the many newsletter, LifeLab and no-cost medical mysteries that afflict media articles, are also vital in our community. Each one of communicating our research our donors assists the vigorous to donors, and generates research effort at QIMR and, significant donations to ensure in the long term, contributes to that life-saving medical research results of immense community continues. benefit. To fast-track QIMR’s judicious Thank you for joining QIMR application of medical science, on the journey of medical The Development Department discovery. has built numerous relationships

68 Official Committees 2005-2006

QIMR COUNCIL Scientific Sub-Committee Biosafety Committee Sir Bruce Watson (Chair) (HREC) Dr Helen Leonard (Chair) Mr Paul Wright (Deputy Chair) Dr Peter Parsons (Chair) Dr David Tscharke (Deputy Prof Bryan Campbell Dr Ian Wilkey (Deputy Chair) Chair) (to Apr 06) Prof Peter Brooks Dr Greg Lawrence Dr Glen Boyle (Deputy Chair) Mr Christopher Coyne Dr Alex Loukas (from Apr 06) Prof Judith Clements Dr Christopher Schmidt A/Prof Peter Upcroft Mr Paul Fennelly Ms Dixie Statham Mr Paul Collins Dr Gerry FitzGerald (to Aug 05) Dr Agnieszka Mitchell Dr Juan Cooper Prof Lyn Griffiths Dr Helen Leonard Dr Geoff Gobert Prof Alan Lopez Dr Kadaba Sriprakash Dr Therese Murphy Dr Paula Marlton (from Feb 06) Dr Marion Woods Mr Michael Staley Dr Jeannette Young (from Sep 05) Dr Susan Jordan Mr Alan Stockman Ms Donalee O’Brien – Secretary Dr Christine Rzepczyk Committees reporting to Mr Andrew King Council: Clinical Trial Protocol Committee Prof Denis Moss (CTPC) Dr Greg Lawrence (to June 06) Finance and Audit Committee Dr Peter Roeser (Chair) Dr Michael Batzloff Sir Bruce Watson (Chair) Dr Jason Lickliter (Deputy Chair) Mr Ron Buttenshaw Prof Bryan Campbell Dr Agnieszka Mitchell Ms Jo Chow - Secretary Mr Bruce Phillips Prof Andrew Boyd Mr Rod Wylie Dr Suzanne Elliott Equipment Committee Dr Greg Lawrence Prof Andrew Boyd (Chair) Appointments & Promotions A/Prof James McCarthy Dr Juan Cooper Committee Prof Denis Moss Dr Kum Kum Khanna Prof Peter Brooks (Chair) Dr Michael Rudd A/Prof James McCarthy Prof Graham Brown Dr Christopher Schmidt Prof Denis Moss Prof Julie Campbell Ms Allison McLean Ms Allison McLean Prof Judith Clements Dr Lesley Ross-Lee Mr Chris Ward Dr Andrew Cuthbertson Dr Geoff Beadle Higher Degrees Committee Prof Lyn Griffiths Dr Michael Moore Dr Tom Sculley (Chair) Prof Alan Lopez Ms Donalee O’Brien – Secretary Prof Michael Good Prof James McCluskey Council Personnel Dr Graham Kay Prof Joe Trapani Administration Committee Dr Nathan Subramaniam Prof Michael Good (ex officio) Sir Bruce Watson (Chair) A/Prof Andreas Suhrbier Ms Patricia McCormack A/Prof Alan Lawson Mr Rod Wylie A/Prof Peter O’Rourke Human Research Ethics Mr Paul Wright Dr Judith Greer Committee (HREC) Dr Peter Ryan Dr Ian Wilkey (Chair) Committees reporting to the Dr Jackie Upcroft Dr Roger Allison Director: Dr Katherine Trenholme Sr Regis Dunne Dr Sue Treloar - Secretary Mr Angus Edmonds Management Advisory Ms Simone Cross Ms Clare Endicott Committee (MAC) Ms Janelle Stirling Ms Patricia Johnson Prof Michael Good (Chair) Ms Sarah-Jane Cozzi Ms Claire Riethmuller Prof Adèle Green Ms Lynette Beattie (to Dec 05) Mr David Russell Prof Andrew Boyd Ms Jyoti Jonnalagadda Dr Christopher Schmidt Prof Martin Lavin Dr Greg Lawrence Prof Denis Moss Mr Michael Staley ex officio Mr Michael Staley Dr Agnieszka Mitchell ex officio Dr Kum Kum Khanna Ms Jo Chow – Secretary A/Prof James McCarthy A/Prof Greg Anderson Ms Janelle Stirling Ms Nerida Fox – Secretary

69 Joint Consultative Committee Consumer and Community Library Committee Ms Nicole Green (Chair) Participation Committee Mr Christopher Ward (Chair) Dr Grant Ramm Prof Adèle Green (Chair) Prof Michael Good Dr Penny Webb Dr Geoff Beadle Mr Michael Staley Prof Michael Good Dr Amanda Spurdle Dr Greg Anderson Mr Michael Staley Prof Denis Moss Prof Andrew Boyd Dr Kum Kum Khanna Ms Janelle Stirling Dr David Whiteman Mr Rick Woods Dr Glen Boyle Ms Jennifer Ho Mr Paul Collins Ms Simone Cross Dr Lihua Zhang Ms Pauline Donnelly Ms Jann O’Keefe Prof Dave Kemp QPSU Representative Ms Michelle Lagana Dr Rajiv Khanna QNU Representative Mr Felipe Beltran Dr Arne Mould QIMR TRUST Medical Advisory Board Dr Darren Krause Mr Paul Wright (Chair) Prof Peter Brooks (Chair) Dr Vicki Whitehall Mr John Garnsey Prof Andrew Boyd (Deputy Ms Melina Georgousakis Mr Ian Manly Chair) Mr Sri Shekar Mr Rod Wylie Dr Paul Bartley Mr Richard Joel (Dec’d Dr Geoff Beadle Committees reporting to the 20/06/06) Dr Ian Bunce Chief Operating Officer: Mr Bruce Phillips Dr Don Cameron Ms Margot de Groot Prof Adèle Green Commercialisation Committee Ms Patricia McCormack Prof Michael Good Dr Tracey Mynott (Chair) Ms Jane Seawright Dr Barbara Leggett Dr Kate Andrews Dr Joseph McCormack Dr Mark Egerton Committees reporting to Dr Paul Sandstrom Mr Michael Staley Trust: Dr Mark Smithers Prof Andrew Boyd Dr John Varghese Prof Dave Kemp Investment Committee Dr Michael O’Rourke A/Prof Andreas Suhrbier Mr Rod Wylie (Chair) Mr Paul Wright Mentoring Committee IT Committee Mr Ian Manly Dr Grant Ramm (Chair) Dr Tom Sculley (Chair) Mr Bruce Phillips Dr David Whiteman Mr Christopher Ward Dr Nick Hayward Mr Michael Staley Marketing Committee Dr Georgia Chenevix-Trench A/Prof Scott Burrows Mr John Garnsey Dr Rajiv Khanna Mr Mark Feodoroff Ms Margot de Groot Scientific Advisory Board Ms Michelle Gatton Ms Jane Seawright Prof Graham Brown (Chair) Ms Heather Matthews Ms Michelle Lagana Prof Beth Newman Ms Nirmala Pandeya Prof Nicos Nicola Prof Peter Upcroft Prof Joe Trapani Dr Nathan Subramaniam Dr David Smyth Seminars Committee Dr Glen Boyle Prof Michael Good (Chair) Mr Mark Spanevello Dr Grant Montgomery Dr Nuri Gueven Prof Martin Lavin Dr Agnieszka Mitchell Dr Katharine Trenholme Dr Juan Cooper Ms Jann O’Keefe Ms Jann O’Keefe

70 Postgraduate Training at QIMR

QIMR offers an outstanding examples include: Alberto environment for advanced Pinzon-Charry who received the training in biomedical research ASMR Queensland Premier’s at an international level through Postgraduate Student Award, the excellence of its scientists, Alyson Ashe who received an its wide network of research award for the best poster at the collaboration both nationally Lorne Genome Conference and and internationally, and its Manuel Ferriera who gave the world class facilities and support best Student Oral Presentation services. Postgraduate students at the 5th Australasian Human represent a valuable part of the Gene Mapping Conference, research effort at QIMR, and The Higher Degrees Committee the Institute strives to provide (HDC) continues to oversee them with a solid grounding in student activities at QIMR. medical research for subsequent careers either in Australia or Among the duties of the abroad. Committee are the evaluation of students prior to their Thirty six new higher degrees acceptance as candidates students were admitted this at the Institute, monitoring year and fifty students visited student progress, providing QIMR. Currently the student education programs for body at QIMR comprises 110 students, establishing policy on PhD, 15 research Masters issues relating to students, and and 29 Honours students. In assessing applicants for travel addition to students working awards, Honours scholarships towards degrees, the Institute and PhD top-up scholarships. maintains an active Summer Vacation Scholarship Program Increasing emphasis on the and welcomes many work timely completion of research experience students from local degrees has meant that the high schools. Most students at monitoring of student progress QIMR are enrolled through The is becoming an ever more University of Queensland with important activity and members particularly strong links existing of the HDC devote considerable with the School of Population time to the rigorous review Health and the School of of students during their study Medicine. An increasing program. This year the HDC number of students now enrol has undertaken 43 reviews of through other Universities students. including Griffith University, The Institute continues a two- the Queensland University of part workshop for supervisors Technology and the University of postgraduate students. of the Sunshine Coast. This workshop is conducted in Postgraduate students from conjunction with the Teaching QIMR have continued to make and Educational Development an impact in the wider scientific Institute and the School of community this year and again Population Health of the have received a number of University of Queensland. significant accolades. Some QIMR Student Retreat 2006

71 Completed Students 2005-2006

Student Name University / Supervisors Thesis Title PhD Jacqui Fleming QUT, JA Lopez, CW Schmidt, T Cross-presentation of tumour antigens by dendritic cells may Fosters require phagocytosis of early apoptotic tumour cells Rebekah Brennan UQ, S Burrows Cytotoxic T cell control of viral infection in humans Mark Pearson UQ, A Loukas, D McManus, D Identification, characterization and vaccine efficacy of membrane Smyth proteins of Schistosoma mansoni Itaru Anraku UQ, A Suhrbier Induction of long lasting protective CD8+ lymphocyte responses buy Kunjin replicon-based vaccine vectors Lynette Beattie QUT, M Good The role of the spleen in malaria: Cellular changes that affect the development of immunity Alan Brockman UQ, D McManus In vitro and genetic studies of Plasmodium falciparum drug resistance in northwestern Thailand Shannon Duffy UQ, A Boyd The role of the EphA1 receptor tyrosine kinase during embryogenesis and cancer Con Stylianou UQ, A Boyd The role of Eph an ephrins in melanoma metastasis and as potential targets for immunotherapy Tanya Bell UQ, D Purdie, A Green, S Treloar Risk factors for Endometriosis Nikki Vickaryous University of Sydney An ENU screen for modifiers of epigenetic state Emma Whitelaw Manuel Ferreira UQ, N Martin, D Duffy Genetic risk factors for allergic asthma Sarah Medland UQ, M Wright, N Martin, D Duffy Genetic epidemiology of behavioural laterality Rayleen Bowman UQ, P Parsons Mechanisms of human bronchial carcinogenesis Sarah Cozzi UQ, P Parsons Molecular targets of anticancer PKC activators in the treatment of melanoma Tanya Newton UQ, P Parsons Factors associated with treatment response and survival among women with late stage ovarian cancer Kerry Roper UQ, B Dugan Cellular and molecular targets of allelochemicals from marine sponges Liam St Pierre QUT, Martin Lavin Identification and comparative analysis of novel factors from the venom gland of the coastal taipan (Oxyuranus scutellatus) and related species Michael Hamilton UQ, K Ellem, C Schmidt The development and use of cytokine producing microcapsules for anti-angiogenic therapy in mouse melanoma Ranbir Sarai UQ, J McCarthy The role of B-tubulin polymorphism in benzimidazole drug resistance Simone Smith GU, K Andrews Towards a humanised rodent malaria cytoadhesion model MPhil Scholars Penny McBride UQ, A Green Association between epidermodysplasia verruciformis-associated human papillomavirus and squamous cell carcinoma, and keratosis development: a follow up study BSc(Hons) Grace Eng QUT, G Ramm, T Pereira, T Walsh Bile aid induction of chemokine expression in cholestatic liver disease Vanessa Oaakes QUT, KK Khanna Janelle Hancock QUT, M Lavin, A Kijas BMedSci Rong Bing The University of Melbourne The role of protein kinase C-zeta in activation and survival of the G Ramm, R Ruddell, M Bertrand- hepatic stellate cell Philippe

72 Student Awards

Alyson Ashe Best Poster Prize Best poster at Lorne Genome Conference, Jan 2006 Simon Apte Basil Shaw Fellowship Australian Rotary Health Research Fund, Jan 2006 Anita Burgess Travel Award Queensland Cancer Fund, Apr 2006 Bennett Datu ANPRN Travel Award Visit laboratories of colleagues in USA and UK, Feb 2006 Matthew Dixon 2nd Prize Best Student Presentation UQ School of Population Health Manuel Ferriera Best Student Oral Presentation 5th Australasian Human Gene Mapping Conference, Nov 2005 Melina QIMR 2005 Best Student Presentation QIMR Student Seminar Series, Dec 2005 Georgousakis Elke Hacker QCF Travel Grant Attend Conference, Sep 2005 Elke Hacker Thenie Baddams Award from the Australian Attend Conference, Aug 2005 Federation of University Women Susan Jordan 1st Prize Best Student Presentation UQ School of Population Health Susan Jordan 2nd Prize Oral Presentation QIMR Student Conference, Nov 2005 Tammy Maxwell 3rd Prize Oral Presentation ASMR Student Conference, June 2006 Tammy Maxwell QCF Travel Grant, QUT Grant-in-aid and Attend International Conference, May-Jun 2006 QIMR Travel Grant Tammy Maxwell QUT Development Program Laboratory Visit Michelle Neller Runner up – Best Oral Presentation UQ School of Medicine Postgraduate Student Conference, Sep 2005 Michelle Neller Poster Prize UQ School of Medicine Postgraduate Student Conference, Sep 2005 Alberto Pinzon- ASMR Queensland Premier’s Award Postgraduate Medical Research Charry Najju Ranjit ARC/NHMRC Parasitology Research Attend Woods Hole Molecular Parasitology Course in Network Travel Award USA, Jun 2006 Nikki Vickaryous Promega Student Award Selected to give presentation at Lorne Genome Conference, Jan 2006 Nicci Wayte Top Up Scholarship Smart State, Queensland, Jan 2006 Nadia Whitelay University Medal University of Sydney Academic Medal

73 Education Program

QIMR continues to focus on science-related resource In the first, 25 biology teachers stimulating, attracting, training directory LEAP (Life Science and school lab assistants and mentoring students in Education Advancement isolated their own DNA, their progression towards a Partnership) for teachers in amplified it using PCR, and then career in science. Students are Queensland. did gel electrophoresis to detect engaged with at three critical their gene polymorphisms. Four stages: Senior High School The QIMR High School Lecture scientists spoke about the way (Biology, Physics, Chemistry), Series had 350 Senior Biology they use this biotechnology as undergraduate science or students and their teachers in their research and to medicine students and during attend the Institute’s biannual define disease patterns. One their postgraduate science or High School Seminars held in teacher shared her use of this medical degree. This year, the October 2005 and April 2006. technology at Cavendish Road focus has been on partnering This year, the series was able State High School. with the QBEN (Queensland to be videoconferenced to In the second workshop, Biotechnology Education some regional schools who had Network), a group of senior teachers and lab assistants videoconferencing facilities, cloned some DNA. Talks biology teachers, providing enthralling students in both professional development followed on the medical, audiences and stimulating a lot research and everyday use of that translates to their science more questions after each of classrooms. recombinant proteins from the seminars. cloned DNA. A tour of the Encouraged by the Queensland Alongside the High School new Protein Discovery Centre Department of Education and Seminars, two “Hands- at QIMR and a presentation Peter Andrews, Queensland’s on-Science: Application to by Peter Musk, Head of Chief Scientist, a partnership Health and Disease” teacher the Biology Department at with similar teacher/student workshops were held in the EBV Gympie State High School science development programs Molecular Biology laboratory of and former QIMR scientist, (BioQuest, SBRI) in the USA QIMR. revealed many applications and is also being formed. This is resources for biology teachers. supported by a Memorandum “ I haven’t been in a lab for 25 Strategic planning by Chris of Understanding by the years – excellent day. I was really Kern and teacher networking Queensland Government with nervous at first, but it was really were also included in the two great getting hands-on, working Washington State to share and day workshops. Education back at the bench” develop biotechnology at all Queensland played a vital part levels. “Although the gel prac was in organising this professional not new - seeing a variety of development for teachers. Recently all Brisbane bioscience- approaches to teaching students related educators have how to master using the Other Education activities formed a cooperative group equipment was invaluable” with high school groups, such called QWAG (Queensland “The informal meeting of staff as tours of QIMR by senior Washington Advancement allowed for networking and physics and biology students Group) whose aim is science discussions on alternate ways for both private and state outreach. This group aims of doing pracs, changes in schools continue, as does the to form practical links and law, waste disposal, funding High School Work Experience share resources both locally procedures and sourcing program. Many of the equipment” and internationally. As part postgraduate students here are of QWAG, Ms Simone Cross, Comments from attendees at increasingly interested in doing QIMR Education Coordinator, the special teachers workshops science outreach within and is compiling a comprehensive – Hands-on-Science outside of QIMR.

74 Awards

Derrick-Mackerras Memorial Lectures

Each year, an eminent member of the scientific community is chosen to deliver the Derrick-Mackerras Memorial Lecture, named for the founding Director and the founding Deputy Director of QIMR

Rationale and Plans for Moving from QIMR Bancroft Modern Genomics, Immunology, 2005 Dr Stephen L. Hoffman and Molecular Biology to Basic Medallists Parasitology and Entomology to Develop an Effective Malaria Vaccine The name Bancroft is 2004 Dr James Watson B2B – From Bone to B Cells synonymous with excellence Human Genes and Cloning People: 2003 Professor Bob Williamson The Medical Realities and the Public in scientific and medical Fears endeavour, and is an enduring Public Health, Human Rights and the memorial to the family whose Development of Civil Societies. What 2002 Professor Fiona Stanley has health and medical research got efforts did so much to shape to do with social justice? the direction of biomedical The Genomics Revolution to Prove a 2001 Sir Gustav Nossal scholarship in Queensland. New Model for Spaceship Earth The QIMR Bancroft Medal Human Organ Transplantation in the 2000 John M Vierling MD New Millennium: Understanding and is awarded to those who Controlling the Immune Response have made an outstanding Disease Eradication and Bioterrorism: contribution to QIMR. 1999 Professor Frank Fenner Opposite Ends of a Public Health Spectrum Indigenous Health: Monitoring the Mr Mark Weaver (2005) 1998 Dr Lois “Lowitja” O’Donoghue Vital Signs Ms Sue Cassidy (2004) Killer Cells and the Control of Viral 1997 Professor Peter Doherty Infections Professor Peter Parsons (2003) The Support of Medical Research: Dr Suzanne Elliott (2003) 1996 Professor Bridget M Ogilvie People, Programs and Policies Mrs Beth Dawe (2003) 1995 Professor C Thomas Caskey Genetics and the Future Mrs Verion Conley (2003) 1994 Dr Baruch Blumberg Evolution, Sex and the Hepatitis B Virus Ms Christine Borthwick (2002) Modern Genetics Research and its 1993 Professor M Ferguson-Smith Consequences for Society Dr Peter Upcroft (2002) Life and Death of Cells in the Mrs Heather Matthews (2001) Immune System: Implications for Mr Erin Fleay (2001) 1992 Professor J J Owen Susceptibility to Infections and Disorders of the Immune Response Mr Chris Ward (2000) Genes, Galaxies and Chosts! Science, Mr Allan Stockman (2000) 1991 Professor Chev Kidson Medicine and the Future of Man Ecology and the Human Future: Professor Brian Kay (2000) 1989 Paul Ehrlich cosystems, Health and Public Health Queensland Medical Overview of the History of the Laboratories (1999) Struggles and the Successes in 1988 The Honourable Mike Ahern the Development of Science and Sullivan & Nicolaides (1999) Technology Policy in Queensland Ms Michelle Lagana (1997) Parasites and Mankind: The 1985 Dr Louis H Miller Challenge of Malaria in Human Ms Lee Casey (1996) History Professor John Kerr 1984 Dr Steven Jay Gould Evolution Beyond Darwin Mr Fergus Wilson The Future of Medicine - Five 1983 Dr Robyn Williams Nightmares Mr Ted Cole Unravelling Causes of Human Dr Ian Taylor 1982 Dr Carleton Gajdusek Disease: Lessons From Adventures in East Asia and the Western Pacific Sir Bruce Watson Major contributions by Australians to Mr Rod Wylie OBE 1981 Professor Ralph Doherty Medical Science

75 QIMR Fellows

Outstanding individuals are named as Fellows of the Institute at the same event each year. This year the Awards went to Mr Paul Wright and Professor John Kerr.

2005 1994 1985 Paul Wright Mervyn Eadie Neville Davis John Kerr Bryan Emmerson Robert Porter 2004 Ian Wilkey Brian Wilson Peter Wills 1993 No awards 1984 2003 Graham Mitchell 1983 Bryan Campbell 1992 Sir Anthony Epstein Clive Berghofer Michael Alpers Douglas Gordon Sam Coco Rod Wylie Elizabeth Marks 2002 1991 1982 Diana Cavaye (deceased) Chev Kidson Carleton Gajdusek Sr Regis Mary Dunne Chamlong Harinasuta David Henderson 2001 Peter Livingstone Owen Powell Phillip Desbrow (deceased) No awards 1990 Julie Sulianti Saroso William O’Sullivan 1989 Edwin Westaway 2000 Sir Edward Stewart Vincent Zigas Lawrie Powell Tao Yixun 1981 Tom Veivers 1988 Sir Macfarlane Burnet (deceased) 1999 Mike Ahern Ralph Doherty Michael Barry Neville McCarthy Frank Fenner Kay Ellem Sir Gustav Nossal Eric French Ian Taylor Des O’Callaghan (posth) Sir Abraham Fryberg 1998 Frank Schofield Douglas Lee Michael O’Rourke No awards 1987 Margaret Macgregor 1997 1986 Aubrey Pye (deceased) Peter Doherty Natth Bhamarapravati William Reeves Paul Korner Louis Miller John Sprent Stephen Lynch Sir Eric Saint Harry Standfast No awards 1996 Robert Shope George Taylor 1995 Sir Bruce Watson AC John Tonge Ted Brown

76 Australian Academy of Science Elects QIMR Scientist

Following his AM and RL Doherty Prize for outstanding achievement and leadership in medical research in 2005, Professor Brian Kay was elected to the Australian Academy of Science in 2006 with the following citation: “Brian Kay is a celebrated expert in epidemiology, insect vectors, and mosquito control. He has made valuable contributions to understanding a range of regional arbovirus problems, especially dengue but also Ross River and Murray Valley encephalitis viruses. His research has led to the control of arbovirus diseases in northern Australia and Asia”. QIMR congratulates Professor Kay, who is only the second person at the Institute to be afforded such an honour, the first being Dr Edward Derrick, the discoverer of Q Fever, in 1954.

Professor Brian Kay AM signing the Academy Charter book in Canberra

Other Awards

Kay Ellem Order of Australia Lifetime of achievement in cancer research, Jun 2006 Named Oration – Research challenges Frontiers in Vaccinology Lecture, Centre for Vaccine Michael Good for vaccines in developing countries Development, Baltimore, USA, 2005 Named Oration – Vaccines for the Paddy Woolcock Oration, The Prince Charles Hospital, Michael Good heart: an opportunity to further improve Brisbane, 2005 cardiovascular health Nick Martin Dobzhansky Award Lifetime contributions to behaviour genetics, 2005 Nathan Subramaniam Senior Research Fellowship Gastroenterological Society of Australia, 2006 David Whiteman 2006 Fulbright Senior Scholarship US-Australia Fulbright Commission, 2006 James McCarthy Clinical Research Fellowship Smart State Queensland, Apr 2006 Chris Schmidt ASMR Queensland Premier’s Award Senior Postdoctoral Award, 2006 Patron of the Endometriosis Association Outstanding work and dedication in the field of Susan Treloar Qld Inc endometriosis research, 2006 ASMR Queensland Premier’s Award for Most meritorious research by an early researcher, Alberto Pinzon-Charry Medical Research 2006 Finalist, ASMR Queensland Premier’s Stuart Macgregor Work on DNA pooling, 2006 Award for Medical Research Young Investigator Award for Basic Best oral presentation in basic science section of June Chia Science, RBWH Research Week RBWH Research Week, 2006 American Association for Cancer ACCR Colorectal Cancer Pathways Conference, Vicki Whitehall Research Scholar in Training Award California, USA, 2005 Helen Bofinger Presidents Prize Best original work at TSANZ Annual Meeting, 2006 Tina Skinner-Adams Best Presentation Queensland Health Annual Conference, 2005 Tina Skinner-Adams Establishment Award Clive and Vera Ramaciotti Grant, 2005 Vicki Whitehall QCF Travel Award Travel to International Conference, 2006 Geoffrey Gobert North American Travel Award Australian Academy of Science, 2005 American Association for the Study of Liver Diseases Chunxia Xu Ian Potter Foundation Travel Award Meeting, San Francisco, USA, 2005

77 Grants and Funding

NHMRC Grants Awarded (Excluding Equipment Grants, Fellowships and Scholarships)

Calendar Year : 2001 2002 2003 2004 2005 2006

Project Grants - Standard 717,557 900,623 2,745,278 3,574,000 4,793,386 7,229,937

Project Grants - Genomics 863,000 853,000 394,000 – – 3,477,500

Program Grants – 2,110,000 2,965,000 4,421,083 5,426,606 4,830,000

Transitional Institute Grant (TIG) – 900,000 900,000 900,000 900,000 919,800

Transitional Block Grant (TBG) 4,863,644 4,049,556 2,466,426 511,146 – –

Development Grants – – 155,000 155,000 156,500 –

International Collaborative Grants – – 150,000 415,942 265,942 –

Total 6,444,201 8,813,179 9,775,704 9,977,171 11,542,434 16,457,237

NHMRC Fellowships and Scholarships Awarded

Calendar Year : 2001 2002 2003 2004 2005 2006

Postgraduate Scholarships 101,824 82,243 92,067 58,977 172,339 106,155

Training Fellowships 327,377 399,910 620,202 434,866 565,746 299,856

Career Development Awards - 160,000 511,000 606,750 884,000 972,500

Research Fellowships 354,576 660,000 787,750 1,305,000 1,548,750 1,532,250

Total 783,777 1,302,153 2,011,019 2,405,593 3,170,835 2,910,761

Leukaemia Foundation of Queensland

2001 2002 2003 2004 2005 2006 Leukaemia Foundation QLD 226,025 361,982 286,115 423,347 283,286 281,585

Grants funding received from all sources 2005-2006

QIMR Trust Qld Health $3,150,007 $5,558,872 QIMR Trust $3,150,007

NIH NHMRC $8,236,936 $19,758,889

78 Major New Grants Awarded in 2005-2006 (over $100,000)

Total Funds or QIMR Source Chief Investigators and Project Title Term Period component of funds ARC FABBRO M: “Preventing genetic damage with BIX – a novel 3 yrs 2006-08 $265,000 player in the DNA damage response pathway.” (Administered by Griffith University) ARC LAVIN M et al: “Identification of functionally important 3 yrs 2006-08 $265,000 autophosphorylation site(s) on ataxia telangiectasia and Rad 3- related (ATR) protein kinase.” ARC MARTIN N, WRIGHT M, LUCIANO M: “Locating genes 3 yrs 2006-08 $510,000 for cognitive traits using linkage and association analyses.” (Administered by The University of Queensland) ARC SMITH R: “Proteomics analysis of interactions between 2 yrs 2006-07 $300,000 Chaperonin 10 and Cell Surface Proteins.” (Administered by The University of Queensland; QIMR Investigator: J GORMAN) CRCAH ANDREWS R: “Filling the Gaps in the Healthy Skin Program.” 3 yrs 2005-08 $240,667 (Administered by the Menzies School of Health Research; QIMR PIs: D. KEMP and S. SRIPRAKASH) EU “Genetic and behavioural risk factors for melanoma.” 5 yrs 2006-10 EURO (Administered by the University of Leeds; QIMR PI: N. $141,084 HAYWARD) KOMEN TRENCH G: “Methylated CpG islands as biomarkers.” 2 yrs 2006-08 US$249,928 NBCF Lopez A et al: “Mammospheres for immunootherapy.” 2 yrs 2005-07 $150,000 NHMRC ANDERSON G, FRAZER D: “The mechanism of intestinal haem 3 yrs 2006-08 $526,500 iron absorption and characterisation of a novel haem-binding protein.” NHMRC CHENEVIX-TRENCH G et al: “Microarray-targeted candidate 3 yrs 2006-08 $601,250 gene approach to finding ovarian cancer susceptibility genes.” NHMRC ENGWERDA C, MYNOTT T: “Development of novel anti-cancer 2 yrs 2005-07 $313,000 and immunosuppressive drugs derived from pineapple stems (Ananus comosus).” NHMRC ENGWERDA C et al: “Defining the roles of TNF, lymphotoxin 3 yrs 2006-08 $401,250 alpha and LIGHT in experimental visceral leishmaniasis.”

NHMRC HARRICH D et al: “The HIV-1 Tat protein is a reverse 3 yes 2006-08 $396,075 transcription co-factor.”

NHMRC HILL G et al: “NKT cells and Graft-versus-Leukaemia Effects.” 3 yrs 2006-08 $292,500 NHMRC KHANNA R, GANDHI M: “Prophlyactic Vaccine for Human 3 yrs 2006-08 $364,875 Cytomegalovirus.”

NHMRC LAVIN M: “Mechanism of activation of ATM by DNA double 3 yrs 2006-08 $466,500 strand breaks and other stimuli.” (Administered by University of Queensland from 1/04/06). NHMRC LOUKAS A et al: “Haemoglobin degrading proteases as targets 3 yrs 2006-08 $511,500 of anti-hookworm vaccines.”

NHMRC MARTIN N, MONTGOMERY G, DUFFY D, VISSCHER P: 4 yrs 2006-09 $1,920,000 “Genome-wide combined linkage-association scan of multiply phenotyped twin sibships.” NHMRC MARTIN N, MONTGOMERY G, DUFFY D: “Genetics of 3 yrs 2006-08 $627,975 melanoma risk factors.”

79 NHMRC MORRIS P, VALERY P et al : “Multicentre Bronchiectasis Study: 5 yrs 2006-10 $1,444,500 A collaborative and international study of bronchiectasis in Indigenous children.” NHMRC MOSS D, KHANNA R, BURROWS S: “Immunobiology of Human 5 yrs 2006-10 $4,830,000 Herpesvirus Infections.” NHMRC PARSONS P, BOYLE G et al: “The role of MIC-1 in the promotion 3 yrs 2006-08 $232,500 and progression of skin squamous cell carcinoma.”

NHMRC SUHRBIER A, DARNELL G: “The human papilloma virus 3 yrs 2006-08 $252,500 oncoprotein E7 degrades the retinoblastoma protein by enhancing calpain activity.” NHMRC VISSCHER P et al: “Statistical methods and algorithms for 5 yrs 2006-10 $1,557,500 analysis of high-throughput genetics and genomics platforms.”

NHMRC WHITELAW E et al: “A role for epigenetic modifiers in 3 yrs 2006-08 $380,250 maintaining chromosome integrity during passage through the male gamete in the mouse.” NMHRC WHITEMAN D, GREEN A et al: “Towards Prognostic Markers for 3 yrs 2006-08 $434,450 Oesophageal Cancer.” NIH BRINDLEY P: “Pathogenesis of liver fluke induced cancer in 5 yrs 2005-10 US$349,914 Thailand.” (Administered by Tulane University in New Orleans; QIMR Investigator: A LOUKAS) NIH CONSTANT S: “Role of hookworm secretions in 4 yrs 2006-10 US$300,000 hostimmunomodulation.” (Administered by George Washington University in Washington; QIMR Investigator: A LOUKAS) NIH HEATH A: “Parental alcoholism and child environmental risk.” 4 yrs 2005-09 US$1,043,649 (Administered by Washington University; QIMR Investigator: N. Martin) NIH LYNSKEY M: “Cannabis and other illicit drug use: A twin study.” 5 yrs 2005-10 US$1,287,442 (Administered by Washington University; QIMR Investigator: N. Martin) NIH TODD R: “Molecular genetics of inattention in Australia.” 5 yrs 2005-10 US1,707,652 (Administered by Washington University; QIMR Investigator: N. Martin) NIH TRENCH G et al: “The role of the ATM gene in familial breast 5 yrs 2005-09 US$3,484,505 cancer.” QCF KELSO A: “Differentiation regulation of perforin and granzyme 2 yrs 2006-07 $150,000 gene expression in CD8+ T lymphocytes” QCF LAVIN M: “Functional Importance of ATR – dependent Mre11 2 yrs 2006-07 $150,000 phosphorylation in response to stalled DNA replication forks.” QCF MacDONALD K: “Lineage specific roles of SOCS3 in the 2 yrs 2006-07 $150,000 regulation of GVHD.” QCF MOSS D: “A phase 1 trial on adoptive transfer of EBV-specific 2 yrs 2006-07 $236,000 cytotoxic T cells to nasopharyngeal carcinoma patients.” QCF WALKER G: “Mechanisms of UVR-induced melanoma in 3 yrs 2006-08 $300,000 melanoma-prone mice.” QCF WEBB P: “Folate and related micronutrients, folate metabolising 2 yrs 2006-07 $150,000 genes and risk of ovarian cancer.” QCF YOUNG J: “Molecular Pathways in Endometrial Cancer.” 2 yrs 2006-07 $150,000 USDD TRENCH G, WEBB P, DUFFY D,: “Identification of Ovarian 3 yrs 2006-09 US$645,502 Cancer Susceptibility Genes involved in Stromal-Epithelial Interactions.”

80 2005-2006 Publications

Agrawal A, Heath AC, Grant JD, Pergadia Anttila V, Kallela M, Oswell G, Kaunisto Beaumont KA, Newton RA, Smit DJ, ML, Statham DJ, Bucholz KK, Martin NG MA, Nyholt DR, Hämäläinen E, Leonard JH, Stow JL and Sturm RA. and Madden PA. Assortative mating for Havanka H, Ilmavirta M, Terwilliger J, Altered cell surface expression of human cigarette smoking and alcohol consumption Sobel E, Peltonen L, Kaprio J, Färkkilä MC1R variant receptor alleles associated in female Australian twins and their M, Wessman M and Palotie A. Trait with red hair and skin cancer risk. Hum Mol spouses. Behav Genet 36: 553-566, 2006 components provide tools to dissect the Genet 14: 2145-2154, 2005 genetic susceptibility of migraine. Am J Hum Agrawal A, Madden PA, Heath AC, Genet 79: 85-99, 2006 Beeby HN, Medland SE and Martin NG. Lynskey MT, Bucholz KK and Martin NG. ViewPoint and ViewDist: Utilities for rapid Correlates of regular cigarette smoking in Arnold JM, Chong DY, Lai J, Campbell graphing of linkage distributions of outliers. a population-based sample of Australian IG, and Chenevix-Trench G. Mutation and Behav Genet 36: 7-11, 2006 twins. Addiction 100: 1709-19, 2005 expression analysis of LZTS1 in ovarian cancer. Cancer Lett 233: 151-157, 2006 Belizario VY, Pasay CJ, Bersabe MJ, de Akesson LS, Duffy DL, Phelps SC, Leon WU, Guerrero DM and Bugaoisan Thompson PJ and Kedda MA. A Asojo OA, Loukas A, Inan M, Barent VM. Field evaluation of malaria rapid polymorphism in the promoter region of the R, Huang J, Plantz B, Swanson A, diagnostic tests for the diagnosis of P. human interleukin-16 gene is not associated Gouthro M, Meagher MM and Hotez PJ. falciparum and non-P. falciparum infections. with asthma or atopy in an Australian Crystallization and preliminary X-ray analysis Southeast Asian J Trop Med Public Health population. Clin Exp Allergy 35: 327-331, of Na-ASP-1, a multi-domain pathogenesis- 36: 552-61, 2005 2005 related-1 protein from the human hookworm parasite Necator americanus. Benyamin B, Wilson V, Whalley LJ, Alsop K, Mead L, Smith LD, Royce SG, Acta Crystallograph Sect F Struct Biol Cryst Visscher PM and Deary IJ. Large, Tesoriero AA, Young JP, Haydon A, Grubb Commun 61: 391-4, 2005 consistent estimates of the heritability of G, Giles GG, Jenkins MA, Hopper JL and cognitive ability in two entire populations Southey MC. Low soma tic K-ras mutation Baker, J, McCarthy J, Gatton M, Kyle of 11-year-old twins from Scottish mental frequency in colorectal cancer diagnosed DE, Belizario V, Luchavez J, Bell D and surveys of 1932 and 1947. Behav Genet 35: under the age of 45 years. Eur J Cancer 42: Cheng Q. Genetic diversity of Plasmodium 525-534, 2005 1357-61, 2006 falciparum histidine-rich protein 2 (PfHRP2) and its effect on the performance of Beraldi D, McRae AF, Gratten J, Slate Anderson CA, McRae AF and Visscher PfHRP2-based rapid diagnostic tests. J Infect J, Visscher PM and Pemberton JM. PM. A simple linear regression method for Dis 192: 870-877, 2005 Development of a linkage map and mapping quantitative trait Loci linkage analysis with of phenotypic polymorphisms in a free- censored observations. Genetics 173: 1735- Banerji U, O’Donnell A, Scurr M, Pacey S, living population of Soay sheep (Ovis aries). 1745, 2006 Stapleton S, Asad Y, Simmons L, Maloney Genetics 173: 1521-1537, 2006 A, Raynaud F, Campbell M, Walton Anderson GJ and Frazer DM. Hepatic iron M, Lakhani S, Kaye S, Workman P and Bethony J, Brooker S, Albonico M, Geiger metabolism. Semin Liver Dis 25: 420-32, Judson I. Phase I pharmacokinetic and SM, Loukas A, Diemert D and Hotez 2005 pharmacodynamic study of 17-allylamino, PJ. Soil-transmitted helminth infections: 17-demethoxygeldanamycin in patients ascariasis, trichuriasis, and hookworm. Anderson GJ and Frazer DM. Recent Lancet 367: 1521–32, 2006 advances in intestinal iron transport. Curr with advanced malignancies. J Clin Oncol Gastroenterol Rep 7: 365-72, 2005 23: 4152-61, 2005 Bethony J, Loukas A, Smout M, Brooker Banovic T, MacDonald KP, Morris ES, S, Mendez S, Plieskatt J, Goud G, Bottazzi Anderson GJ, Frazer DM, McKie AT, Vulpe ME, Zhan B, Wang Y, Williamson A, CD and Smith A. Mechanisms of haem Rowe V, Kuns R, Don A, Kelly J, Ledbetter S, Clouston AD and Hill GR. TGF-beta in Lustigman S, Correa-Oliveira R, Xiao S and non-haem iron absorption: lessons and Hotez PJ. Antibodies against a secreted from inherited disorders of iron metabolism. allogeneic stem cell transplantation: friend or foe? Blood 106 : 2206-14, 2005 protein from hookworm larvae reduce the Biometals 18: 339-348, 2005 intensity of hookworm infection in humans Anderson GJ and Frazer DM. Iron Battistutta D, Pandeya N, Strutton GM, and vaccinated laboratory animals. FASEB J metabolism meets signal transduction. Nat Fourtanier A, Tison S and Green AC. 19: 1743-5, 2005 Genet 38: 503-4, 2006 Skin surface topography grading is a valid measure of skin photoaging. Photodermatol Bhatia M, Howard SC, Clark TG, Neale Andrews KT, Fairlie DP, Madala PK, Photoimmunol Photomed 22: 39-45, 2006 R, Qizilbash N, Murphy MF and Rothwell Ray J, Wyatt DM, Hilton PM, Melville PM. Apolipoproteins as predictors of LA, Beattie L, Gardiner DL, Reid RC, Baz A, Jackson DC, Kienzle N and Kelso ischaemic stroke in patients with a previous Stoermer MJ, Skinner-Adams T, Berry A. Memory cytolytic T-lymphocytes: transient ischaemic attack. Cerebrovas Dis C, and McCarthy JS. Potencies of human induction, regulation and implications for 21: 323-8, 2006 immunodeficiency virus protease inhibitors vaccine design. Expert Rev Vaccines 4: 711- 23. 2005 Birley AJ, Gillespie NA, Heath AC, in vitro against Plasmodium falciparum and Sullivan PF, Boomsma DI and Martin NG. in vivo against murine malaria. Antimicrob Batzloff MR, Yan H, Davies MR, Hartas J, Heritability and nineteen-year stability of Agents Chemother 50: 639-648, 2006 Lowell GH, White G, Burt DS, Leanderson long and short EPQ-R Neuroticism scales. Andrews KT, Adams Y, Viebig NK, T and Good MF. Toward the development Pers Indiv Diff 40: 737-747, 2006 Lanzer M, and Schwartz-Albiez R. of an antidisease, transmission- blocking intranasal vaccine for group A Birley AJ, Whitfield JB, Neale MC, Duffy Adherence of Plasmodium falciparum DL, Heath AC, Boomsma DI and Martin infected erythrocytes to CHO-745 cells and streptococcus. J Infect Dis 192: 1450-55, 2005 NG. Genetic time-series analysis identifies inhibition of binding by protein A in the a major QTL for in vivo alcohol metabolism presence of human serum. Int J Parasitol 35: not predicted by in vitro studies of structural 1127-34, 2005 protein polymorphism at the ADH1B or ADH1C loci. Behav Genet 35: 509-24, 2005

81 Birrell GW, Earl S, Masci PP, de Jersey Chang AB, Torzillo PJ, Boyce NC, White Chung WY, Gardiner DL, Hyland C, J, Wallis TP, Gorman JJ and Lavin MF. AV, Stewart PM, Wheaton GR, Purdie Gatton M, Kemp DJ and Trenholme KR. Molecular diversity in venom from the DM, Wakerman J and Valery PC. Zinc and Enhanced invasion of blood group A1 Australian Brown snake, Pseudonaja textilis. vitamin A supplementation in Indigenous erythrocytes by Plasmodium falciparum. Mol Cell Proteomics 5: 379-89, 2006 Australian children hospitalised with lower Mol Biochem Parasitol 144:128-30, 2005 respiratory tract infection: a randomised Bridle K, Cheung TK, Murphy T, Walters controlled trial. Med J Aust 184: 107-12, Chung WY, Gardiner DL and Trenholme M, Anderson G, Crawford DG and 2006 KR. Plasmodium falciparum and red cell Fletcher LM. Hepcidin is down-regulated polymorphisms. Aust J Med Sci 26: 150 -56, in alcoholic liver injury: Implications for Chang AB, Hills YC, Cox NC, Cleghorn GJ, 2005 the pathogenesis of alcoholic liver disease. Valery PC, Lewindon PJ, Ee LC, Withers Alcohol Clin Exp Res 30: 106-12, 2006 GD, Beem C and Hills BA. ‘Free’ surfactant Cook AL, Smith AG, Smit DJ, Leonard JH in gastric aspirates and bronchoalveolar and Sturm RA. Co-expression of SOX9 and Bundell CS, Jackaman C, Suhrbier A, lavage in children with and without reflux SOX10 during melanocytic differentiation in Robinson BW and Nelson DJ. Functional oesophagitis. Intern Med J 36: 226-30, vitro. Exp Cell Research 308: 222-35, 2005 endogenous cytotoxic T lymphocytes are 2006 generated to multiple antigens co-expressed Cornes BK, Medland SE, Ferreira MAR, by progressing tumors; after intra-tumoral Charlesworth B, Keightley P and Morley KI, Duffy DL, Heijmans BT, IL-2 therapy these effector cells eradicate Visscher P. Introduction: population Montgomery GW and Martin NG. Sex- established tumors. Cancer Immunol genetics, quantitative genetics and animal limited genome-wide linkage scan for body Immunother 55: 933-47, 2006 improvement: papers in honour of William mass index in an unselected sample of 933 (Bill) Hill. Philos Trans R Soc Lond B Biol Sci Australian twin families. Twin Res and Hum Burgess A, Buck M, Krauer K, and Sculley 360: 1365-66, 2005 Genet 8: 616-32, 2005. T. Nuclear localization of the Epstein-Barr virus EBNA3B protein. J Gen Virol 87: 789- Chen H, Lin D, Li YS, Liu YM, McManus Dalton JP, Caffrey C, Sajid M, Stack C, 93, 2006 DP Huang XH, Feng Z. Studies on effect Donnelly S, Loukas A, Don T, McKerrow of artemether to control infection and J, Halton DW and Brindley PJ. Proteases Burns M, Baker J, Auliff AM, Gatton ML, prevent acute infection of S. japonicum in in trematode biology. In: Parasitic Edstein MD and Cheng Q. Efficacy of high endemic areas. Chin J Schistostomiasis flatworms: molecular biology, biochemistry, sulfadoxine-pyrimethamine in the treatment Control 18: 32-35, 2006 immunology and physiology. Ed: Maule A. of uncomplicated Plasmodium falciparum CABI Publishing, UK, pp 348-368, 2006 malaria in East Timor. Am J Trop Med Hyg Chenevix-Trench G, Healey S, Lakhani S, 74: 361-366, 2006 Waring P, Cummings M, Brinkworth R, Davies H, Hunter C, Smith R, Stephens Deffenbaugh AM, Burbidge LA, Pruss D, P, Greenman C, Bignell G, Teague J, Burrows SR, Rossjohn J and McCluskey J. Judkins T, Scholl T, Bekessy A, Marsh A, Butler A, Edkins S, Stevens C, Parker Have we cut ourselves too short in mapping Lovelock P, Wong M, Tesoriero A, Renard A, O’Meara S, Avis T, Barthorpe S, CTL epitopes? Trends Immunol. 27: 11-16, H, Southey M, Hopper JL, Yannoukakos Brackenbury L, Buck G, Clements J, Cole 2006 K, Brown M, Easton D, Tavtigian SV, J, Dicks E, Edwards K, Forbes S, Gorton Goldgar D and Spurdle AB; kConFab M, Gray K, Halliday K, Harrison R, Hills Burrows SR and Hislop AD. The immune K, Hinton J, Jones D, Kosmidou V, Laman response to Epstein-Barr virus. In: Epstein- Investigators. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA R, Lugg R, Menzies A, Perry J, Petty R, Barr Virus. Eds: Tselis AC and Jenson HB. Raine K, Shepherd R, Small A, Solomon Marcel Dekker, Inc. pp 79-97, 2006 sequence variants of unknown clinical significance. Cancer Res 66: 2019-27, 2006 H, Stephens Y, Tofts C, Varian J, Webb Butler GJ, Neale R, Green AC, Pandeya A, West S, Widaa S, Yates A, Brasseur N, and Whiteman DC. Nonsteroidal anti- Chen H, Huang G, Su T, Gao H, Attieh F, Cooper CS, Flanagan AM, Green A, inflammatory drugs and the risk of actinic ZK, McKie AT, Anderson GJ and Vulpe Knowles M, Leung SY, Looijenga LH, keratoses and squamous cell cancers of the CD. Decreased hephaestin activity in the Malkowicz B, Pierotti MA, Teh BT, Yuen skin. J Am Acad Dermatol 53: 966-72, 2005 intestine of copper-deficient mice causes ST, Lakhani SR, Easton DF, Weber BL, systemic iron deficiency. J Nutr 136: 1236- Goldstraw P, Nicholson AG, Wooster R, Cameron B, Bharadwaj M, Burrows J, 41, 2006 Stratton MR and Futreal PA. Somatic Fazou C, Wakefield D, Hickie I, Ffrench R, mutations of the protein kinase gene family Khanna R and Lloyd A. Dubbo Infection Chhatwal GS, McMillan DJ and Talay SR. in human lung cancer. Cancer Res 65: 7591- Outcomes Study. Prolonged illness after Pathogenicity Factors in Group C and G 15, 2005 infectious mononucleosis is associated with Streptococci. In: Gram-positive pathogens, altered immunity but not with increased 2nd Edition. Eds: Fischetti DC, Novick RP, Davies MR, McMillan DJ, Sriprakash KS viral load. J Infect Dis 193: 664-671, 2006 Ferretti JJ, Portnoy DA and Rood JI. ASM and Chhatwal GS. Genetic profiling of Press, Washington, pp 213-221, 2006 human group C and G streptococci using a Castles A, Bates T, Coltheart M, Luciano group A streptococcal virulence array. In: M and Martin NG. Cognitive modelling Chin D, Boyle GM, Porceddu S, Theile Streptococci - New Insights Into an Old and the behaviour genetics of reading. J Res DR, Parsons PG and Coman WB. Head Enemy. International Congress Series 1289, Reading 29: 92-103, 2006 and neck cancer: past, present and future. Elsevier BV, pp 184-87, 2006. Expert Rev Anticancer Ther 6: 1111-8, 2006 Chai M, McManus DP, McInnes R, Davies MR, Tran TN, McMillan DJ, Moertel L, Tran M, Loukas A, Jones MK Chow E, Lipton L, Lynch E, D’Souza R, Gardiner DL, Currie BJ and Sriprakash KS. and Gobert GN. Transcriptome profiling Aragona C, Hodgkin L, Brown G, Winship Inter-species genetic movement may blur of lung schistosomula, in vitro cultured I, Barker M, Buchanan D, Cowie S, the epidemiology of streptococcal diseases schistosomula and adult Schistosoma Nasioulas S, du Sart D, Young J, Leggett in endemic regions. Microbes Infect 7: japonicum. Cell Mol Life Sci 63: 919-29, B, Jass J and Macrae F. Hyperplastic 1128-38, 2005 2006 polyposis syndrome: phenotypic presentations and the role of MBD4 and MYH. Gastroenterology 131: 30-39, 2006

82 Davies MR, Tran TN, McMillan DJ and Dougall A, Holt DC, Fischer K, Currie BJ, Filippovich I, Sorokina N, St Pierre L, Sriprakash KS. Evidence for increased Kemp DJ and Walton SF. Identification Flight S, de Jersey J, Perry N, Masci PP horizontal gene transfers among and characterization of Sarcoptes scabiei and Lavin MF. Cloning and functional streptococci from group A streptococcal and Dermatophagoides pteronyssinus expression of venom prothrombin activator endemic regions. In: Streptococci - New glutathione S-transferases: implication as a protease from Pseudonaja textilis with insights into an old enemy. International potential major allergen in crusted scabies. whole blood procoagulant activity. Br J Congress Series 1289, Elsevier BV, pp 188- Am J Trop Med Hyg 73: 977-84, 2005 Haematol 131: 237-246, 2005 92, 2006 Dunn J, Lynch B, Rinaldis M, Pakenham Frazer DM and Anderson GJ. Iron Day B, To C, Himanen JP, Smith FM, K, McPherson L, Owen N, Leggett B, Imports. I. Intestinal iron absorption and its Nikolov DB, Boyd AW and Lackmann M. Newman B and Aitken J. Dimensions of regulation. Am J Physiol Gastrointest Liver Three distinct molecular surfaces in ephrin- quality of life and psychosocial variables Physiol 289: G631-5, 2005 A5 are essential for a functional interaction most salient to colorectal cancer patients. with EphA3. J Biol Chem 280: 26526-32, Psycho-oncology 15: 20-30, 2006 Frazer DM, Wilkins SJ, Vulpe CD and 2005 Anderson GJ. The role of duodenal Edstein MD, Kotecka BM, Anderson KL, cytochrome b in intestinal iron absorption Day BW, Smith FM, Chen K, McCarron Pombo DJ, Kyle DE, Rieckmann KH and remains unclear. Blood 106: 4413, 2005 JK, Herath NI, Lackmann M, and Boyd Good MF. Lengthy antimalarial activity of AW. Eph/ephrin membrane proteins: a atovaquone in human plasma following Fujiwara RT, Loukas A, Mendez S, mammalian expression vector pTIg-BOS-Fc atovaquone-proguanil administration. Williamson AL, Bueno LL, Wang Y, allowing rapid protein purification. Protein Antimicrob Agents Chemother 49: 4421- Samuel A, Zhan B, Bottazzi ME, Hotez Pept Lett 13: 193-96, 2006 22, 2005 PJ and Bethony JM. Vaccination with irradiated Ancylostoma caninum third stage Delatycki MB, Allen KJ, Nisselle AE, Ellis MK, Li Y, Rong Z, Chen H and larvae induces a Th2 protective response in Collins V, Metcalfe S, du Sart D, McManus DP. Familial aggregation dogs. Vaccine 24: 501-9, 2006 Halliday J, Aitken MA, Macciocca I, Hill of human infection with Schistosoma V, Wakefield A, Ritchie A, Gason AA, japonicum in the Poyang Lake region, Gan XX, Shen LY, Wang Y, Ding JZ, Shen Nicoll AJ, Powell LW and Williamson China. Int J Parasitol 36: 71-77, 2006 HY, Zeng XP, McManus DP, Brindley PJ, R. Use of community genetic screening and Fan J. Recombinant tegumental protein to prevent HFE-associated hereditary Engwerda CR, Beattie L and Amante FH. Shistosoma japonicum very lowdensity haemochromatosis. Lancet 366: 314-16, The importance of the spleen in malaria. lipoprotein binding protein as a vaccine 2005 Trends Parasitol 21: 356-57, 2005 candidate against Schistosoma japonicum. Mem Inst Oswaldo Cruz 101: 9-13, 2006 de Snoo FA and Hayward NK. Cutaneous Engwerda CR, Belnoue E, Gruner AC and melanoma susceptibility and progression Renia L. Experimental models of cerebral Gandhi M and Khanna R. Epstein-Barr genes. Cancer Lett 230: 153-86, 2005 malaria. Curr Top Microbiol Immunol 297: virus and advanced chronic lymphocytic 103-43, Review, 2005 leukemia: innocent until proven guilty? Leuk Dickson PA, James MR, Heath AC, Lymphoma 47: 779-80, 2006 Montgomery GW, Martin NG, Whitfield Fabbro M, Zhou BB, Takahashi JB and Birley AJ. Effects of variation at M, Sarcevic B, Lal P, Graham ME, Gandhi MK, Lambley E, Burrows J, Dua the ALDH2 locus on alcohol metabolism, Gabrielli BG, Robinson PJ, Nigg EA, U, Elliott S, Shaw PJ, Prince HM, Wolf M, sensitivity, consumption and dependence in Ono Y and Khanna KK. Cdk1/Erk2- and Clarke K, Underhill C, Mills T, Mollee P, Europeans. Alcohol Clin Exp Res 30: 1093- Plk1-dependent phosphorylation of a Gill D, Marlton P, Seymour JF and Khanna 1100, 2006 centrosome protein, Cep55, is required for R. Plasma Epstein-Barr virus (EBV) DNA its recruitment to midbody and cytokinesis. is a biomarker for EBV-positive Hodgkin’s Dickson PA, Montgomery GW, Henders Dev Cell 9: 477-88, 2005 lymphoma. Clin Cancer Res 12: 460-464, A, Campbell M, Martin NG and James 2006 MR. Evaluation of multiple displacement Ferreira MA, O’Gorman L, Le Souef P, amplification in a 5cM STR genome wide Burton PR, Toelle BG, Robertson CF, Gandhi MK and Khanna R. Viruses and scan. Nucleic Acids Res 33: e119, 2005 Visscher PM, Martin NG and Duffy DL. lymphoma. Pathology 37: 420-33, 2005 Robust estimation of experimentwise P D’Onofrio BM, Turkheimer E, Emery RE, values applied to a genome scan of multiple Gardiner DL, Trenholme KR, Skinner- Slutske W, Heath AC, Madden PA and asthma traits identifies a new region of Adams TS, Stack CM and Dalton JP. Martin NG. A genetically informed study significant linkage on chromosome 20q13. Overexpression of leucyl aminopeptidase in of marital instability and its association A J Hum Genet 77: 1075-85, 2005. Plasmodium falciparum parasites. Target for with offspring psychopathology. J Abnorm the antimalarial activity of bestatin. J Biol Psychol 114: 570-86, 2005 Ferreira MA, O’Gorman L, Le Souef Chem 281: 1741-45, 2006. P, Burton PR, Toelle BG, Robertson D’Onofrio BM, Turkheimer E, Emery RE, CF, Martin NG and Duffy DL. Variance Gardiner DL, McCarthy JS and Trenholme Slutske WS, Heath AC, Madden PA and components analyses of multiple asthma KR. Malaria in the post-genomics era: light Martin NG. A genetically informed study traits in a large sample of Australian families at the end of the tunnel or just another of the processes underlying the association ascertained through a twin proband. Allergy train? Postgrad Med J 81: 505-509, 2005 between parental marital instability and 61: 245-53, 2006 Gardiner RA, Burger MJ, Steginga S, offspring adjustment. Dev Psychol 42: 486- Walsh T, Schmidt C, Nicol DL, Lavin MF 99, 2006 Ferreira MA, Visscher PM, Martin NG and Duffy DL. A simple method to localise and Clements JA. Integrating molecular, Donnelly S, Dalton JP and Loukas A. pleiotropic susceptibility loci using univariate proteomic and vaccine development, Proteases in helminth- and allergen- induced linkage analyses of correlated traits. Eur J Quality of life and psychometric evaluations inflammatory responses. In: Parasites and Hum Genet 14: 953-62, 2006 in a comprehensive research program. In: Allergy. Volume 90 in the series: Chemical Horizons in Cancer Research. Ed: Colombus Immunology and Allergy. Eds. Trottein F and F. Nova Science, pp 189-216, 2006 Capron M. Karger Press, Switzerland, pp 45-64, 2006

83 Georgousakis MM, Sriprakash KS, Good Green AC, Greenberg P, Fitzgerald G and Hansell NK, Pang D, Heath AC, Martin MF and Batzloff MR. Immunogenicity of Clutton C. Translating health research into NG and Whitfield JB. Erythrocyte aldehyde recombinant polytope constructs containing clinical advice and health recommendations: dehydrogenase activity: lack of association protective group A streptococcal antigens. the NHMRC experience 2000-2005. Intern with alcohol use and dependence or alcohol In: Streptococci - New Insights Into an Old Med J 36: 335-7, 2006 reactions in Australian twins. Alcohol Enemy. International Congress Series 1289, Alcohol 40: 343-48, 2005 Elsevier BV, pp 320-23, 2006 Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N and Lavin MF. Regulation Hansell NK, Wright MJ, Luciano M, Gibbs MJ, Smeianov VV, Steele JL, of the Atm promoter in vivo. Genes Geffen GM, Geffen LB and Martin NG. Upcroft P and Efimov BA. Two families of Chromosomes Cancer 45: 61-71, 2006 Genetic covariation between event-related rep-like genes that probably originated by potential (ERP) and behavioral non-ERP interspecies recombination are represented Gueven N, Becherel OJ, Birrell G, Chen measures of working-memory, processing in viral, plasmid, bacterial, and parasitic P, DelSal G, Carney JP, Grattan-Smith speed, and IQ. Behav Genet 35: 695-706, protozoan genomes. Mol Biol Evol 23: P and Lavin MF. Defective p53 response 2005 1097-100, 2006 and apoptosis associated with an ataxia- telangiectasia-like phenotype. Cancer Res Hansen JL, Reed DR, Wright MJ, Martin Gill S, Lindor NM, Burgart LJ, Smalley 66: 2907-2912, 2006 NG and Breslin PA. Heritability and genetic R, Leontovich O, French AJ, Goldberg covariation of sensitivity to PROP, SOA, RM, Sargent DJ, Jass JR, Hopper JL, Gui GP, Joubert DJ, Reichert R, Ward A, quinine HCl and caffeine. Chem Senses 31: Jenkins MA, Young J, Barker MA, Walsh Lakhani S, Osin P, Nerurkar A, A’Hern R, 403-13, 2006 MD, Ruszkiewicz AR and Thibodeau Benson K and Underwood SR. Continued SN. Isolated loss of PMS2 expression in axillary sampling is unnecessary and Harty MW, Huddleston HM, Papa colorectal cancers: frequency, patient age, provides no further information to sentinel EF, Puthawala T, Tracy AP, Ramm GA, and familial aggregation. Clin Cancer Res node biopsy in staging breast cancer. Eur J Gehring S, Gregory SH and Tracy TF Jr. 11: 6466-71, 2005 Surg Oncol 31: 707-14, 2005 Repair after cholestatic liver injury correlates with neutrophil infiltration and matrix Gillespie NA and Martin NG. Direction Guo J, Li Y, Gray D, Ning A, Hu G, metalloproteinase 8 activity. Surgery 138: of causation models. In: Encyclopedia of Chen H, Davis GM, Sleigh AC, Feng Z, 313-20, 2005 Statistics in Behavioral Science. Eds: Everitt McManus DP and Williams GM. A drug- BS and Howell DC. Wiley, Chichester, pp based intervention study on the importance Heijmans BT, Beekman M, Putter H, 496-99, 2005 of buffaloes for human Schistosoma Lakenberg N, van der Wijk HJ, Whitfield japonicum infection around Poyang Lake, JB, Posthuma D, Pedersen NL, Martin Gillespie NA and Martin NG. Multivariate People’s Republic of China. Am J Trop Med NG, Boomsma DI and Slagboom PE. genetic analysis. In: Encyclopedia of Hyg 74: 335-41, 2006 Meta-analysis of four new genome scans for Statistics in Behavioral Science. Eds: Everitt lipid parameters and analysis of positional BS and Howell DC. Wiley, Chichester, pp Hacker E, Muller HK, Irwin N, Gabrielli candidates in positive linkage regions. Eur J 1363-70, 2005 B, Lincoln D, Pavey S, Powell MB, Hum Genet 13: 1143-53, 2005 Malumbres M, Barbacid M, Hayward Gillespie NA and Martin NG. Neuroticism N and Walker G. Spontaneous and UV Henderson J, Withford-Cave JM, Duffy as a genetic marker for mood and anxiety. radiation-induced multiple metastatic DL, Cole SJ, Sawyer NA, Gulbin JP, In: Biology of Pers Indiv Diff. Ed: Canli T. melanomas in Cdk4R24C/R24C/TPras mice. Hahn A, Trent RJ and Yu B. The EPAS1 Guilford Press, New York, pp 225-50, 2006 Cancer Res 66: 2946-52, 2006 gene influences the aerobic-anaerobic contribution in elite endurance athletes. Gobert GN, Chai M, Duke M and Hacker E, Irwin N, Muller HK, Powell Hum Genet 118: 416-43, 2005 McManus DP. Copro-PCR based detection MB, Kay G, Hayward N and Walker G. of Schistosoma eggs using mitochondrial Neonatal ultraviolet radiation exposure is Herath NI, Spanevello MD, Sabesan DNA markers. Mol Cell Probes 19: 250-54, critical for malignant melanoma induction in S, Newton T, Cummings M, Duffy S, 2005 pigmented Tpras transgenic mice. J Invest Lincoln D, Boyle G, Parsons PG and Boyd Dermatol 125: 1074-77, 2005 AW. Over-expression of Eph and ephrin Gobert GN, Moertel LP and McManus DP. genes in advanced ovarian cancer: ephrin Microarrays: new tools to unravel parasite Hall P, Kennedy G, Morton J, Hill GR and gene expression correlates with shortened transcriptomes. Parasitology 131: 439-48, Durrant S. Twenty-four hour continuous survival. BMC Cancer 6: 144, 2006 2005 infusion of amphotericin B for the treatment of suspected or proven fungal infection in Herath NI, Leggett BA and MacDonald Good MF. Identification of early cellular haematology patients. Intern Med J 35: GA. Review of genetic and epigenetic immune factors regulating growth of 374, 2005 alterations in hepatocarcinogenesis. J malaria parasites in humans. Immunity 23: Gastroenterol Hepatol 21: 15-21, 2006 241-42, 2005 Hamilton MJ, Huang QX, Li CL and Ellem KA. The development and characterization Hill GR, Morris ES, Fuery M, Hutchins C, Goud GN, Bottazzi ME, Zhan B, Mendez of an HEK293-derived cell line for use in an Butler J, Grigg A, Roberts A, Bradstock K, S, Deumic V, Plieskatt J, Liu S, Wang Y, intratumoral cytokine delivery system. Cell Szer J, Kennedy G, Morton J and Durrant Bueno L, Fujiwara R, Samuel A, Ahn SY, Transplant 15: 343-50, 2006 S. Allogeneic stem cell transplantation Solanki M, Asojo OA, Wang J, Bethony with peripheral blood stem cells mobilized JM, Loukas A, Roy M and Hotez PJ. Hansell NK, Medland SE, Ferreira MA, by pegylated-G-CSF. Biol Blood Marrow Expression of the Necator americanus Geffen GM, Zhu G, Montgomery GW, Transplant 12: 603-7, 2006 hookworm larval antigen Na-ASP-2 in Pichia Duffy DL, Wright MJ and Martin NG. pastoris and purification of the recombinant Linkage analyses of event-related potential Hill GR. Host gamma delta T cells: an innate protein for use in human clinical trials. slow wave phenotypes recorded in a bridge to the epithelial targets of GVHD? Vaccine 23: 4754-64, 2005 working memory task. Behav Genet 36: Blood 106: 393-94, 2005 29-44, 2006

84 Hitchins M, Suter C, Wong J, Cheong Hur YM, Luciano M, Martin NG, Jordan S, Green A and Webb P. Benign K, Hawkins N, Leggett B, Scott R, Boomsma DI, Iacono WG, McGue M, epithelial ovarian tumours – cancer Spigelman A, Tomlinson I, Martin D and Shin JS, Jun JK, Ooki S, van Beijsterveldt precursors or markers for ovarian cancer Ward R. Germline epimutations of APC CE and Han JY. A comparison of twin risk? Cancer Causes Control 17: 623-32, are not associated with inherited colorectal birthweight data from Australia, the 2006 polyposis. Gut 55: 586-587, 2006 Netherlands, the United States, Japan, and South Korea: are genetic and environmental Jordan SJ, Webb PM, Green AC. Height, Holliday EG, Handoko HY, James MR, variations in birthweight similar in age at menarche, and risk of epithelial McGrath JJ, Nertney DA, Tirupati S, Caucasians and East Asians? Twin Res Hum ovarian cancer. Cancer Epidemiol Biomarkers Thara R, Levinson DF, Hayward NK, Genet 8: 638-48, 2005 Prev 14: 2045-48, 2005 Mowry BJ and Nyholt DR. Association study of the dystrobrevin-binding gene Imwong M, Pukrittayakamee S, Cheng Jung CG, Kim HJ, Kawaguchi M, Khanna with schizophrenia in Australian and Indian Q, Moore C, Looareesuwan S, Snounou KK, Hida H, Asai K, Nishino H and Miura samples. Twin Res Hum Genet 9: 531-539, G, White NJ and Day NP. Limited Y. Homeotic factor ATBF1 induces the 2006 polymorphism in the dihydropteroate cell cycle arrest associated with neuronal synthetase gene (dhps) of Plasmodium vivax differentiation. Development 132: 5137-45, Hopper JL, Hayes VM, Spurdle AB, isolates from Thailand. Antimicrob Agent 2005 Chenevix-Trench G, Jenkins MA, Milne Chemother 49: 4393-4395, 2005 RL, Dite GS, Tesoriero AA, McCredie MR, Jurgens LA, Khanna R, Weber J and Giles GG and Southey MC. A protein- Jacquemier J, Padovani L, Rabayrol L, Orentas RJ. Transduction of primary truncating mutation in CYP17A1 in three Lakhani SR, Penault-Llorca F, Denoux lymphocytes with Epstein-Barr Virus (EBV) sisters with early-onset breast cancer. Hum Y, Fiche M, Figueiro P, Maisongrosse latent membrane protein-Specific T-cell Mutat 26: 298-302, 2005. V, Ledoussal V, Martinez Penuela J, receptor induces lysis of virus-infected Udvarhely N, El Makdissi G, Ginestier cells: A novel strategy for the treatment Hotez PJ, Arora S, Bethony J, Bottazzi C, Geneix J, Charafe-Jauffret E, Xerri of Hodgkin’s disease and nasopharyngeal ME, Loukas A, Correa-Oliveira R and L, Eisinger F; European Working Group carcinoma. J Clin Immunol 26: 22-32, 2006 Brooker S. Helminth infections of children: for Breast Screening Pathology; Breast Kang HJ, Kim HJ, Kim SK, Barouki R, prospects for control. Adv Exp Med Biol Cancer Linkage Consortium. Typical 568: 135-44, 2005 Cho CH, Khanna, KK, Rosen EM and Bae medullary breast carcinomas have a basal/ I. BRCA1 modulates xenobiotic stress- Hottenga JJ, Whitfield JB, de Geus EJ, myoepithelial phenotype. J Pathol 207: inducible gene expression by interacting Boomsma DI and Martin NG. Heritability 260-68, 2005 with ARNT in human breast cancer cells. J and stability of resting blood pressure in James MR, Roth RB, Shi MM, Kammerer Biol Chem 281: 14654-62, 2006 Australian twins. Twin Res and Hum Genet S, Nelson MR, Stark MS, Dumenil T, 9: 205-9, 2006 Karagas MR, Nelson HH, Sehr P, Montgomery GW, Hayward NK, Martin Waterboer T, Stukel TA, Andrew A, Green Houben R, Michel B, Vetter-Kauczok CS, NG, Braun A and Duffy DL. BRAF AC, Bavinck JN, Perry A, Spencer S, Pföhler C, Laetsch B, Wolter MD, Leonard polymorphisms and risk of melanocytic Rees JR, Mott LA and Pawlita M. Human JH, Trefzer U, Ugurel S, Schrama D and neoplasia. J Invest Dermatol 125: 1252-58, papillomavirus infection and incidence of Becker JC. Absence of classical MAP kinase 2005 squamous cell and basal cell carcinomas pathway signalling in Merkel cell carcinoma. Janas ML, Groves P, Kienzle N and of the skin. J Natl Cancer Inst 98: 389-95, J Invest Dermatol 126: 1135-42, 2006 Kelso A. IL-2 regulates perforin and 2006 + Howe O, O’Malley K, Lavin M, Gardner granzyme gene expression in CD8 T cells Karagas MR, Zens MS, Stukel TA, RA, Seymour C, Lyng F, Mulvin D, independently of its effects on survival and Swerdlow AJ, Rosso S, Osterlind A, Quinlan DM and Mothersill C. Cell proliferation. J Immunol 175: 8003-10, Mack T, Kirkpatrick C, Holly EA, Green A, death mechanisms associated with G2 2005 Gallagher R, Elwood JM and Armstrong radiosensitivity in patients with prostate Jeffery JAL, Kay BH and Ryan PA. BK. Pregnancy history and incidence of cancer and benign prostatic hyperplasia. Development time and survival of Verrallina melanoma in women: a pooled analysis. Radiat Res 164: 627-34, 2005 funerea (Theobald) (Diptera: Culicidae) Cancer Causes Control 17: 11-19, 2006 Huang XQ, Hamilton MJ, Li CL, Schmidt immatures and other brackish water Kedda MA, Lose F, Duffy D, Bell E, C and Ellem KA. An extraordinarily high mosquito species in southeast Queensland, Thompson PJ and Upham J. The CD14 C- level of IL-15 expression by a cell line Australia. Aust J Entomol 44: 226-32, 2005 159T polymorphism is not associated with transduced with a modified BMGneo Jiang CP, McManus DP and Jones M. Liver asthma or asthma severity in an Australian vector displays hypoxic upregulation. Mol alveolar echinococcosis in China: clinical adult population. Thorax 60: 211-14, 2005 Biotechnol 33: 49-56, 2006 aspect with relative basic research. World J Kedda MA, Worsley P, Shi J, Phelps S, Hughes K, Leggett BA, Del Mar C, Croese Gastroenterol 11: 4611-17, 2005 Duffy D and Thompson PJ. Polymorphisms J, Fairley S, Masson J, Aitken J, Clavarino Jones MK and Good MF. Malaria parasites in the 5-lipoxygenase activating protein A, Janda M, Stanton WR, Tong S and up close. Nat Med 12: 170-71, 2006 (ALOX5AP) gene are not associated with Newman B. Guaiac versus immunochemical asthma in an Australian population. Clin Exp tests: faecal occult blood test screening for Jones MK and McManus DP. Trematodes. Allergy 35: 332-38, 2005 colorectal cancer in a rural community. Aust Manual of Clinical Microbiology, 9th NZ J Public Health 29: 358-64, 2005 Edition. ASM Press, Washington, 2006 Keller MC, Coventry WL, Heath AC and Martin NG. Widespread evidence for non- Hugo LE, Kay BH,Eaglesham GK, Holling Jones RL, Lakhani SR, Ring AE, Ashley additive genetic variation in Cloninger’s and N and Ryan PA. Investigation of cuticular S, Walsh G and Smith IE. Pathological Eysenck’s personality dimensions using a hydrocarbons for determining the age and complete response and residual DCIS twin plus siblings design. Behav Genet 35: survivorship of Australasian mosquitoes. Am following neoadjuvant chemotherapy for 707-21, 2005 J Trop Med Hyg 74: 462-74, 2006 breast carcinoma. Br J Cancer 94: 358-62, 2006

85 Kendall BJ and Whiteman DC. Temporal Lakhani SR, Reis-Filho JS, Fulford L, Lewis AG, Flanagan J, Marsh A, Pupo changes in the endoscopic frequency of new Penault-Llorca F, van der Vijver M, Parry GM, Mann G, Spurdle AB, Lindeman GJ, cases of Barrett’s esophagus in an Australian S, Bishop T, Benitez J, Rivas C, Bignon YJ, Visvader JE, Brown MA, Chenevix-Trench Health Region. Am J Gastroenterol 101: Chang-Claude J, Hamann U, Cornelisse G; Kathleen Cuningham Foundation 1178-82, 2006 CJ, Devilee P, Beckmann MW, Nestle- Consortium for Research into Familial Kramling C, Daly PA, Haites N, Varley J, Breast Cancer. Mutation analysis of Kennedy GA, Butler J, Morton J, Hill G, Lalloo F, Evans G, Maugard C, Meijers- FANCD2, BRIP1/BACH1, LMO4 and SFN in Western R, Cummings J, Allison R and Heijboer H, Klijn JG, Olah E, Gusterson familial breast cancer. Breast Cancer Res 7: Durrant S. Myeloablative allogeneic stem BA, Pilotti S, Radice P, Scherneck S, R1005-16, 2005 cell transplantation for advanced stage Sobol H, Jacquemier J, Wagner T, Peto multiple myeloma: very long-term follow J, Stratton MR, McGuffog L and Easton Li YS, Li Y, Luo XS, Yu XL, Ross AG and up of a single center experience. Clin Lab DF; Breast Cancer Linkage Consortium. McManus DP. Acquired immunity and Haematol 28: 189-97, 2006 Prediction of BRCA1 status in patients with reinfection due to S. japonicum in the breast cancer using estrogen receptor and Dongting Lake, China. Bull Med Res 34: Kennedy GA, Butler J, Western R, 27-28, 2005 Morton J, Durrant S and Hill GR. basal phenotype. Clin Cancer Res 11: 5175- Combination antithymocyte globulin and 80, 2005 Li YS, Chen HG, He HB, Hou XY, Ellis M soluble TNFalpha inhibitor (etanercept) Lambros MB, Simpson PT, Jones C, and McManus DP. A double-blind field trial +/- mycophenolate mofetil for treatment Natrajan R, Westbury C, Steele D, Savage on the effects of artemether on Schistosoma of steroid refractory acute graft-versus-host K, Mackay A, Schmitt FC, Ashworth A japonicum infection in a highly endemic disease. Bone Marrow Transplant 37: 1143- and Reis-Filho JS. Unlocking pathology focus in southern China. Acta Trop 96: 47, 2006 archives for molecular genetic studies: 184-90, 2005 Khanna KK, Gatei M and Tribbick G. a reliable method to generate probes Li YS, Zhao ZY, Ellis M, and McManus Phospho-specific antibodies as a tool to for chromogenic and fluorescent in situ DP. Applications and outcomes of periodic study in vivo regulation of BRCA1 after hybridization. Lab Invest 86: 398-408, 2006 epidemiological surveys for schistosomiasis DNA damage. Methods Mol Med 120: 441- Lavin MF and Gueven N. The complexity and related economic evaluation in the 52, 2006 of p53 stabilization and activation. Cell People’s Republic of China. Acta Trop 96: 266-75, 2005 Khanna R and Diamond DJ. Human Death Differ 13: 941-50, 2006 cytomegalovirus vaccine: time to look for Lavin MF, Delia D and Chessa L. ATM and Ligthart L, Boomsma DI, Martin NG, alternative options. Trends Mol Med 12: the DNA damage response. Workshop on Stubbe JH and Nyholt DR. Migraine with 26-33, 2006 ataxia-telangiectasia and related syndromes. aura and migraine without aura are not EMBO Rep 7: 154-60, 2006 distinct entities: further evidence from a Kijas AW, Harris JL, Harris JM and Lavin large Dutch population study. Twin Res Hum MF. Aprataxin forms a discrete branch in the Le TH, van De N, Blair D, Sithitharworn Genet 9: 54-63, 2006 HIT (histidine triad) superfamily of proteins P and McManus DP. Clonorchis sinensis with both DNA/RNA binding and nucleotide and Opisthorchis viverrini: development of Loehlin JC, Jonsson EG, Gustavsson JP, hydrolase activities. J Biol Chem 281: a mitochondrial-based multiplex PCR for Stallings MC, Gillespie NA, Wright MJ 13939-48, 2006 their identification and discrimination. Exp and Martin NG. Psychological masculinity- Parasitol 112: 109-14, 2006 femininity via the gender diagnosticity Kuschel B, Chevenix-Trench G, Spurdle approach: heritability and consistency across AB, Chen X, Hopper JL, Giles GG, Le TH, van De N, Blair D, McManus, DP, ages and populations. J Pers 73: 1295- McCredie M, Chang-Claude J, Gregory Kino H and Agatsuma T. Paragonimus 1319, 2005 CS, Day NE, Easton DF, Ponder BA, heterotremus Chen and Hsia, (1964), in Dunning AM and Pharoah PDP. Common Vietnam: a molecular identification and Loehlin JC, Medland SE, Montgomery polymorphisms in ERCC2 (Xeroderma relationships of isolates from different hosts GW and Martin NG. Eysenck’s Psychoticism pigmentosum D) are not associated with and geographical origins. Acta Trop 98: and the X-linked androgen receptor gene breast cancer risk. Cancer Epidemiol 25-33, 2006 CAG polymorphism in additional Australia Biomarkers Prev 14: 1828-31, 2005 samples. Pers Indiv Dif 39: 661-68, 2005 Lee CM, Knight B, Yeoh GC, Ramm Laha T, Kewgrai N, Loukas A and Brindley GA and Olynyk JK. Lymphotoxin- López JA and Pinzon-Charry A. PJ. Characterization of SR3 reveals beta production following bile duct Immunosuppression and Dendritic abundance of non-LTR retrotransposons of ligation: possible role for Kupffer cells. J Cell Dysfunction. Modern Aspects of the RTE clade in the genome of the human Gastroenterol Hepatol 20: 1762-68 2005 Immunobiology 18: 20-21, 2006 blood fluke, Schistosoma mansoni. BMC Genomics 6: 154, 2006 Lee EY, Williamson R, Watt P, Hughes Lose F, Lovelock P, Chenevix-Trench G, MC, Green AC and Whiteman DC. Sun Mann GJ, Pupo GM and Spurdle AB; Laha T, Kewgrai N, Loukas A and Brindley exposure and host phenotype as predictors the Kathleen Cuningham Foundation PJ. The dingo non-long terminal repeat of cutaneous melanoma associated with Consortium for Research into Familial retrotransposon from the genome of the neval remnants or dermal elastosis. Int J Breast Cancer. Variation in the RAD51 gene hookworm, Ancylostoma caninum. Exp Cancer 119: 636–42, 2006 and familial breast cancer. Breast Cancer Res Parasitol 113: 142-53, 2005 8: R26, 2006 Levine MM, Brown GV, Good MF, Kaslow DC, Liu MA, Nabel GJ, Nardin Lose F, Thompson PJ, Duffy D, Stewart E, Rabinovich NR, Shaw AR, Webster GA and Kedda MA. A novel tissue HK and Zoon KC. Battling Malaria. inhibitor of metalloproteinase-1 (TIMP-1) Strengthening the U.S. Military Malaria polymorphism associated with asthma in Vaccine Program. Monograph Review for Australian women. Thorax 60: 623-28, the Institute of Medicine of the National 2005 Academies. Eds: Graves PM and Levine MM, 25 May, 2006

86 Loukas A and Bethony JM. Progress in Lynskey MT, Grant JD, Nelson EC, Bucholz Marshall JA, Forster TH, Purdie DM, hookworm vaccines. In: Research advances KK, Madden PA, Statham DJ, Martin NG Lanagan CM, O’Connor LE, O’Rourke in infectious diseases. Global Research and Heath AC. Duration of cannabis use MG, Johnson MK, See JL, Ellem KA, Network, Kerala, India, pp 51-60, 2006 – a novel phenotype? Addict Behav 31: Martinez NR, López JA and Schmidt CW. 984-94, 2006 Immunological characteristics correlating Loukas A and Hotez P. Anthelminthics - with clinical response to immunotherapy drugs used in the chemotherapy of helminth Lynskey MT, Nelson EC, Neuman RJ, in patients with advanced metastatic infections. Goodman and Gilman’s The Bucholz KK, Madden PAF, Knopik VS, melanoma. Immunol Cell Biol 84: 295-302, pharmacological basis of therapeutics, 11th Slutske W, Whitfield J, Martin NG 2006 edition. McGraw-Hill Professional, New and Heath AC. Limitations of DSM-IV York, 2005 operationalizations of alcohol abuse and Maxwell TJ, Tang C, Forster T, Pietersz dependence in a sample of Australian twins. G, Apostolopoulos V and Lopez JA. Lovelock PK, Healey S, Au W, Sum Twin Res Hum Genet 8: 574-84, 2005 Efficient antigen delivery into dendritic cell EY, Tesoriero A, Wong EM, Hinson S, by transfection of mRNA conjugated with Brinkworth R, Bekessy A, Diez O, Izatt MacDonald KP, Rowe V, Bofinger HM, oxidisedmannan and polyethylenimine. L, Solomon E, Jenkins M, Renard H, Thomas R, Sasmono T, Hume DA and Tissue Antigens. 66: 490, 2005 Hopper J, Waring P, Tavtigian SV, Goldgar Hill GR. The colony stimulating factor-1 D, Lindeman GJ, Visvader JE, Couch FJ, receptor is expressed on dendritic cells McCurdy RD, Feron F, Perry C, Chant Henderson BR, Southey M, Chenevix- during differentiation and regulates their DC, McLean D, Matigian N, Hayward Trench G, Spurdle AB, Brown MA; expansion. J Immunol 175: 1399-405, 2005 NK, McGrath JJ and Mackay-Sim A. kConFab Investigators. Genetic, functional, Cell cycle alterations in biopsied olfactory and histopathological evaluation of two Macgregor S and Khan IA. GAIA: An easy- neuroepithelium in schizophrenia and C-terminal BRCA1 missense variants. J Med to-use web-based application for interaction bipolar I disorder using cell culture and gene Genet 43: 74-8, 2006 analysis of case-control data. BMC Med expression analyses. Schizophr Res 82: 163- Genet 7: 34, 2006 73, 2006 Luciano M, Kirk KM, Heath AC and Martin NG. The genetics of tea and coffee Macgregor S, Knott SA and Visscher PM. McGregor JA, Shayeghi M, Vulpe CD, drinking and preference for source of False disease region identification from Anderson GJ, Pietrangelo A, Simpson caffeine in a large community sample of identity-by-descent haplotype sharing in RJ and McKie AT. Impaired iron transport Australian twins. Addiction 100: 1510-17, the presence of phenocopies. Twin Res Hum activity of ferroportin1 in hereditary iron 2005 Genet 9: 9-16, 2006 overload. J Membr Biol 206: 3-7, 2005 Luciano M, Posthuma D, Wright MJ, de Macgregor S, Knott SA, White I and McManus DP. Back to the future for Geus EJ, Smith GA, Geffen GM, Boomsma Visscher PM. Quantitative trait locus schistosome vaccines? Parasite Immunol 28: DI and Martin NG. Perceptual speed does analysis of longitudinal quantitative trait 246-47, 2006 not cause intelligence, and intelligence does data in complex pedigrees. Genetics 171: not cause perceptual speed. Biol Psychol 70: 1365-76, 2005 McManus DP. Molecular characterization of 1-8, 2005 taeniid cestodes. Parasitology International Mah S, Nelson MR, DeLisi LE, Reneland 55 Suppl: S31-S37, 2006 Luciano M, Wainwright MA, Wright RH, Markward N, James MR, Nyholt MJ and Martin NG. The heritability DR, Hayward N, Handoko H, Mowry B, McManus DP. Prospects for development of conscientiousness facets and their Kammerer S and Braun A. Identification of a transmission blocking vaccine against relationship to IQ and academic of the semaphorin receptor PLXNA2 as a Schistosoma japonicum. Parasite Immunol achievement. Pers Indiv Diff 40: 1189-99, candidate for susceptibility to schizophrenia. 27: 297-308, 2005 Mol Psychiatry 11: 471-78, 2006 2006 McManus DP and Ito A. Application of Luciano M, Wright MJ, Duffy DL, Mann GJ, Thorne H, Balleine RL, Butow molecular techniques for identification of Wainwright MA, Shu G, Evans DM, PN, Clarke CL, Edkins E, Evans GM, human Taenia spp. In: WHO/FAO/OIE Geffen GM, Montgomery GW and Fereday S, Haan E, Gattas M, Giles GG, Guidelines for the Surveillance, Prevention Martin NG. Genome-wide scan of IQ finds Goldblatt J, Hopper JL, Kirk J, Leary JA, and Control of Taeniosis/Cysticercosis, OIE significant linkage to a quantitative trait Lindeman G, Niedermayr E, Phillips KA, Publications, Paris, France, pp 52-55, 2005 locus on 2q. Behav Genet 36: 45-55, 2006 Picken S, Pupo GM, Saunders C, Scott CL, Spurdle AB, Suthers G, Tucker K and McManus DP. Genetic discrimination Lucke AJ, Boyle GM, Parsons PG and Chenevix-Trench G; Kathleen Cuningham of Echinoccocus species and strains. In: Fairlie DP. New cysteine derivatives with Consortium for Research in Familial Parasitic Flatworms: Molecular Biology, antiproliferative activity on melanoma cells. Breast Cancer. Analysis of cancer risk and Biochemistry, Immunology and Physiology. Med Chem 2: 123-32, 2006 BRCA1 and BRCA2 mutation prevalence in Eds: Maule A. and Marks NJ. CABI. the kConFab familial breast cancer resource. Wallingford, Oxon, UK, pp 81-95, 2006 Lynch BM, Owen N, Newman B, Breast Cancer Res 8: R12, 2006 Pakenham K, Leggett B, Dunn J and McMillan DJ, Geffers R, Schouls LM, Aitken JF. Reliability of a measure of Marsh A, Wicking C, Wainwright B and Vlaminckx B, Sriprakash KS, Wannet W prediagnosis physical activity for cancer Chenevix-Trench G. DHPLC analysis of and Chhatwal GS. Virulence gene profiling survivors. Med Sci Sports Exerc 38: 715-19, patients with Nevoid Basal Cell Carcinoma of GAS isolates from the Netherlands. In: 2006 Syndrome reveals novel PTCH missense Streptococci - New Insights Into an Old mutations in the sterol-sensing domain. Enemy. International Congress Series 1289, Lynch SK, Turkheimer E, D’Onofrio BM, Hum Mut 26: 283, 2005 Elsevier BV, pp 180-83, 2006 Mendle J, Emery RE, Slutske WS and Martin NG. A genetically informed study of McNaughton S, Marks G and Green AC. the association between harsh punishment Role of dietary factors in the development and offspring behavioral problems. J Fam of basal cell cancer and squamous cell Psychol 20: 190-98, 2006 cancer of the skin. Cancer Epidemiol Biomarkers Prev 14: 1596-1607, 2005

87 McRae AF and Beraldi D. Examination of Miles JJ, Silins SL, Brooks AG, Davis JE, Moss DJ, Burrows R and Khanna R. a region showing linkage map discrepancies Misko I and Burrows SR. T-cell grit: large Immunobiology of Epstein-Barr virus. In: across sheep breeds. Mamm Genome 17: clonal expansions of virus-specific CD8+ Human herpesviruses: Biology, Therapy 346-53, 2006 T cells can dominate in the peripheral and Immunoprophylaxis. Eds: Arvin AM, circulation for at least 18 years. Blood 106: Campadielli-Fume G, Roizman B, Whitley McRae AF, Bishop SC, Walling GA, Wilson 4412-13, 2005 R and Yamanishi K. Cambridge University AD and Visscher PM. Mapping of multiple Press, pp 882-892, 2006 quantitative trait loci for growth and carcass Mitrovic SM, Hamilton B, McKenzie L, traits in a complex commercial sheep Furey A and James KJ. Persistence of Mould AW, Greco SA, Cahill MM, Tonks pedigree. Anim Sci 80: 135-41, 2005 yessotoxin under light and dark conditions. ID, Bellomo D, Patterson C, Zournazi A, Mar Environ Res 60: 397-401, 2005 Nash A, Scotney P, Hayward NK and Kay McRae AF, Pemberton JM and Visscher GF. Transgenic overexpression of vascular PM. Modeling linkage disequilibrium Moffatt CR, Green AC and Whiteman DC. endothelial growth factor-B isoforms by in natural populations: the example of Diagnostic accuracy in skin cancer clinics: endothelial cells potentiates postnatal vessel the Soay sheep population of St. Kilda, the Australian experience. Int J Dermatol growth in vivo and in vitro. Circ Res 97: Scotland. Genetics 171: 251-58, 2005 45: 656-60, 2006 e60-70, 2005 Medland SE, Duffy DL, Spurdle AB, Molven A, Grimstvedt MB, Steine SJ, Nagle CM, Purdie DM, Webb PM, Green Wright MJ, Geffen GM, Montgomery Harland M, Avril MF, Hayward NK, Akslen AC and Bain CJ. Searching for cancer GW and Martin NG. Opposite effects of LA. A large Norwegian family with inherited deaths in Australia: National Death Index vs. androgen receptor CAG repeat length on malignant melanoma, multiple atypical nevi, cancer registries. Asian Pac J Cancer Prev 7: increased risk of left-handedness in males and CDK4 mutation. Genes Chromosomes 41-5, 2006 and females. Behav Genet 35: 735-44, Cancer 44: 10-18, 2005 2005 Naidich A, McManus DP, Canova SG, Montgomery GW, Campbell MJ, Dickson Gutierrez AM, Zhang W, Guarnera EA Medland SE, Duffy DL, Wright MJ, Geffen P, Herbert S, Siemering K, Ewen-White and Rosenzvit MC. Patent and pre-patent GM and Martin NG. Handedness in twins: KR, Visscher PM and Martin NG. detection of Echinococcus granulosus joint analysis of data from 35 samples. Twin Estimation of the rate of SNP genotyping genotypes in the definitive host. Mol Cell Res Hum Genet 9: 46-53, 2006 errors from DNA extracted from different Probes 20:5-10, 2006 tissues. Twin Res Hum Genet 8: 346-52, Meiser B, Dunn S, Dixon J and Powell LW. 2005 Navarro P, Visscher PM, Knott SA, Burt Psychological adjustment and knowledge DW, Hocking PM and Haley CS. Mapping about hereditary hemochromatosis in a Morgan AJ and Khanna R. Epstein- of quantitative trait loci affecting organ clinic-based sample: a prospective study. J Barr virus: Section VI: Vaccines and weights and blood variables in a broiler Genet Couns 14: 453-63, 2005 Immunotherapy. In: Human herpesviruses: layer cross. Br Poult Sci 46: 430-42, 2005 Biology, Therapy and Immunoprophylaxis. Mendle J, Turkheimer E, D’Onofrio BM, Eds: Arvin AM, Campadielli-Fume G, Neale RE, Forman D, Murphy MF, and Lynch SK, Emery RE, Slutske WS and Roizman B, Whitley R and Yamanishi K. Whiteman DC. Site-specific occurrence of Martin NG. Family structure and age at Cambridge University Press, pp 1265-77, nonmelanoma skin cancers in patients with menarche: a children-of-twins approach. 2006 cutaneous melanoma. Br J Cancer 93: 597- Dev Psychol 42: 533-42, 2006 601, 2005 Morley KI, Medland SE, Ferreira MA, Metharom P, Ellem KA and Wei MQ. Lynskey MT, Montgomery GW, Heath AC, Newton TR, Parsons PG, Lincoln DJ, Gene transfer to dendritic cells induced a Madden PA and Martin NG. A possible Cummings MC, Wyld DK, Webb PM, protective immunity against melanoma. Cell smoking susceptibility locus on chromosome Green AC and Boyle GM. Expression Mol Immunol 2: 281-88, 2005 11p12: evidence from sex-limitation linkage profiling correlates with treatment response Middelberg R, Heath AC, Martin NG and analyses in a sample of Australian twin in women with advanced serous epithelial Whitfield JB. Evidence of age-dependent families. Behav Genet 36: 87-99, 2006 ovarian cancer. Int J Cancer 119: 875-83, 2006 genetic influences on plasma total Morris ES, MacDonald KP and Hill GR. cholesterol. Eur J Cardiovasc Prev Rehabil Stem cell mobilization with G-CSF analogs: Newton RA, Smit SE, Barnes CC, Pedley 12: 380-86, 2005 a rational approach to separate GVHD and J, Parsons PG and Sturm RA. Activation of Middeldorp CM, Birley AJ, Cath DC, GVL? Blood 107: 3430-35, 2006 the cAMP pathway by variant human MC1R Gillespie NA, Willemsen G, Statham alleles expressed in HEK and in melanoma Morris ES, Macdonald KP, Rowe V, cells. Peptides. 26: 1818-24, 2005 DJ, de Geus EJ, Andrews JG, van Dyck Banovic T, Kuns RD, Don AL, Bofinger R, Beem AL, Sullivan PF, Martin NG HM, Burman AC, Olver SD, Kienzle N, Nyholt DR. On the probability of dizygotic and Boomsma DI. Familial clustering of Porcelli SA, Pellicci DG, Godfrey DI, twins being concordant for two alleles at major depression and anxiety disorders in Smyth MJ and Hill GR. NKT cell-dependent multiple polymorphic loci. Twin Res Hum Australian and Dutch twins and siblings. leukemia eradication following stem cell Genet 9: 194-197, 2006 Twin Res Hum Genet 8: 609-15, 2005 mobilization with potent G-CSF analogs. J Clin Invest 115: 3093–3103, 2005 Nyholt DR, Morley KI, Medland SE, Miles JJ, Elhassen D, Borg NA, Silins SL, Ferreira MA, Boomsma DI, Heath AC, Tynan FE, Burrows JM, Purcell AW, Kjer- Moss DJ, Burrows SR and Khanna R. Merikangas KR, Montgomery GW and Nielsen L, Rossjohn J, Burrows SR and Developing vaccines against EBV-associated Martin NG. Genomewide significant linkage McCluskey J. CTL recognition of a bulged diseases. In: Epstein-Barr Virus. Ed: to migrainous headache on chromosome viral peptide involves biased TCR selection. J Robertson ES. Caister Academic Press, pp 5q21. Am J Hum Genet 77: 500-12, 2005 Immunol 175: 3826-34, 2005 651-67, 2005 Moss DJ, Burrows SR and Khanna R. Vaccine Based Approaches. In: Infection, Pathogenesis, Molecular Biology and Control of Epstein-Barr virus. Ed: Robertson ES. Horizon Press, pp 253-267, 2005

88 Olive C, Ho MF, Dyer J, Lincoln D, Barozzi Pasquetto V, Bui HH, Giannino R, Banh Pinzon-Charry A, Ho CSK, Laherty R, N, Toth I and Good MF. Immunisation C, Mirza F, Sidney J, Oseroff C, Tscharke Maxwell T, Walker D, Gardiner RA, with a tetraepitopic lipid core peptide DC, Irvine K, Bennink JR, Peters B, O’Connor L, Pyke C, Schmidt C, Furnival vaccine construct induces broadly protective Southwood S, Cerundolo V, Grey H, C and Lopez JA. A population of HLA-DR+ immune responses against group A Yewdell JW and Sette A. HLA-A*0201, immature cells accumulate in the blood streptococcus. J Infect Dis 193: 1666-1676, HLA-A*1101, and HLA-B*0702 transgenic dendritic cell compartment of patients with 2006 mice recognize numerous poxvirus different types of cancer. determinants from a wide variety of viral Tissue Antigens 66: 484, 2005 Olsen CM, Hughes MC, Pandeya N and gene products. J Immunol 175: 5504-15, Green AC. Anthropometric measures 2005 Pinzon-Charry A, Ho CS, Laherty R, in relation to Basal Cell Carcinoma: a Maxwell T, Walker D, Gardiner RA, longitudinal study. BMC Cancer 6: 82, 2006 Pearson MS, McManus DP, Smyth DJ, O’Connor L, Pyke C, Schmidt C, Furnival Lewis FA and Loukas A. In vitro and in C and López JA. A population of HLA-DR+ Olver S, Groves P, Buttigieg K, Morris silico analysis of signal peptides from the immature cells accumulates in the blood ES, Janas ML, Kelso A and Kienzle N. human blood fluke, Schistosoma mansoni. dendritic cell compartment of patients Tumor-derived interleukin-4 reduces tumor FEMS Immunol Med Microbiol 45: 201-11, with different types of cancer. Neoplasia 7: clearance and deviates the cytokine and 2005 1112-22, 2005 granzyme profile of tumor-induced CD8+ T cells. Cancer Res 66: 571-80. 2006 Pergadia ML, Heath AC, Agrawal A, Pinzon-Charry A, Maxwell T, Prato S, Buchholz KK, Martin NG and Madden PA. Furnival C, Schmidt C and López JA. Olynyk JK, Knuiman MW, Divitini ML, The implications of simultaneous smoking HLA-DR+ immature cells exhibit reduced Bartholomew HC, Cullen DJ and Powell initiation for inferences about the genetics antigen-presenting cell function but respond LW. Effects of HFE gene mutations and of smoking behavior from twin data. Behav to CD40 stimulation. Neoplasia 7: 1123-32, alcohol on iron status, liver biochemistry Genet 36: 567-76, 2006 2005 and morbidity. J Gastroenterol Hepatol 20: 1435-1441, 2005 Pergadia ML, Heath AC, Martin NG and Pinzon-Charry A, Maxwell T, McGuckin Madden PA. Genetic analyses of DSM-IV MA, Schmidt C, Furnival C and López JA. O’Neil J and Powell L. Clinical aspects of nicotine withdrawal in adult twins. Psychol Spontaneous Apoptosis of Blood Dendritic hemochromatosis. Semin Liver Dis 25: 381- Med 36: 963-72, 2006 Cells in Patients with Breast Cancer. Tissue 91, 2005 Antigens 66: 513, 2005 Pettigrew C, Wayte N, Lovelock PK, Oseroff C, Kos F, Bui HH, Peters B, Tavtigian SV, Chenevix-Trench G, Pijlman GP, Suhrbier A and Khromykh AA. Pasquetto V, Glenn J, Palmore T, Sidney Spurdle AB and Brown MA. Evolutionary Kunjin virus replicons: an RNA-based, non- J, Tscharke DC, Bennink JR, Southwood conservation analysis increases the cytopathic viral vector system for protein S, Grey HM, Yewdell JW and Sette A. colocalization of predicted exonic splicing production, vaccine and gene therapy HLA class I-restricted responses to vaccinia enhancers in the BRCA1 gene with missense applications. Expert Opin Biol Ther 6: 135- recognize a broad array of proteins mainly sequence changes and in-frame deletions, 45, 2006 involved in virulence and viral gene but not polymorphisms. Breast Cancer Res regulation. Proc Natl Acad Sci USA 102: 7: R929-R939, 2005 Posthuma D, Visscher PM, Willemsen G, 13980-85, 2005 Zhu G, Martin NG, Slagboom PE, de Geus Pietersz GA, Tang CK, Sheng K, Maxwell EJ and Boomsma DI. Replicated linkage for Oster N, Abdel-Aziz IZ, Stich A, Coulibaly T, Pouniotis D, Lodding J, Minigo G, eye colour on 15q using comparative ratings B, Kouyaté B, Andrews KT, McLean JE and Plebanski M, McKenzie I, López JA and of sibling pairs. Behav Genet 36: 12-17, Lanzer M. Comparison of different PCR Apostolopoulos V. Mannan-mediated 2006 protocols for the detection and diagnosis of delivery of protein, DNA, RNA to antigen Plasmodium falciparum. Parasitol Res 97: presenting cells. Tissue Antigens. 66: 512, Posthuma D, Luciano M, de Geus EJ, 424-28, 2005 2005 Wright MJ, Slagboom PE, Montgomery GW, Boomsma DI and Martin NG. A Panaretto KS, Dallachy D, Manessis V, Pinzon-Charry A, Schmidt CW and genomewide scan for intelligence identifies Larkins S, Tabrizi S, Upcroft J, Garland S. López JA. The key role of CD40 ligand in quantitative trait loci on 2q and 6p. Am J Cervical smear participation and prevalence overcoming tumor-induced dendritic cell Hum Genet 77: 318-26, 2005 of sexually transmitted infections in dysfunction. Breast Cancer Res 8: 402-3, women attending a community-controlled 2006 Powell EE, Ali A, Clouston AD, Dixon Indigenous health service in north JL, Lincoln DJ, Purdie DM, Fletcher LM, Queensland. Aust N Z J Public Health 30: Pinzon-Charry A, Schmidt C and López Powell LW and Jonsson JR. Steatosis is a 171-76 2006 JA. Dendritic cell immunotherapy for breast cofactor in liver injury in hemochromatosis. cancer. Expert Opin Biol Ther 6: 591-604, Gastroenterology 129: 1937-1943, 2005 Pasay C, Walton S, Fischer K, Hot D and 2006 McCarthy J. PCT-based assay to survey Powell LW. Liver function tests (Chapter for knockdown resistance to pyrethroid Pinzon-Charry A, Maxwell T, McGuckin 14). In: Abnormal laboratory Results, 2nd acaricides in human scabies mites (Sarcoptes MA, Schmidt C, Furnival C and López JA. Edition. Ed: Kellerman G. McGraw-Hill, scabiei var hominis). Am J Trop Med Hyg Spontaneous apoptosis of blood dendritic Australia, pp 88-94, 2004 74: 649-57, 2006 cells in patients with breast cancer. Breast Cancer Res 8: R5, 2006 Powell LW, Dixon JL, Ramm GA, Papp LV, Lu J, Striebel F, Kennedy D, Purdie DM, Lincoln DJ, Anderson GJ, Holmgren A and Khanna KK. The redox Pinzon-Charry A, Maxwell T and López Subramaniam VN, Hewett DG, Searle state of SECIS binding protein 2 controls its JA. Dendritic cell dysfunction in cancer: JW, Fletcher LM, Crawford DH, Rodgers localization and selenocysteine incorporation a mechanism for immunosuppression. H, Allen KJ, Cavanaugh JA and Bassett function. Mol Cell Biol 26: 4895-910, 2006 Immunol Cell Biol 83: 451-61, 2005 ML. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med 166: 294- 301, 2006

89 Prato S, Fleming J, Schmidt CW, Corradin Rosenzvit MC, Zhang W, Motazedian H, Shekar SN, Banerjee T and Biswas A. G and López JA. Cross-presentation of a Smyth D, Pearson M, Loukas A, Jones Hypotheses on the effect of cadmium on human malaria CTL epitope is conformation MK and McManus DP. Identification of glutathione content of red blood corpuscles. dependent. Mol Immunol 43: 2031-36, membrane-bound and secreted proteins Twin Res Hum Genet 9: 73-75, 2006 2006 from Echinococcus granulosus by signal sequence trap. Int J Parasitol 36: 123-130, Shekar SN, Duffy DL, Montgomery Quinn HE, Gatton ML, Hall G, Young 2006 GW and Martin NG. A genome scan for M and Ryan PA. Analysis of Barmah epidermal skin pattern in adolescent twins Forest virus disease activity in Queensland, Rosner BA, Colditz GA, Webb PM and reveals suggestive linkage on 12p13.31. J Australia, 1993-2003: identification of a Hankinson SE. Mathematical models of Invest Dermatol 126: 277-82, 2006 large, isolated outbreak of disease. J Med ovarian cancer incidence. Epidemiology 16: Entomol 42: 882-90, 2005 508-15, 2005 Shekar SN, Luciano M, Duffy DL and Martin NG. Genetic and environmental Ramm GA and Ruddell RG. Hepatotoxicity Ross JA, Zvyagin AV, Heckenberg NR, influences on skin pattern deterioration. J of iron overload: mechanisms of iron- Upcroft J, Upcroft P, Rubinsztein-Dunlop Invest Dermatol 125: 1119-29, 2005 induced hepatic fibrogenesis. Semin Liver H. Measurement of action spectra of Dis 25: 433-49, 2005 light-activated processes. J Biomed Opt 11: Shera J, Sriprakash KS and McMillan DJ. 014008, 2006 The Nutritional Requirements for Biofilm Ramm GA, Pereira TN and Lewindon PJ. Formation by Group A Streptococcus. In: Role of serum markers in detection and Rossi E, Wallace DF, Subramaniam VN, St Streptococci - New Insights Into an Old monitoring progression of CF liver disease. Pierre TG, Mews C and Jeffrey GP. Clinical Enemy. International Congress Series 1289, Pediatr Pulmonol 40: 169-71, 2005 expression of C282Y homozygous HFE Elsevier BV, pp 139-142, 2006 haemochromatosis at 14 years of age. Ann Ramprasad VL, Sripriya S, Ronnie G, Clin Biochem 43: 233-36, 2006 Shi J, Misso NL, Duffy DL, Bradley B, Nancarrow D, Saxena S, Hemamalini A, Beard R, Thompson PJ and Kedda MA. Kumar D, Vijaya L and Kumaramanickavel Rulli NE, Suhrbier A, Hueston L, Heise MT, Cyclooxygenase-1 gene polymorphisms in G. Genetic homogeneity for inherited Tupanceska D, Zaid A, Wilmes A, Gilmore patients with different asthma phenotypes congenital microcoria loci in an Asian Indian K, Lidbury BA and Mahalingam S. Ross and atopy. Eur Respir J 26: 249-56, 2005 pedigree. Mol Vis 11: 934-40, 2005 River virus: Molecular and cellular aspects of disease pathogenesis. Pharmacol Ther 107: Shteyer E, Ramm GA, Xu C, White Ranjit N, Jones MK, Stenzel DJ, Gasser 329-42, 2005 FV and Shepherd RW. Outcome after RB and Loukas A. A survey of the portoenterostomy in biliary atresia: intestinal transcriptomes of the hookworms, Russell T, Kay BH and Ryan PA. Mosquito pivotal role of degree of liver fibrosis and Necator americanus and Ancylostoma control and Bacillus thuringiensis var. intensity of stellate cell activation. J Pediatr caninum, using tissues isolated by laser israelensis use, an Australian perspective. Gastroenterol Nutr 42: 93-99, 2006 microdissection microscopy. Int J Parasitol Biotechnology of Bacillus thuringiensis. 5: 36: 701-10, 2006 57-72, 2005 Simpson F, Lammerts van Bueren K, Butterfield N, Bennetts JS, Bowles J, Reis-Filho JS, Milanezi F, Carvalho S, Schaft N, Lankiewicz B, Drexhage J, Adolphe C, Simms LA, Young J, Walsh Simpson PT, Steele D, Savage K, Lambros Berrevoets C, Moss DJ, Levitsky V, MD, Leggett B, Fowles LF and Wicking MB, Pereira EM, Nesland JM, Lakhani Bonneville M, Lee SP, McMichael AJ, C. The PCNA-associated factor KIAA0101/ SR and Schmitt FC. Metaplastic breast Gratama JW, Bolhuis RL, Willemsen R p15(PAF) binds the potential tumor suppressor carcinomas exhibit EGFR, but not HER2, and Debets R. T cell re-targeting to EBV product p33ING1b. Exp Cell Res 312: 73- gene amplification and overexpression: antigens following TCR gene transfer: 85, 2006 immunohistochemical and chromogenic in CD28-containing receptors mediate situ hybridization analysis. Breast Cancer Res enhanced antigen-specific IFNgamma Siskind V, Whiteman DC, Aitken JF, 7: R1028-35, 2005 production. Int Immunol 18: 591-601, 2006 Martin NG and Green AC. An analysis of risk factors for cutaneous melanoma by Reis-Filho JS, Milanezi F, Steele D, Savage Schmidt C, Martinez N, Neller M, Lai anatomical site (Australia). Cancer Causes K, Simpson PT, Nesland JM, Pereira EM, M, Lopez JA, Lanagan C, O’Connor L, Control 16: 193-99, 2005 Lakhani SR and Schmitt FC. Metaplastic Nicholas D, Johnson M, See J, Hallt breast carcinomas are basal-like tumours. S, Slater G, O’Rourke MGE, Pavey S, Skinner-Adams TS, Guddat LW, Gardiner Histopathology 49: 10-21, 2006 Hayward N and Ellem KA. Towards DL, McCarthy JS and Andrews KT. Are a response model for dendritic cell Plasmodium falciparum plasmepsins the Reis-Filho JS, Simpson PT, Gale T and immunotherapy of advanced metastatic target of HIV protease inhibitors? J Infect Lakhani SR. The molecular genetics melanoma. Tissue Antigens 66: 533, 2005 Dis 191: 1382-83, 2005 of breast cancer: the contribution of comparative genomic hybridization. Pathol Sebastiani G, Wallace DF, Davies SE, Smit CM, Wright MJ, Hansell NK, Geffen Res Pract 201: 713-25, 2005 Kulhalli V, Walker AP and Dooley JS. GM and Martin NG. Genetic variation of Fatty liver in H63D homozygotes with individual alpha frequency (IAF) and alpha Roberts DW, Newton RA, Beaumont KA, hyperferritinemia. World J Gastroenterol 12: power in a large adolescent twin sample. Int Leonard JH and Sturm RA. Quantitative 1788-92, 2006 J Psychophysiol 61: 235-43, 2006 analysis of MC1R gene expression in human skin cell cultures. Pigment Cell Res 19: 76- Shayeghi M, Latunde-Dada GO, Oakhill Smith NC, Tilley L, Thompson RC, Ryan 89, 2006 JS, Laftah AH, Takeuchi K, Halliday N, UM, Loukas A, Jenkins D and McFadden Khan Y, Warley A, McCann FE, Hider GI. An Australian network to support the Roberts KH, Munafo MR, Rodriguez RC, Frazer DM, Anderson GJ, Vulpe CD, understanding and control of parasites. D, Drury M, Murphy MF, Neale RE and Simpson RJ and McKie AT. Identification Trends Parasitol 22: 97-99, 2006 Nettle D. Longitudinal analysis of the effect of an intestinal heme transporter. Cell 122: of prenatal nicotine exposure on subsequent 789-801, 2005 smoking behavior of offspring. Nicotine Tob Res 7: 801-8, 2005

90 Smith P, McGuffog L, Easton DF, Mann Spurdle AB, Antoniou AC, Kelemen L, Tesoriero AA, Wong EM, Jenkins MA, GJ, Pupo GM, Newman B and Chenevix- Holland H, Peock S, Cook MR, Smith Hopper JL, Brown MA, Chenevix- Trench G; kConFab Investigators; Szabo PL, Greene MH, Simard J, Plourde M, Trench G, Spurdle AB and Southey MC; C, Southey M, Renard H, Odefrey F, Southey MC, Godwin AK, Beck J, Miron kConFab. Molecular characterization and Lynch H, Stoppa-Lyonnet D, Couch F, A, Daly MB, Santella RM, Hopper JL, John cancer risk associated with BRCA1 and Hopper JL, Giles GG, McCredie MR, EM, Andrulis IL, Durocher F, Struewing JP, BRCA2 splice site variants identified in Buys S, Andrulis I and Senie R; BCFS, Easton DF, Chenevix-Trench G; Australian multiple-case breast cancer families. Human BRCAX Collaborators Group; Goldgar DE, Breast Cancer Family Study, Australian Mutation, 26: 495, 2005. Oldenburg R, Kroeze-Jansema K, Kraan J, Jewish Breast Cancer Study, Breast Meijers-Heijboer H, Klijn JG, van Asperen Cancer Family Registry, Interdisciplinary Tey S, Butler J, Durrant S, Hill G, Morton C, van Leeuwen I, Vasen HF, Cornelisse Health Research International Team on J and Kennedy G. A prognostic model CJ, Devilee P, Baskcomb L, Seal S, Barfoot Breast Cancer Susceptibility, The Kathleen for prolonged event-free survival after R, Mangion J, Hall A, Edkins S, Rapley Cunningham Foundation Consortium autologous or allogeneic blood or marrow E, Wooster R, Chang-Claude J, Eccles D, for Research into Familial Breast Cancer, transplantation for relapsed and refractory Evans DG, Futreal PA, Nathanson KL and and Epidemiological Study of Familial Hodgkin’s disease. Bone Marrow Transplant Weber BL; Breast Cancer Susceptibility Breast Cancer Study Collaborators. 36: 553-54, 2005 Collaboration (UK); Rahman N and The AIB1 polyglutamine repeat does not Thakkinstian A, McElduff P, D’Este C, Stratton MR. A genome wide linkage modify breast cancer risk in BRCA1 and Duffy D and Attia J. A method for meta- search for breast cancer susceptibility genes. BRCA2 mutation carriers. Cancer Epidemiol analysis of molecular association studies. Genes Chromosomes Cancer 45: 646-55, Biomarkers Prev 15: 76-79, 2006 Stat Med 24: 1291-1306, 2005. 2006 Steele TM, Frazer DM and Anderson Thomson PA, Wray NR, Millar JK, Smith KJ, O’Brien SM, Smithers BM, GJ. Systemic regulation of intestinal iron Evans KL, Hellard SL, Condie A, Muir Gotley DC, Webb PM, Green AC and absorption. IUBMB Life 57: 499-503, 2005 WJ, Blackwood DH and Porteous DJ. Whiteman DC. Interactions among Stewart I, Robertson IM, Webb PM, Association between the TRAX/DISC locus smoking, obesity, and symptoms of acid and both bipolar disorder and schizophrenia reflux in Barrett’s esophagus. Cancer Schluter PJ and Shaw GR. Cutaneous hypersensitivity reactions to freshwater in the Scottish population. Mol Psychiatry Epidemiol Biomarkers Prev 14: 2481-86, 10: 657-68, 2005 2005 cyanobacteria - human volunteer studies. BMC Dermatol 6: 6, 2006 Thomson PA, Wray NR, Thomson AM, Smyth DJ, Glanfield A, McManus DP, Dunbar DR, Grassie MA, Condie A, Hacker E, Blair S, Anderson GJ and Jones Stewart I, Webb PM, Schluter PJ, Fleming LE, Burns JW Jr, Gantar M, Backer LC and Walker MT, Smith DJ, Pulford DJ, Muir MK. Two isoforms of a divalent metal W, Blackwood DH and Porteous DJ. transporter (DMT1) in Schistosoma mansoni Shaw GR. Epidemiology of recreational exposure to freshwater cyanobacteria – an Sex-specific association between bipolar suggest a surface-associated pathway for affective disorder in women and GPR50, an iron absorption in schistosomes. J Biol Chem international prospective cohort study. BMC Public Health 6: 93, 2006 X-linked orphan G protein-coupled receptor. 281: 2242-48, 2006 Mol Psychiatry 10: 470-78, 2005 St Pierre L, Woods R, Earl S, Masci PP So A, Duffy DL, Gordon RD, Jeske YW, Tomlinson VA, Newbery HJ, Wray NR, Lin-Su K, New MI and Stowasser M. and Lavin MF. Identification and analysis of venom gland-specific genes from the coastal Jackson J, Larionov A, Miller WR, Dixon Familial hyperaldosteronism type II is linked JM and Abbott CM. Translation elongation to the chromosome 7p22 region but also taipan (Oxyuranus scutellatus) and related species. Cell Mol Life Sci 62: 2679-93, 2005 factor eEF1A2 is a potential oncoprotein shows predicted heterogeneity. J Hypertens that is overexpressed in two-thirds of breast 23: 1477-84, 2005 St Pierre L, Masci PP, Filippovich I, tumours. BMC Cancer 5: 113, 2005 Sorokina N, Marsh N, Millere DJ and Southey MC, Jenkins MA, Mead L, Tonks I, Hacker E, Irwin N, Muller HK, Whitty J, Trivett M, Tesoriero AA, Smith Lavin MF. Comparative analysis of prothrombin activators from the venom of Keith P, Mould A, Zournazi A, Pavey LD, Jennings K, Grubb G, Royce SG, S, Hayward NK, Walker G and Kay GF. Walsh MD, Barker MA, Young JP, Jass Australian elapids. Mol Biol Evol 22: 1853- 64, 2005 Melanocytes in conditional Rb-/- mice are JR, St John DJ, Macrae FA, Giles GG normal in vivo but exhibit proliferation and and Hopper JL. Use of molecular tumor Struijk L, Hall L, van der Meijden E, pigmentation defects in vitro. Pigment Cell characteristics to prioritize mismatch repair Wanningen P, Bavinck JN, Neale R, Green Res 18: 252-64, 2005 gene testing in early-onset colorectal cancer. AC, Ter Schegget J and Feltkamp MC. J Clin Oncol 23: 6524-32, 2005 Markers of cutaneous human papillomavirus Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, Don Speilmann T, Gardinerf DL, Beck HP, infection in individuals with tumor-free skin, actinic keratoses, and squamous cell TA, McManus DP, Correa-Oliveira R, Trenholme KR and Kemp DJ. Organization and Loukas A. Tetraspanins on the surface of ETRAMPs and EXP-1 at the parasite- carcinoma. Cancer Epidemiol Biomarkers Prev 15: 529-35, 2006 of Schistosoma mansoni are protective host cell interface of malaria parasites. Mol antigens against schistosomiasis. Nat Med Microbiol 59: 779-94, 2006 Subramaniam VN, Wallace DF, Dixon JL, 12: 835-840, 2006 Fletcher LM and Crawford DH. Ferroportin disease due to the A77D mutation in Treloar SA, Wicks J, Nyholt DR, Australia. Gut 54: 1048-49, 2005 Montgomery GW, Bahlo M, Smith V, Dawson G, Mackay IJ, Weeks DE, Bennett Tenesa A, Visscher PM, Carothers AD, ST, Carey A, Ewen-White KR, Duffy DL, Knott SA. Mapping quantitative trait loci O’Connor DT, Barlow DH, Martin NG using linkage disequilibrium: marker-versus and Kennedy SH. Genomewide linkage trait-based methods. Behav Genet 35: 219- study in 1176 affected sister pair families 28, 2005 identifies a significant susceptibility locus for endometriosis on chromosome 10q26. Am J Hum Genet 77: 365-76, 2005

91 Treloar SA, Zhao ZZ, Armitage T, Duffy Valery PC, Torzillo PJ, Boyce NC, White Wainwright M, Wright MJ, Luciano M, DL, Wicks J, O’Connor DT, Martin NG and AV, Stewart PA, Wheaton GR, Purdie Montgomery GW, Geffen GM and Martin Montgomery GW. Association between DM, Wakerman J and Chang AB. Zinc NG. A linkage study of academic skills polymorphisms in the progesterone receptor and vitamin A supplementation in Australian defined by the Queensland core skills test. gene and endometriosis. Mol Hum Reprod Indigenous children with acute diarrhoea: a Behav Genet 36: 56-64, 2006 11: 641-47, 2005 randomised controlled trial. Med J Aust 182: 530-35, 2005 Wainwright MA, Wright MJ, Luciano M, Truman JP, Gueven N, Lavin M, Leibel Geffen GM and Martin NG. Multivariate S, Kolesnick R, Fuks and Haimovitz- Valle A, O’Connor DT, Taylor PW, Zhu G, genetic analyses of academic skills of the Friedman A. Down-regulation of ATM Montgomery GW, Slagboom PE, Martin Queensland core skills test and IQ highlight protein sensitizes human prostate cancer NG and Whitfield JB. Butyrylcholinesterase: the importance of genetic g. Twin Res Hum cells to radiation-induced apoptosis. J Biol association with the metabolic syndrome Genet 8: 602-8, 2005 Chem 280: 23262-72, 2005 and identification of 2 gene loci affecting activity. Clin Chem 52: 1014-20, 2006 Wall E, Visscher PM, Hospital F and Tynan FE, Elhassen D, Purcell AW, Woolliams JA. Genomic contributions in Burrows JM, Borg NA, Miles JJ, van der Pols JC, Williams GM, Neale RE, livestock gene introgression programmes. Williamson NA, Green KJ, Tellam J, Kjer- Clavarino A and Green AC. Long-term Genet Sel Evol 37: 291-313, 2005 Nielsen L, McCluskey J, Rossjohn J and increase in sunscreen use in an Australian Burrows SR. The immunogenicity of a viral community after a skin cancer prevention Wallace DF, Jones MD, Pedersen P, Rivas cytotoxic T cell epitope is controlled by its trial. Prev Med 42: 171-76, 2006 L, Sly LI and Subramaniam VN. Purification MHC-bound conformation. J Exp Med 202: and partial characterisation of recombinant 1249-60, 2005 van der Pols JC, Xu C, Boyle GM, Parsons human hepcidin. Biochimie 88: 31-37, 2006 PG, Whiteman DC and Green AC. Tynan FE, Burrows SR, Buckle AM, Expression of p53 tumor suppressor protein Wallace DF, Summerville L, Lusby PE and Clements CS, Borg NA, Miles JJ, Beddoe in sun-exposed skin and associations with Subramaniam VN. Prohepcidin localises T, Whisstock JC, Wilce MC, Silins SL, sunscreen use and time spent outdoors: a to the Golgi compartment and secretory Burrows JM, Kjer-Nielsen L, Kostenko L, community-based study. Am J Epidemiol pathway in hepatocytes. J Hepatol 43: 720- Purcell AW, McCluskey J and Rossjohn 163: 982-8, 2006 28, 2005 J. T cell receptor recognition of a ‘super- Wallace DF, Summerville L, Lusby PE bulged’ major histocompatibility complex Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Styllianou C, and Subramaniam VN. First phenotypic class I-bound peptide. Nat Immumol 6: description of transferrin receptor 2 1114-22, 2005 Spanevello M, Brechbiel M, Boyd AW, Scott A and Lackmann M. Concurrent knockout mouse, and the role of hepcidin. Uimari P, Kontkanen O, Visscher PM, binding of anti-EphA3 antibody and Gut 54: 980-86, 2005 Pirskanen M, Fuentes R and Salonen JT. ephrin A5 amplifies EphA3 signalling and Warren RM, Thompson D, Pointon LJ, Genome-wide linkage disequilibrium from downstream responses: potential as EphA3- Hoff R, Gilbert FJ, Padhani AR, Easton DF, 100,000 SNPs in the East Finland founder specific tumour-targeting reagents. Cancer Lakhani SR and Leach MO; Collaborators population. Twin Res Hum Genet 8: 185-97, Res 65: 6745-54, 2005 in the United Kingdom Medical Research 2005 Visscher PM and Duffy DL. The value Council Magnetic Resonance Imaging in Underwood SL, Christoforou A, Thomson of relatives with phenotypes but missing Breast Screening (MARIBS) Study Group. PA, Wray NR, Tenesa A, Whittaker J, genotypes in association studies for Evaluation of a prospective scoring system Adams RA, Le Hellard S, Morris SW, quantitative traits. Genet Epidemiol 30: designed for a multicenter breast MR Blackwood DH, Muir WJ, Porteous DJ 30-36, 2006 imaging screening study. Radiology 239: and Evans KL. Association analysis of the 677-85, 2006. Visscher PM, Haley CS, Ewald H, Mors chromosome 4p-located G protein-coupled Warren RM, Pointon L, Thompson D, receptor 78 (GPR78) gene in bipolar O, Egeland J, Thiel B, Ginns E, Muir W and Blackwood DH. Joint multi-population Hoff R, Gilbert FJ, Padhani A, Easton D, affective disorder and schizophrenia. Mol Lakhani SR and Leach MO; UK Magnetic Psychiatry 11: 384-94, 2006 analysis for genetic linkage of bipolar disorder or “wellness” to chromosome 4p. Resonance Imaging in Breast Screening Upcroft JA, Dunn LA, Wright JM, Am J Hum Genet B Neuropsychiatr Genet (MARIBS) Study Group. Reading protocol Benakli K, Upcroft P and Vanelle P. 133:18-24, 2005 for dynamic contrast-enhanced MR images 5-Nitroimidazole drugs effective against of the breast: sensitivity and specificity metronidazole-resistant Trichomonas Visscher PM, Medland SE, Ferreira MAR, analysis. Radiology 236: 779-88, 2005. Zhu G, Cornes BK, Montgomery GW and vaginalis and Giardia duodenalis. Antimicrob Warrilow D, Gardner J, Darnell GA, Agents Chemother 50: 344-47, 2006 Martin NG. Assumption-free estimation of heritability from genome-wide identity-by- Suhrbier A, and Harrich D. HIV-1 Upcroft JA, Delgadillo-Correa MG, Dunne descent sharing between full siblings. PLoS Inhibition by protein kinase C modulatory RL, Sturm AW, Johnson PJ and Upcroft Genet 2: 316-25, 2006 compounds. AIDS Res Hum Retroviruses 22: P. Genotyping Trichomonas vaginalis. Int J 854-64, 2006 Parasitol 36: 821-8, 2006 Voisey J, Gomez-Cabrera MC, Smit DJ, Leonard JH, Sturm RA and van Daal A. Wei MQ, Metharom P, Ellem KA and Valery PC, Coory M, Stirling J and Green A polymorphism in the agouti signalling Barth S. Search for “weapons of mass AC. Cancer diagnosis, treatment, and protein (ASIP) is associated with decreased destruction” for cancer -- immuno/ gene survival in Indigenous and non-Indigenous levels of mRNA. Pigment Cell Res 19:226- therapy comes of age. Cell Mol Immunol 2: Australians: a matched cohort study. Lancet 31, 2006 351-57, 2005 367: 1842-48, 2006 Wade TD, Bergin JL, Martin NG, Gillespie Valery PC, Holly EA, Sleigh AC, Williams NA and Fairburn CG. A transdiagnostic G, Kreiger N and Bain C. Hernias and approach to understanding eating disorders. Ewing’s sarcoma family of tumours: a J Nerv Ment Dis 194: 510-17, 2006 pooled analysis and meta-analysis. Lancet Oncol 6: 485-90, 2005

92 Weisenberger DJ, Siegmund KD, Campan Yang YR, Cheng L, Yang SK, Pan X, Sun Zhang DM, Pan WQ, Qian L, Duke M, M, Young J, Long TI, Faasse MA, Kang T, Li X, Hu S, Zhao R, Craig PS, Vuitton Shen LH and McManus DP. Investigation GH, Widschwendter M, Weener D, DA and McManus DP. A hospital-based of recombinant Schistosoma japonicum Buchanan D, Koh H, Simms L, Barker M, retrospective survey of human cystic and paramyosin fragments for immunogenicity Leggett B, Levine J, Kim M, French AJ, alveolar echinococcosis in Ningxia Hui and vaccine efficacy in mice. Parasite Thibodeau SN, Jass J, Haile R and Laird Autonomous Region, PR China. Acta Trop Immunol 28: 77-84, 2006 PW. CpG island methylator phenotype 97: 284-91, 2006 underlies sporadic microsatellite instability Zhang W and McManus DP. Recent and is tightly associated with BRAF mutation Yang YR, Ellis M, Sun T, Li Z, Li X, Vuitton advances in the immunology and diagnosis in colorectal cancer. Nat Genet 38: 787-93, DA, Bartholomot B, Giraudoux P, Craig of echinococcosis. FEMS Immunol Med 2006 PS, Boufana B, Wang Y, Feng X, Wen H, Microbiol 47: 24-41, 2006 Ito A and McManus DP. Unique family Whiteman DC and Green A. Divergent clustering of human echinococcosis cases in Zhao ZZ, Nyholt DR, James MR, Mayne pathways to cutaneous melanoma. In: From a Chinese community. Am J Trop Med Hyg R, Treloar SA and Montgomery GW. A Melanocytes to Melanoma: The Progression 74: 487-94, 2006 comparison of DNA pools constructed to Malignancy. Eds: Hearing VJ and Leong following whole genome amplification for SPL. Humana Press, Totowa, New Jersey pp Yang YR, Sun T, Li Z, Li X, Zhao R, Cheng two-stage SNP genotyping designs. Twin 311-28, 2005 L, Pan X, Craig PS, Vuitton DR and Res Hum Genet 8: 353-61, 2005 McManus DP. Echinococcosis, Ningxia, Widyarini S, Allanson M, Gallagher NL, China. Emerg Infect Dis 11: 1314-16, 2005 Pedley J, Boyle GM, Parsons PG, Whiteman DC, Walker C and Reeve Yang YR, Sun T, Zhang JZ and McManus VE. Isoflavonoid photoprotection in DP. Molecular confirmation of a case of mouse and human skin is dependent on multiorgan cystic echinococcosis. J Parasitol metallothionein. J Invest Dermatol 126: 92: 206-8, 2006 198-204, 2006 Yang YR, Vuitton DR, Bartholomot B, Williamson AL, Lustigman S, Oksov Y, Wang YH, Ito A, Craig PS and McManus Deumic V, Plieskatt J, Mendez S, Zhan DP. Simultaneous alveolar and cystic B, Bottazzi ME, Hotez PJ and Loukas A. echinococcosis of the liver. Trans Roy Soc Ancylostoma caninum MTP-1, an astacin- Trop Med Hyg 100: 597-600, 2006 like metalloprotease secreted by infective Yang YR, Vuitton DR, Jones MK, Craig hookworm larvae, is involved in tissue PS and McManus DP. Brain metastasis of migration. Infect Immun 74: 961-67, 2006 alveolar echinococcosis in a hyperendemic Wilkins SJ, Frazer DM, Millard KN, focus of Echinococcus multilocularis McLaren GD and Anderson GJ. Iron infection. Trans Roy Soc Trop Med Hyg 99: metabolism in the hemoglobin-deficit 937-941, 2005 mouse: Correlation of diferric transferrin Yang YR, Williams GM, Craig PS, Sun T, with hepcidin expression. Blood 107: 1659- Yang SK, Cheng L, Vuitton DA, Giraudoux 64, 2006 P, Li X, Hu S, Liu X, Pan X and McManus Wray NR. Allele frequencies and the r2 DP. Hospital and community surveys reveal measure of linkage disequilibrium: impact the severe public health problem and socio- on design and interpretation of association economic impact of human echinococcosis studies. Twin Res Hum Genet 8: 87-94, in Ningxia Hui Autonomous Region, China. 2005 Trop Med Int Health 11: 880-88, 2006 Wykes M and Good MF. Memory B cell Yoonim N, Olive C, Pruksachatkunakorn responses and malaria. Parasite Immunol C, Good MF and Pruksakorn S. M protein 28: 31-34, 2006 typing of Thai group A streptococcal isolates by PCR-Restriction fragment length Wykes MN, Zhou YH, Liu XQ and Good polymorphism analysis. BMC Microbiol 5: MF. Plasmodium yoelii can ablate vaccine- 63, 2005 induced long-term protection in mice. J Immunol 175: 2510-2516, 2005 Young DB, Jonnalagadda J, Gatei M, Jans DA, Meyn S and Khanna KK. Identification Wynn K and Khanna R. Animal models for of domains of ataxia-telangiectasia mutated cytomegalovirus. Drug Discovery Today: required for nuclear localization and Disease Models 3: 91-96, 2006 chromatin association. J Biol Chem 280: 27587-94, 2005 Wynter CV, Kambara T, Walsh MD, Leggett BA, Young J and Jass JR. DNA Zhan B, Liu S, Perally S, Xue J, Fujiwara R, methylation patterns in adenomas from FAP, Brophy P, Xiao S, Liu Y, Feng J, Williamson multiple adenoma and sporadic colorectal A, Wang Y, Bueno LL, Mendez S, Goud carcinoma patients. Int J Cancer 118: 907- G, Bethony JM, Hawdon JM, Loukas 15, 2005 A, Jones K and Hotez PJ. Biochemical characterization and vaccine potential of a Yang YR Rosenzvit, MC, Zhang LH, Zhang heme-binding glutathione transferase from JZ and McManus DP. Molecular study the adult hookworm Ancylostoma caninum. of Echinococcus in west-central China. Infect Immun 73: 6903-11, 2005 Parasitology 131: 547-55, 2005

93 Patents

Title QIMR scientist Patent Commercial status

Novel molecules (testisin) Toni Antalis PCT/AU98/00085 Licensed

Receptor Ligand System and Assay Andrew Boyd USA 7,037,662 Licensed

A basal cell carcinoma tumor suppressor Assigned to US Department Georgia Trench US6552181 gene of Health

Ferroportin-1 Mutant Nathan Subramaniam PCT/AU02/01335 Term sheet

Anti protozoal vaccine Michael Good PCT/AU03/00246 Phase I development

Modulation of Cell Adhesion and Tumour Andrew Boyd PCT/AU2004/000142 Licensed Cell Metastasis

Immunogenic Agent and Pharmaceutical Composition for use against homologous Michael Good PCT/AU2004/000870 Phase I development and heterologous pathogens

G-CSF Derivative for inducing Geoff Hill PCT/AU2004/001116 Phase I development immunological tolerance

Flavivirus Vaccine Delivery System Andreas Suhrbier PCT/AU02/01598 Replikun*

Cancer and testis proteins and use thereof Nathan Subramaniam PCT/AU2005/000437 Available for licensing

Flavivirus Replicon Packaging System Andreas Suhrbier PCT/AU2004/000752 Replikun*

Flavivirus Replicon Delivery System Alex Khromykh PCT/AU98/00993 Replikun*

A Method of treatment and agents useful Geoff Hill PCT/AU02/01512 Assigned to UQ for same

Flaviviral Replicon constructs for Tumour Andreas Suhrbier Prov 2005900714 Replikun* Therapy

A Method for Treatment Andrew Boyd WO 00/24413 Term Sheet

Helminth Antigen and Immunotherapy Alex Loukas PCT/AU2006/000807 Available for licensing

Polytope Vaccines Andreas Suhrbier PCT/AU95/00461 Licensed (non-Exclusive)

Synthetic peptides and vaccines comprising Michael Good PCT/AU95/00681 Term Sheet the same

Cytotoxic T-cell epitopes Denis Moss PCT/AU95/00140 Available for licensing

EBV CTL epitopes Rajiv Khanna PCT/AU97/00328 Available for licensing

CTL epitopes from EBV Scott Burrows PCT/AU98/00531 Available for licensing

EBV peptide epitopes, polyepitopes and Rajiv Khanna PCT/AU03/01451 Available for licensing delivery system therefor

* Refer to QIMR Start-Up Companies

94 Invited Lectures and Presentations

Dr Fiona Amante Role of Regulatory T cells in the Development of Brisbane Immunology Group, Seminar Program, Brisbane, Sep Experimental Cerebral Malaria 2005 Associate Professor Greg Anderson Ironing in the new millennium: How the body regulates Center for Endocrinology and Diabetes Research, Princess the homeostasis of an essential metal Alexandra Hospital, Brisbane, Mar 2006 Dr Michael Batzloff Evaluation of a totally synthetic self-adjuvanting XVIth Lancefield International Symposium on Streptococci and lipopeptide GAS vaccine candidate Streptococcal Diseases, Palm Cove, Sep 2005 Associate Professor Scott Burrows Immune control of an old foe – Epstein-Barr virus Biochemistry and Molecular Biology Department, Monash University, Melbourne, Sep 2005 Epitope selection in the cytotoxic T cell response to viral The Centre for Molecular Biodiscovery, The University of infection Auckland, Auckland, New Zealand, Nov 2005 Epitope selection in the cytotoxic T cell response to viral Malaghan Institute of Medical Research, Wellington, New infection Zealand, Nov 2005 Epitope selection in the cytotoxic T cell response to viral Hanson Institute, Adelaide, Nov 2005 infection The immunogenicity of a viral cytotoxic T cell epitope is Australasian Society for Immunology Meeting, Melbourne, Dec controlled by its MHC-bound conformation 2005 An Epstein-Barr virus vaccine: Have we cut ourselves too Australian Virology Group Meeting, Phillip Island, Victoria, Dec short in mapping CTL epitopes? 2005 Have we cut ourselves too short in mapping CTL Mater Medical Research Institute, Brisbane, May 2006 epitopes? Dr Georgia Chenevix-Trench Update on kConFab kConFab Conference, Couran Cove, Aug 2005 Benign or Malignant? Understanding the role of genetic Children’s Medical Research Institute, Sydney, Oct 2005 variation in the BRCA1, BRCA2 and ATM genes in breast cancer susceptibility Benign or Malignant? Understanding the role of genetic Human Genetics Society of Australasia, South Australian branch, variation in the BRCA1, BRCA2 and ATM genes in breast Adelaide, Nov 2005 cancer susceptibility Breast cancer genetics: is the sun rising again after a Human Genetics Society of Australasia, Queensland branch, decade of darkness? Brisbane, Jun 2005 Dr Qin Cheng Genetic Diversity in Antigens Targeted by Malaria RDTs WHO Informal consultation of the malaria RDT specimen bank, Kisumu, Kenya, Jun 2006 Genetic Diversity in Antigens Targeted by Malaria RDTs WHO Informal consultation on development of methods for testing malaria rapid diagnostic tests, Geneva, Switzerland, Feb 2006 Genetic diversity of P. vivax parasites in relapsing patients Vivax malaria research: 2005 and beyond,Washington DC, USA, Dec 2005 Dr Suyinn Chong The phenotypic effects of DNA methyltransferase Sydney Transcription Group meeting, Sydney, Jul 2005 haploinsufficiency in the mouse The phenotypic effects of DNA methyltransferase ComBio 2005, Adelaide, Sep 2005 haploinsufficiency in the mouse Dr Christian Engwerda Balancing Immunity and Pathology in Malaria and Inaugural ARC/NHMRC Research Network for Parasitology Leishmaniasis Conference, Melbourne, Jul 2005 Regulatory T cells Brisbane Immunology Group Annual Meeting, Gold Coast, Aug 2005 Defining pathways of pathogenesis in Experimental Centre for Immunology and Cancer Research, Princess Alexander Cerebral Malaria Hospital, Brisbane, Sep 2005 Balancing immunity and pathology in experimental Australian Society for Immunology, Melbourne, Dec 2005 cerebral malaria

95 Defining pathways of pathogenesis in Experimental Centre for Immunology and Cancer Research, Princess Alexander Cerebral Malaria Hospital, Brisbane, Mar 2006 Leishmania The University of Queensland, School of Integrative Biology, Brisbane, Mar 2006 Balancing immunity and pathology in experimental Woods Hole Immunoparasitology Meeting, Woods Hole, MA, cerebral malaria USA, Apr 2006 Dr Don Gardiner Aminopeptidases in Plasmodium falciparum parasites: Symposium on Malaria Protein Structure and Function, overexpression allows identification of target for the anti- Melbourne, Feb 2006 malaria activity of bestatin Professor Michael Good Vaccination for group A streptococcus Royal Brisbane and Women’s Hospital Health Care Symposium, Brisbane, Oct 2005 Medicine and Science in 2005 – Is there a role for the Royal Brisbane and Women’s Hospital Health Care Symposium, clinician scientist in basic science research? Brisbane, Oct 2005 Vaccines for the heart – an opportunity to further Woolcock Oration, The Prince Charles Hospital Foundation, improve cardiovascular health Brisbane, Oct 2005 Research challenges for vaccines for developing countries Frontiers in Vaccinology, Baltimore, USA, Nov 2005 Towards development of a vaccine to prevent rheumatic John Curtin School of Medical Research, ANU, Canberra, Nov fever 2005 Research Challenges for developing a vaccine to prevent 3rd Indo-Australian Conference in Biotechnology: Vaccines for rheumatic heart disease Cancer, Infectious Diseases, Lifestyle and Degenerative Diseases, Hyderabad, India, Mar 2006 Immunity, memory, vaccines – reflections on Third International Malaria Meeting, Johns Hopkins Malaria immunological strategies after 23 years of subunit Research Institute, Baltimore, USA, Mar 2006 approaches Toward vaccine development for group A streptococcus Merck & Co. Inc, West Point, Pennsylvania, USA, Mar 2006 using the conserved region of the M protein Pre-clinical evaluation of a streptococcal vaccine – An Grand Rounds Clinical Meeting, Redcliffe Hospital, Brisbane, May opportunity to further improve cardiovascular health 2006 Toward development of a vaccine to prevent group A RACP Congress, Paediatrics & Child Health Annual Meeting, streptococcus infection and rheumatic fever Cairns, May 2006 Vaccines for public benefit – the CRC-VT approach CRC-VT Symposium, Capturing Value from Biomedical Research, Melbourne, May 2006 Immunity, memory, vaccines – reflections on 1st Australasian Vaccines and Immunotherapeutics Development immunological strategies after 23 years of subunit Meeting, Melbourne, May 2006 approaches: revisiting whole parasite options Professor Adèle Green Sunscreen & Melanoma: what is the evidence? Sunscreen & Melanoma: what is the evidence? Dr David Harrich Tat is a reverse treanscription co-factor QIMR Diamond Anniversary Symposia, Brisbane, Nov 2005 Alternative roles for Tat and TAR RNA in HIV-1 replication Institute for Molecular Biology Seminar, Brisbane, Oct 2005 Molecular analysis of HIV-1 early events during cell Australian Society for HIV Medicine,Hobart,Aug 2005 infection: prospects towards novel antiviral drug targets and strategies. Dr Nick Hayward Mapping low penetrance melanoma genes 6th World Congress on Melanoma, Vancouver, Canada, Sep 2005 Mapping novel naevogenesis genes 19th International Pigment Cell Conference, Reston, USA, Sep 2005 Biospecimen processing in the Australian Cancer Study 3rd Australian Biospecimens Network Meeting, Brisbane, Nov 2005 Integrative functional genomics of melanoma Discovery Science and Biotechnology Meeting, Melbourne, May 2006 Dr Geoff Hill GVHD and immune regulation immune regulation 7th World congress on Inflammation, Melbourne, Aug 2005 Update on transplantation Sydney Childrens Hospital Cancer Institute meeting, Sydney, Jun transplantation. 2006

96 Allogeneic stem cell transplantation: killing to cure. New directions in Leukaemia Research, 1st meeting, Sunshine Coast, Apr 2006 Plenary speaker: Microchimerism in transplantation, state Transplantation Society of Australia and NZ annual meeting, of the art. Canberra, Mar 2006 GVHD and GVL in transplantation Amgen Haematology and Oncology update, Melbourne, Feb 2006 Opening Address Australian Transplant Coordinators and Nurses Annual meeting, Noosa, 2005 Science and Innovation in Queensland. Queensland Government, Brisbane, 2005 Leukaemia and its management Leukaemia Foundation of Queensland, Brisbane, 2005 Opening address, annual meeting Leukaemia Foundation of Australia, Brisbane, 2005 Separation of GVHD and GVL MMRI annual stem cell meeting, Brisbane, 2006 Dr Malcolm Jones What’s Coming off in the Laser Microdissection QIMR Diamond Jubilee Symposium, Brisbane, Nov 2005 laboratory Dr Jason Jeffery Developing a practical control strategy for Verrallina 4th International Congress of Vector Ecology, Reno, USA, Oct funerea, a medically important mosquito species in 2005 Queensland, Australia Professor Brian Kay Astounding success in dengue control in Vietnam 4th International Congress of Vector Ecology, Reno, USA, Oct 2005 New methods to control mosquito-borne diseases Australian Academy of Science, Canberra, May 2005 New approaches to control of dengue vectors Centers for Disease Control - Bill and Melinda Gates Foundation global, workshop on dengue vector control Fort Collins, USA, May 2006 Dr Graham Kay Analysis of allelic choice of Xist Transcription in X ComBio 2005, Adelaide, Sep 2005 inactivation Professor Anne Kelso Development and specialisation of cytolytic T Centre for Immunology and Cancer Research, University of lymphocytes Queensland, Princess Alexandra Hospital, Brisbane, Jul 2005 Postcard from the jungle Brisbane Immunology Group Annual Retreat, Gold Coast, Aug 2005 Modern Immunological Concepts and Vaccine Design Third Indo-Australian Conference on Biotechnology, Hyderabad, India, Mar 2006 Building an Australian biotechnology industry – Cooperative Research Centres Association Conference, Brisbane, opportunities and challenges for medical sector CRCs May 2006 Dr Norbert Kienzle Mechanisms by which IL-4 impairs T cell immunity Department of Microbiology and Immunology, The University of against tumours Melbourne, Melbourne, May 2006 Impact of IL-4 on tumor immunity and differentiation of James Cook University, Townsville, Nov 2005 CD8+ T cells Dr Kum Kum Khanna Functional characterization of novel interactors of ATM The 2005 International Workshop on Ataxia Telangiectasia, ATM kinase and the DNA damage Response, Lake Maggiore, Italy, Jun 2005 Regulation of ATM kinase activity by protein Australian Society of Biochemistry and Molecular Biology, phosphatase, PP2A Combio meeting, Adelaide, Sep 2005 DNA damage response and cancer susceptibility Regina Elena Cancer Institute, Rome, Italy, Nov 2005 Professor Sunil Lakhani Molecular Pathology of Breast Cancer Radiation Oncology Group, Brisbane, Jul 2005 Molecular Pathology of Preinvasive Breast Disease Manipal Hospital and Medical School, Manipal, India, Aug 2005 Molecular Pathology of Invasive Breast Disease Manipal Hospital and Medical School, Manipal, India, Aug 2005 Immunohistochemistry in breast cancer diagnosis Royal College of Surgeons of Sri Lanka and British Society of Surgical Oncology, Colombo, Sri Lanka, Aug 2005 Molecular Classification of Breast Cancer Royal College of Surgeons of Sri Lanka and British Society of Surgical Oncology, Colombo, Sri Lanka, Aug 2005

97 Myoepithelial Cells and Breast Cancer IARC Congress, Lyon, Paris, Sep 2005 Molecular Pathology of Breast Cancer Cancer Collaborative Group Seminar, PA Hospital, Brisbane, Oct 2005 Pathology of Familial Breast Cancer Wesley Breast Clinic, Brisbane, Oct 2005 Epithelial Cells from Normal Lobes Versus DCIS From Gene to Cure Conference, Amsterdam, Netherlands, Feb 2006 Molecular Pathology of Breast Cancer Breast Multidisciplinary Team – Royal Brisbane & Women’s Hospital Dinner, Brisbane, Nov 2005 Pathology of Familial Breast Cancer Japanese Society of Pathology, Omiya, Japan, May 2006 Molecular Pathology of Breast Cancer Japanese Society of Pathology, Omiya, Japan, May 2006 Myoepithelial Cell and Cancer Malta College of Pathologists, Malta, May 2006 Associate Professor Rajiv Khanna Prophylactic vaccine for Human Cytomegalovirus Disease Indo-Australian conference on Biotechnology in Infectious Diseases at Manipal Academy of Higher Education, India, March 2005. Novel immunotherapeutic strategies for the treatment of East West Symposium on Nasopharyngeal Cancer, Toronto, nasopharyngeal carcinoma Canada, June 2005. T cell perturbations during persistent viral infections John Curtin School of Medicine, Canberra, ACT, May 2005 Immune monitoring of HCMV infection in transplant Annual Scientific Meeting of Australian Society for Microbiology, patients Canberra, ACT Sept 2005 Designing prophylactic vaccine for HCMV disease Panacea Biotech, New Delhi, India, Mar 2005 Invited Valedictory Lecture Indo-Australian Meeting on Biotechnology, Hyderabad, India, Mar 2006 Technology Transfer: Vaccine, Diagnostic and Annual Scientific meeting of Australian Society for Microbiology, Therapeutics Gold Coast, Jul 2006 Pathogenesis of Hodgkin Lymphoma – Epstein-Barr Virus Amgen Hematology Symposium, Sydney, Feb 2005 (EBV) in Hodgkin Lymphoma (HL) Professor Martin Lavin Spinocerebellar ataxia, oxidative stress and DNA damage Cellular Responses to DNA damage, Copenhagen, Denmark, Aug response 2005 Activation of ATM kinase and downstream signalling The 2005 International workshop on Ataxia-Telangiectasia, ATM and the DNA damage response, Belgirate, Italy, Jun 2005 Role of DNA damage response in spino-cerebellar ataxias ComBio 2005, Adelaide, Nov 2005 Ataxia telangiectasia and oculomotor Ataxia 2005, Gold Coast, Nov 2005 Orion International Technologies Low Level Radiation Effects Summit, Carlsbad, New Mexico, Jan 2006 The Radiation Casualty Medical Research Centre Hiroshima University, Hiroshima, Japan, Feb 2006 Radiation 2006 University of Sydney, Sydney, Apr 2006 A subgroup of spinocerebellar ataxias defective in DNA First Genome Dynamics in Neuroscience Meeting, Oslo, damage response Copenhagen, Apr 2006 Professor Barbara Leggett The malignant potential of hyperplastic polyps Australian Gastroenterology Week, Brisbane, Oct 2005 Dr Corinne Lendon Molecular Genetic mechanisms in Alzheimers Peking University, China, Dec 2005 Molecular Genetic mechanisms in Alzheimers Jinan Hospital, China, Dec 2005 Associate Professor Alejandro López A CD40lLigand-responsive population of HLA-DR+ 35th Annual ASI Meeting. Tumour Immunology Workshop, immature cells accumulate in the blood dendritic cell Melbourne, Dec 2005 compartment of patients with different types of cancer A population of HLA-DR+ immature cells accumulate in ASMR National Scientific Conference, Couran Cove, Nov 2005 the blood dendritic cell compartment of patients with different types of cancer Malignant melanoma and its influence on clinical Australasian Dermatopathology Society Conference, Brisbane, and immunological responses following dendritic cell Aug 2005 immunotherapy Dendritic cells and breast cancer: A growing hope CICR, Princess Alexandra Hospital, Brisbane, May 2006

98 ASMR a snapshot ASMR Postgraduate Conference, Wesley Hospital, Brisbane, May 2006 A Novel Dendritic Cell mRNA Delivery Strategy for ASMR Postgraduate Conference, Cancer Immunotherapy Wesley Hospital, Brisbane, May 2006 Dr Alex Loukas Proteins at the host-parasite interface in human helminth ARC/NHMRC Research Network for Parasitology Annual infections Conference, Melbourne, Jul 2005 Vaccines against blood-feeding helminths Federal University of Minas Gerais, Belo Horizonte, Brazil, Sep 2005 Mice vaccinated with Schistosoma mansoni tetraspanin, Schistosomiasis Symposium, Belo Horizonte, Brazil, Sep 2005 Sm-TSP-2 are protected against larval challenge Hookworm Vaccines World Association for the Advancement of Veterinary Parasitology/ASP Meeting, Christchurch, NZ, Oct 2005 Expression of proteases in insect cells Protein Expression Symposium, Brisbane, Nov 2005 Vaccines against blood-feeding helminths The University of Queensland, Brisbane, Apr 2006 Vaccines against blood-feeding helminths University of Technology, Sydney, May 2006 Associate Professor James McCarthy Will filariasis control programs lead to anthelmintic drug Mectizan Expert Committee, London, UK, Jan 2006 resistance? Anthelmintic drug resistance in humans: what’s the 54th Annual Meeting of the American Society of Tropical evidence Medicine and Hygiene, Washington DC USA, Dec 2005 Professor Nick Martin Progress in finding genes for intelligence Behavior Genetics Association, Storrs CT USA, Jun 2006 Genetics of melanoma risk factors Human Gene Mapping meeting, Helsinki, May 2006 Achievements and prospects in QTL mapping for Twin Methodology workshop, Boulder, USA, Mar 2006 complex traits Finding QTLs Advanced Course on QTL mapping, Egmond, Holland, 2005 Linkage for depression World Congress of Psychiatric genetics, Boston, USA, Oct 2005 Dr Kelli MacDonald Antigen presentation in GVHD. CICR Seminar, Brisbane, Jul 2005 Dendritic cells in GVHD. QIMR Diamond Anniversary Symposium, Brisbane, Oct 2005 RelB translocation within APC is critical for the initiation American Society of Hematology Annual Meeting, Atlanta, USA, and maintenance of GVHD Dec 2005 Professor Don McManus Molecular variation in Echinococcus Taeniasis/Cysticercosis and Echinococcosis International Symposium with Focus on Asia and The Pacific, Asahikawa, Japan, Jul 2005 A vaccine against Asian schistosomiasis Alternative Routes for Vaccine Design Against Parasitic Diseases. American Society for Tropical Medicine and Hygiene Meeting, Washington DC, USA, Dec 2005 Dr David McMillan Research in Germany : my experience German Queensland Science and Technology Week, Brisbane, Apr 2006 Dr Grant Montgomery SNP typing in human disease genetics AGRF Special Workshop, Brisbane, Jul 2005 Basic concepts for DNA analysis DNA and the Law Conference, Brisbane, Nov 2005 Basic concepts for DNA analysis DNA Conference, Department of Public Prosecutions, Brisbane, Dec 2005 Finding susceptibility genes for endometriosis Pan Asia HUGO Conference, Taipei, Taiwan, Mar 2006 Genetic studies of twinning in sheep and humans Department of Reproductive Medicine, UCSD, San Diego, USA, Mar 2006 Genetic studies on endometriosis School of Biological Sciences, Griffith University, Brisbane, May 2006 Dr Edward Morris NKT cells in transplantation. Australian Society of Immunology, Annual meeting, Melbourne, Dec 2005

99 Professor Denis Moss Moving towards an immunotherapeutic cure for Epstein- Third India and Australia Biotechnology Conference, Hyderabad, Barr virus-associated malignancies India, Mar 2006 Immunotherapeutic options for EBV-associated disease Croucher Foundation Advanced Studies Conference, Hong Kong, Jan 2006 Building a Scientific Career at QIMR Annual Post-graduate Students Annual Retreat, Wesley Hospital, Brisbane, Apr 2006 Moving towards an immunotherapeutic cure for Australian Society of Immunology Annual Conference, nasopharyngeal carcinoma Melbourne, Dec 2005 Prospects for immunotherapeutic control of EBV- Gordon Ada Lecture, Melbourne, Dec 2005 associated malignancies – tricky but not without hope Therapeutic Development and Clinical Research Division QIMR/IMB Retreat, Noosa, Jul 2005 Dr Tamara Pereira Mechanisms of Hepatic Fibrogenesis in Paediatric Liver School of Biomolecular and Biomedical Sciences Seminar Series, Diseases Griffith University, May 2006 Professor Peter Parsons Induction of senescence by diterpene esters in human International Pigment Cell Congress, Washington DC, USA, Sep melanoma cells 2005 Professor Lawrie Powell Iron storage in disease in the Asia- Pacific region Asian Pacific Association for the Study of the Liver, Bali, Aug 2006 My paradigm for a raised serum ferritin level Gastroenterological Society of Australia, Brisbane, Oct 2005 Recent advances in haemochromatosis Alfred Hospital Symposium, Melbourne, Mar 2006 Associate Professor Grant Ramm Genesis of Hepatic Fibrosis: Candidate Molecules and The Asian Pacific Association for the Study of Liver (APASL) Serum Markers in Paediatric Cholestatic Liver Disease Biennial Conference, Aug 2005 Role of Serum Markers in Detection and Monitoring North American Cystic Fibrosis Conference, Oct 2005 Progression of CF Liver Disease Hepatic Fibrogenesis: Mechanisms, Markers and Department of Gastroenterology, The University of Western Candidate Molecules Ontario, USA, Oct 2005 Molecular Mechanisms of Hepatic Fibrogenesis The Asian Pacific Association for the Study of Liver (APASL) Annual Conference, Mar 2006 Clinical Complications of Cirrhosis The Asian Pacific Association for the Study of Liver (APASL) Annual Conference, Mar 2006 Current status of serum markers for hepatic fibrosis Brisbane Inter-Hospital Liver Group (BILG) Meeting, Mar 2006 Dr Peter Ryan Strategies and new methodology in dengue vector Institute Pasteur, Ho Chi Minh City, Vietnam, Feb 2006 control Medical research – making a difference to people’s lives Mt Crosby-Moggill Lions Club, Brisbane, May 2006 Dr Chris Schmidt Melanoma immunotherapy: a response model Australasian Dermatopathology Society, 26th Annual Conference, Brisbane, Aug 2005 Towards a response model for dendritic cell QIMR 60th Anniversary Symposium, Brisbane, Nov 2005 immunotherapy of advanced metastatic melanoma Towards a response model for dendritic cell Australasian Society for Immunology, Melbourne, Dec 2005 immunotherapy of advanced metastatic melanoma. Immunotherapy for Melanoma and Prostate Cancer Third Indo-Australian Conference on Biotechnology, Hyderabad, India, Mar 2006 Cancer Immunotherapy:a response model Malaghan Institute, Wellington, New Zealand, Jun 2006 Dr Tina Skinner-Adams Efficacy of HIV protease inhibitors against malaria University of Queensland Lecture, Brisbane, Sep 2005

Associate Professor Sri Sriprakash Are commensal streptococci in bad company among their Strep-Euro conference, Lund, Sweden, Apr 2006 pathogenic relatives?

100 Group G streptococcus - Is it a wolf in sheep’s clothing? Indian Institute of Science, Bangalore, India, Mar 2006 Group A streptococcus and avoidance of innate immunity Indian Institute of Science, Bangalore, India, Mar 2006 Are Commensal Streptococci in Bad Company Among National symposium on Recent trends in Streptococcal diseases, Their Pathogenic Relatives? - Ongoing lateral movement Chennai, India, Feb 2006 of genetic traits (Keynote Address) Group A streptococcus and Innate immunity. Christian Medical College, Vellore, India, Jan 2006 Group A streptococcus and avoidance of innate James Cook University, Townsville, Oct 2005 immunity. Ms Janelle Stirling Update on Research at QIMR” Indigenous Health Session, RBWH Health Care Symposium, Brisbane, Oct 2005 Cancer in Aboriginal and Torres Strait Islander people in Qld Cancer Fund Cancer care course for Aboriginal and Torres Queensland Strait Islander health Care Workers, Brisbane, Oct 2005 Dr Nathan Subramaniam Non-HFE Haemochromatosis Australian Gastroenterology Week 2005, Annual Conference of the Gastroenterological Society of Australia, Brisbane, Oct 2005 Genetics of non-HFE Haemochromatosis QIMR Diamond Anniversary Symposium, Brisbane, Nov 2005 Associate Professor Andreas Suhrbier Immunostimulatory chemotherapy using local PEP005 The 3rd India Australia Biotech Conference. Hydrabad, India, March 2006 Immunostimulatory chemotherapy using local PEP005 Peplin Research Forum, Manchester, UK, Jan 2006 From common weed to new topical chemotherapy; Cancer Studies seminar series, Birmingham University, UK, Jul necrosis, PKC and immunopotentiation 2005 Immunostimulatory Chemotherapy. Kunjin GM-CSF TIG Meeting. Perth, May 2006 gene therapy. Getting IP out of Institutions and into the commercial AusBiotech Biotechnology Summit, Canberra, Mar 2006 world. Tribulations and innovations in viral gene therapy. The 3rd Scientific Meeting of the Australian Virology Group. Phillip Island, Dec 2005 ABC Documentary and Panel Discussion Queensland New Innovators. 5th Annual Health and Medical Research Conference. Brisbane, Nov 2005 Dr Sue Treloar Understanding gene tic influences on maternal perinatal National Perinatal Epidemiology Unit special seminar, University factors through twin research. of Oxford, Richard Doll Building auditorium, Oxford, England, Sep 2005 Dr Jacqueline Upcroft Kaletra - an effective anti-trichomonal and anti-giardial International Conference on Anaerobic Protists, Sardinia, Italy, agent Sept 2005 Associate Professor Peter Upcroft Genome organisation of Trichomonas vaginalis International Conference on Anaerobic Protists, Sardinia, Italy, Sept 2005 Dr Patricia Valery Cancer in Aboriginal and Torres Strait Islander people in Clinical Oncological Society of Australia, Crossing Cancer Queensland Boundaries, Brisbane, Nov 2005 Dr Nikki Vickaryous An ENU mutageneis screen for modifiers Lorne Genome Conference, Lorne, Jan 2006 Dr Michael Walsh Population screening for hereditary non-polyposis St John of God Healthcare, Perth, Mar 2006 colorectal cancer in Western Australia Mismatch repair protein immunohistochemistry: Western Australian Clinical Oncology Group, Perth, Mar 2006 applications and pitfalls

Dr Penny Webb Ovaraian cancer and the Ovarian Cancer Study NSW Cancer Council, Sydney, Sep 2006

101 Epidemiology of Ovarian Cancer 36th International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan, Nov 2005 Molecular Epidemiology of Endometrial Cancer: the Familial cancer 2005: research and practice. Couran Cove, Aug Australian National Endometrial Cancer Study (ANECS) 2005 SNPs in gene mapping and population genetics research AGRF workshop Brisbane, Brisbane, Jul 2005 Estimation of heritability from actual relationships Wellcome Trust advanced course in statistical genetics, Oxford, between relatives UK, Jul 2005 Gene mapping strategies Brain Institute, Sydney, Sep 2005 Quantitative Genetic Theory Advanced Course on QTL mapping, Netherlands, Oct 2005 Estimation of heritability from actual relationships 2005 Gene Mappers Meeting, Mt Buller, Nov 2005 between relatives Future impact – genomics Sheep Genomics meeting, Sydney, Jul 2005 Dr David Whiteman Molecular epidemiology at the cross-roads: the Australasian Faculty of Public Health Medicine/Public Health intersection of genomics and public health Association, Brisbane, Jul 2005 Divergent Causal Pathways to Melanoma 6th World Congress on Melanoma, Vancouver, Canada, Sep 2005 Progress in melanoma and skin cancer 4th Annual American Association for Cancer Research Conference on Frontiers in Cancer Prevention Research, Baltimore MD, USA, Oct 2005 Epidemiology of Barrett’s Oesophagus and Oesophageal 10th Annual Coolum Update in Gastroenterology and Adenocarcinoma Hepatology, Coolum, Jun 2006 Do all melanomas arise through the same causal Melanoma Research: Australia 2006, Sydney, Jun 2006 pathway? Epidemiologic and histologic explorations Professor Emma Whitelaw An ENU mutageneis screen for modifiers Epigenetics Gordon Conference, New Hampshire, USA, Aug 2005 Swan Song School of Molecular and Microbial Biosciences, University of Sydney, Sydney, Sep 2005 An ENU mutageneis screen for modifiers of epigenetic ARC Centre of Excellence in Biotechnology and Development, 3rd state in the mouse Scientific Meeting, Melbourne, Oct 2005 Epigenetics Murdoch Children’s Research Institute, Epigenetics Symposium, Melbourne, Oct 2005 Epigenetics and the Environment 2005 Environmental Genomics Meeting, Durham, North Carolina, USA, Nov 2005 Epigenetics Fetal Basis of Adult Disease, NIEHS Workshop, Durham, NC, USA, Nov 2005 Transgenerational epigenetic inheritance Department of Biology, University of Toronto, Toronto, Canada, Nov 2005 Transgenerational epigenetic inheritance Congress on Developmental Origins of Health and Disease, Toronto, Canada, Nov 2005 An ENU mutageneis screen for modifiers of epigenetic Sir Mark Oliphant Conference: Epigenetic Regulation in Disease state in the mouse and Development, Canberra, Dec 2005 Epigenetics CINP/ASPR Australian Society for Psychiatric Research, Brisbane, Dec 2005 An ENU mutageneis screen for modifiers of epigenetic Keystone Symposium on Epigenetics, Keysone, Colorado, USA, state in the mouse Jan 2006 Epigenetics and the Environment International Association for the Study of Obesity Stock Conference, Epigenetics and Obesity, Bangkok, Thailand, Mar 2006 An ENU mutageneis screen for modifiers of epigenetic Novartis Foundation Open Meeting, Decoding the Genetic state in the mouse Control of Immune Reactions, Canberra, Mar 2006 Epigenetics and Human Disease Comparative Genomics Centre, James Cook University, Townsville, Apr 2006 Epigenetics and Human Disease Queensland Institute of Medical Research, Brisbane, Apr 2006

102 Epigenetics and Human Disease Genetic Resolution of Disease Phenotypes, Epigenetics Workshop, Scripps Research Institute, San Diego, USA, May 2006 Epigenetics NGED Annual Meeting, Cairns, May 2006 Functional Genomics in Australia EU Workshop on Functional Genomics, Human Genome Meeting 2006, Helsinki, Finland, May 2006 Epigenetics and Human Disease Human Genome Meeting 2006, Helsinki, Finland, May 2006 An ENU mutageneis screen for modifiers of epigenetic Gordon Conference on Gametogenesis and Embryogenesis, state in the mouse Connecticut, USA, Jun 2006 Dr John Whitfield Guidelines for genetic testing: Evidence, issues and International Congress of Clinical Chemistry, Orlando, USA, Jul evolution 2005 The challenges of personalised medicine and AACC-AACB Conference. Laboratory Medicine into the Future: pharmacogenomics Planning for Tomorrow’s Technology, Cairns, May 2005 Dr Michelle Wykes The effect of malaria on B cell memory of vaccines Australian Society of Parasitology Network Conference, Melbourne, Jul 2005 Why vaccines to malaria may not work! ADCD Meeting, Sydney, Aug 2005 The effect of malaria on B cell memory of vaccines National Institutes of Health, Washington, USA, Mar 2006 Immunological impediments to developing a blood stage QIMR Institute Seminar, Brisbane, Apr 2006 malaria vaccine The effect of malaria on B cell memory of vaccines 1st Australasian Vaccines and Immunotherapeutics Development Meeting, Melbourne, May 2006 Dr Joanne Young Genetics of Serrated Neoplasia Researchers on the Move Series, Australian Gastroenterology Week, Brisbane, Oct 2005 Genetic Predisposition to Serrated Neoplasia Familial Cancer: Research and Practice, Couran Cove, Aug 2005

103 Trust Report

In my 6 years as Chairman of 112 of this report, who through The Queensland Institute of individual contributions, Medical Research Trust I have fundraising events and bequests had the privilege and honour have assisted our scientists of working with some of the in the daily battle to defeat most passionate, motivated and disease. Mr Clive Berghofer intelligent people in Australia. is one of these people whose contribution warrants a special These people – the 700 mention as a result of his dedicated scientists at QIMR unwavering funding which has – continually astound me with enabled vital cancer projects their zeal for discovery, their to continue, particularly fast- Mr Paul Wright AM boundless enthusiasm for tracking our cutting-edge Chairman improving human health and clinical trials. their ability to focus on the smallest molecule or cell and To all of our cherished friends to envisage this minute cell who provide donations towards within the larger framework our valuable research, we offer of eliminating or reducing the you our sincerest thanks. Every burden of disease. dollar goes directly towards positioning more cancer patients Visiting QIMR always makes on our trials, purchasing much- me feel positive and proud of needed scientific equipment, our team of intrepid scientists and providing us with the ability whose life’s work is not about to pursue innovative research self-glory or material gain but projects, many of which are about the greater good of outlined in this Annual Report. human kind. In fact a baby born To those of you who have left a on this day this year will live on provision in your will to QIMR, I average 93 days longer than a am confident this lasting legacy baby born on this day last year. will ensure that the “constant” This improved longevity is as a of QIMR, following 60 years direct result of medical research. of research and results and our I know that our many dedication to human health will supporters are as proud of the continue to provide hope for QIMR team as I am - and it is generations to come. your donations and support that Finally, a special thanks to those inspire our scientists to find the of you who have provided vaccines, treatments, cures and your time, commitment diagnostic tests to enable better and inspiration to our vision health and longer lives for us all. of a “Disease Free World” – particularly the voluntary Medical research is about members of the QIMR Trust and people. People who dedicate the Development & Marketing their lives to saving the lives team. of others. People who couldn’t do this without donations from Together we are achieving people like you. extraordinary achievements everyday. QIMR is indebted to all of these people, our friends, many of Paul Wright AM whom are listed on pages 107- Chairman

104 QIMR Trust Members 2005-2006

Mr Paul Wright AM FAIM F Management and The Royal Mr Rodney Wylie OBE B Fin FAICD (Chairman, QIMR Flying Doctor Service. He is Comm BA FCA FAICD Trust and Deputy Chairman of currently Chairman of The QIMR Council) CyberInstitute Pty Ltd and Rod Wylie is a Brisbane- Phoenix Eagle Company based Chartered Accountant Paul Wright has combined Pty Ltd. Other current with substantial experience banking, health, hospitality and Board appointments include in investment, company consulting into a career which PQ Lifestyles Pty Ltd and management and corporate has encompassed over twenty- Queensland Fruit and Vegetable governance issues across a five years in senior executive Growers Limited. wide range of organisations, management with a breadth in many cases with nationwide and depth in leadership roles. Mr John Garnsey FAIA (Dip) and international activities. He has been General Manager The Trust benefits immeasurably He has been involved through (Queensland and Northern from Mr John Garnsey’s Board/Council membership in Territory) of Medical Benefits accomplishments in strategic the administration of a number Fund of Australia Limited and marketing and his knowledge of of professional and community provided executive services both national and international non-profit groups. Mr Wylie as General Manager of The advertising campaign develop- chairs the QIMR Investment Brisbane Club. ment. He is former Chairman Committee and is a member of the QIMR Finance and Paul has also been a company and Managing Director of Audit Committee and QIMR director for more than twenty Garnsey Clemenger Advertising Personnel Administration years and has served as Agency and past Chairman of Committee. the Chairman/President of the Advertising Federation of The Australian Institute of Australia. Mr Garnsey chairs the QIMR Marketing Committee.

QIMR Trust Members From left: Back row: Mr Ian Manly, Mr Paul Wright AM (Chair), Mr Bruce Phillips From left: Front row: Ms Jane Seawright, Mr John Garnsey, Ms Patricia McCormack

105 Mr Ian Manly MBA FAIM Officer of the Office of Mr Bruce Phillips Dip COM Ian Manly has extensive Economic Development for the Bruce Phillips has extensive experience in business city of Brisbane for 17 years experience in the field of management and corporate and prior to that, Managing investment advice with some development. He is the Director of the diversified public 40 years of active involvement Managing Director of First 5 company Walter Reid and in the Securities Industry. He Minutes Pty Ltd, a company Company Ltd for 10 years. is a former member of the providing fire and emergency Australian Stock Exchange He has been a Director of procedures and training to the Ltd, a past Chairman of the several public and government property industry throughout Brisbane Stock Exchange and companies and was a Director Australia. Mr Manly is also is a Fellow of The Securities of Queensland Railways a member of the QIMR Institute of Australia. He has until May 2006. Richard Investment Committee. been a Director of The Bank had extensive experience in of Queensland Limited since marketing and public relations Ms Jane Seawright BA November 1996 and is a both in Queensland and LLB(Hons) MBus (Marketing) consultant to ABN AMRO overseas and has undertaken a Jane Seawright is a lawyer Morgans Limited. Mr Phillips number of business courses in with extensive experience in is a member of the QIMR these areas. He was awarded marketing and Strategy. Having Investment Committee and an Order of Australia and the worked as a solicitor and run the QIMR Finance and Audit 2000 Centennial Medal for a marketing consultancy for a Committee. services in promoting economic number of years, she currently development in Brisbane. practises as a senior corporate Ms Patricia McCormack BA (Psych and IR) and commercial lawyer at Sadly Richard Joel passed away Phillips Fox. She is also a Law on 20 June 2006. Patricia McCormack is a highly Society-accredited mediator, regarded People Management and registered adjudicator Ms Margot de Groot LLB professional with extensive under the Building and GradDip (Legal Practice) experience in all facets of Construction Industry Payments Margot de Groot is the Human Resource Management. Act 2004. Ms Seawright Managing Partner of de Groots She established People Focus in is a member of the QIMR Wills and Estate Lawyers, 2002 with the aim of providing Marketing Committee. a Notary Public and former HR services specialising in Director of Energex Retail organisation development and Mr Richard Joel AM MAICD Pty Ltd and Queensland Law human resources management. Richard Joel was principal of Foundation Limited. Mrs de Ms McCormack is a member Richard Joel and Associates Groot is a member of the QIMR of the QIMR Personal Strategic Consultants. He was Marketing Committee. Administration Committee. previously Chief Executive

Mr Richard Joel AM Ms Margot de Groot Mr Rodney Wylie OBE

106 Donors to the Institute 2005-2006

Visionary (over $50000) Efron Family Foundation Ltd Resident’s Association Berghofer Clive EQiTX Limited Stevenson Briar Blackburne Developments Pty Ltd Family Centre Medical Services Suncoast Social Dancers Association Bridge to Brisbane Fun Run John Tarrant Graham Conroy & Associates Gow Helen The CM & JA Whitehouse Foundation Coremark Ltd Grand Court of QLD Order of The The Cory Charitable Foundation Duells Lawyers Amaranth Thomas & Coral Willians Trust Estate of Agnes Jane Wolfensberger Hannaford Bill & Pamela Watson Sir Bruce & Lady June Estate of Isabelle Ellen Hergarty Henry Cyril Robjohns & Stella May Witchery Estate of Penelope May Williams Robjohns Memorial Trust Wylie Rod Estate of Viva Adele Busteed Hicks Beryl B Silver Friend Supporter Jeteld Pty Ltd Indooroopilly Golf Club ($1000-$4999) Kerry Holdings Limited Macquarie Financial Services Group Acton CMA C R Lee Irene McIntyre Doug & Elva Adam Greg Nova Knights at the Round Table O’Boyle Denise Alfred E Chave Pty Ltd Pratt Foundation Parker Family Bequest All High Rise Scaffolding Pty Ltd Public Trustee of Queensland Pauls Limited Allan Anne Queensland Newspapers Pty Ltd Purcell Peter AMI Radio Pty Ltd Suncorp Ride 4 Research Riverside Charity Golf Day Appleton Charlie Suncorp-Metway Ltd Rotary Club of Noosa Aria Property Group Thynne & Macartney Solicitors and Sharpe Frank A Artistic Appeal Hair Studio Notaries Squires Elsie Audi Greg Trust Company of Australia Limited Stanton Anne Austin Sylvia Wantz Committee Dinner Suncorp Sun Safe Merchandise Austral Motors Platinum Friend Supporter The Wesley Medical Centre Axford and Family Jack ($20000-$49999) Theodore Unmack Lodge No. 60 Bale Shirley ABC Learning Centres Thiess Pty Ltd Barnett L R AMAQ VMO Committee Transpacific Industries Pty Ltd BB Capital Finance Australian Rotary Health Research Fund Wilson K J H Biella Beauty Salon Australian Rugby Union Gold Friend Supporter Big Night In Bellberry Limited ($5000-$9999) Bradbury Steven Bryan Rob & Kay ABC Learning Centres Pro Am Golf Day Brett LG & BA BT Investment Management Pty Ltd All British Classic Car Club Brisbane Abruzzo Association Champer’s Ball (Kathryn Bourke) Arthur Earle Youth Foundation Limited Broncos Early Risers’ Breakfasts Aylward James Cage Ben Estate of Mavis Jarrott Biggs & Biggs Solicitors Caloundra Timbers Pty Ltd Estate of Elise Squires Clinton J E Cameron Ian Estate of Gertrude Elizabeth Cruse Comino George & Muriel Central Qld Petroleum Estate of Leslie Rixon Conrad Treasury Bachelor Auction Chancellor Park Retirement Village Estate of Robert James Lack Daniel Henry & Joan Chermside Meals on Wheels Inc Estate of Ronald Russell Drescher Sunny Church Of Christ Fitton Charity Stallion Tender English John & Dora Coates Hire Foster’s Australia Estate of Barbara Dalton Coco Sam Hair Raising Cure Estate of Jean Mullen Commercial Property Cleaning Hayes Kevin & Elsie Estate of M L Morgan Cowlishaw D O Joan Lindsey Estate of Norah Jenkins Cox Cecily Leighton Contractors Pty Ltd Francis G D & I A Curnow Ralph B Minter Ellison GWA Group Limited Currie & Company Mitchell Ivan Holzapfel Dan Cutting Edge Ongley Norman & Marjorie Holzapfel Una Daley E J Qld Property Foundation Luncheon Hornibrook Bus Lines Diagnostic Imaging for Women Queensland Government Hutchinson Builders Dipple G D & R Suncorp Metway Kilkenny Rose & Assoc Dreitzer Howard & Alan Sunlaw Solicitors Lorna Hill Memoral Fund Duckwitz Graham & Lorraine The Public Trustee of Queensland McKay Barbara Dunne Greg Tony Proctor Solicitor NOVA 106.9 Dupont Pheobe Walking on Sunshine Dinner Ozanne Memorial Fund Easton N Benefactor ($10000-$19999) Peter Lacey Sports Foundation EMAC Airconditioning Services Pty Ltd ANZ Bank Port Binnli Pty Ltd English Loretta ANZ Trustees Reuben Pelerman Benevolent Estate of Mrs Mai Henderson Clayton Utz Foundation Foundation Fisher Adams Kelly Coles Mary Salford Waters Retirement Estate FKP Commercial Developments Pty Ltd

107 Foreman D A Ltd The Rotary Club of Mission Beach Inc Forrester Tom Morris Alex The White Foundation Limited Freeman Bill & Lesley Nambour Golf Club Inc. Toowoomba Quilters Club Inc Garland Waddington National Servicemen’s Association Tracquip Finance & Leasing PL Gibson BC & MJ Neumann Jenice Turner Yvonne Goakes S W Nichols MJ & PM Unigas Gold K A & G M Nundah Industries Pty Ltd Unitab Limited Gossow M Ohye John & Betty Vaessen Jak Greg Thiess Plant Hire Pty Ltd Optimedia Australia Pty Ltd Van Klinken A Hale John A Order Of The Eastern Star - Moreton Vugler Garry & Lorraine Hallis Bay Chapter No 152 Waldock Cheryl Haly Frank & Thea Ostwald Bros Civil Pty Ltd Walker Colin Hardworx Pty Ltd Paradise Point Bowls Club Inc Walker N Hargroup Qld Pty Ltd Partridge Rhoda Warren Family Homes Pty Ltd Hayes G M Peachester District Horticultural Society Webb Pamela G HB479 Pty Ltd Inc Weis R A & J M Herron K & J Peacock R L West N R Hillhouse Burrough McKeown Perel I D Wheeler Elizabeth Hirst Ross Perpetual Trustees Whitney Amy I Holmes Carmel Pfizer Australia Pty Ltd Whittaker Noel & Geraldi Horton Park Golf Club Maroochydore Phillips Bruce Whittaker Peggy Inc Potter Paula Williamson Bill & Beulah Hughes Mary Powter Trustee for E & S Powter S Wynn R G Huybers E F Press Gordon Zaccari F I-Med/Mia Network Price J B Zonta Club of Beaudesert Independent Fuels QCWA - Inglestone Branch English Kevin Inner Wheel Club of Brisbane South Inc Quest Community Newspaper Macquarie Bank IPA Personnel Pty Ltd Quinn Donna Wilson HTM Investment Group ITHACA South Brisbane BCOF Sub- Quota International of Beenleigh Inc Bronze Friend Supporter Branch Limited Ranbury Management Group ($500-$999) James Varitimos Solicitor Red Suit Advertising A H Knowles & Co Jameson Charitable Foundation Redman Jean Abgal Pty Ltd Jolley V Reinvention ABN AMRO Morgans Jones Lang LaSalle Rhino Finance Pty Ltd Action Tanks Kedron Wavell Ladies Auxiliary Rotary Club of Blackwater ADF Group Kennedy Beryl Rotary Club of Emerald Sunrise Inc Advertising Works Killarney Abattoir Pty Ltd Rowland P R Aileen Marshall Hair & Beauty Knight Paul RW Pascoe Aitchison Don & Nola KPMG Australia Sands Management Pty Ltd Andrews Peter Law Bob & Jean Schwarz Norma Anna’s Salon LCR Lindores Group Pty Ltd Serco Pty Ltd Anthony John Group Lendal Pty Ltd Sheeran Lola Apel David Leonard Colin & Shirley Sicilian Association Inc Apel John Lions Club of Brisbane Macgregor Slaughter Jessie Archer Management Loughnan Anthony & Jill Smith Luke Art & Craft on the Coast Pty Ltd Lovell WT & NB Smith Susan Askew Jan Lowe Mark South Brisbane District Grand Chapter Aspiri Financial Services Pty Ltd Lowe Tony Order of the Eastern Star Back Ruby MacGillivrays Solicitors Southport Worker’s Club Badke Allan Macquarie Bank Foundation Spooner Anne Barry & Nilsson Social Club Madonna Delle Grazie Committee State of Origin Dinner Bauer I J Man John Stearne Noela Bertling J L Maryborough City Council Stendrup Kym Bhp Billiton, Mistubishi, Alliance Materials Handling Finance Pty Ltd Stewart Jim Bidgood Lynette McFadden Anthony Sullivan J Biniris Pty Ltd MDA National Insurance Suncorp-Metway Ltd Dress Down Day Blackwell Ernest & Jean Medfin Australia Pty Ltd Synergy Executive Sourcing Blondies for Hair Maureen Meehan A M Taylor Patricia Brenmont Pty Ltd Meringandan Sports & Social Club Inc The ACMA Foundation Brisbane Bullets Money Mentors The Domain Residents Association Brisbane District Grand Chapter Moreton Hire Service (Gold Cst) Pty Incorporated Broncos Leagues Club The Maleny Contract Bridge Club Bundaberg Sugar Ltd

108 Bupengary Tavern Indigo Projects (Management) Pty Ltd Peninsula Terrace & Haven Campbell I G & R Insight Investment Services Phillips Ralph Challands John International Quarterback Pidgeon E A Chambers Betty Interstate Locum Services Pollock Heather Charlie’s Place J J Richards & Sons Pty Ltd Porter Christine Chick Ron Jackson Peter Potts J G & P M P Christopher Bruce Jensen Mal & Kathy Practical Peripheral Corporation Pty Ltd Cohn David & Claudia Johnson Don & Dell Prowse John Coil Steel Pty Ltd Johnsson DK QCMM Finance Pty Ltd Colorado Group Ltd Jovewood Pty Ltd Quadric Pty Ltd Comserv (no 1643) Pty Ltd June Dally-Watkins Queensland Vintage Vehicle Connelly W Karingal Nursing Home Association Cosmopolitan Development Kaytone Engineering Pty Ltd Quota Club of Beaudesert Cottrell Bob Kedron Wavell Ex Service Women’s Rablin Renee Cox Geoffrey & Elsie Assoc Radio 4BC Creative Worx Kelso Anne Ray White Asset Leasing Curves Kone Elevators Ray White Real Estate Pty Ltd Custance Roger Laughlan Paula Redcliffe District Rugby League Dalley Hope E Lawrence A M J M Football Club Inc Davidson Recruitment Leighton John Rooney F N Day George L Leighton Holdings Limited Rosbrook Robert Deloitte L’estrange Donna Rose Cilla DFS Financial Services Logan Douglas Rotary Club of Acacia Ridge Downer Engineering Low H Russell Ian & Anne Dumbarton Hotels Pty Ltd Mackay Steve Rutherford Lucy-Grace Dunavant Enterprises Pty Ltd Maher Peter Salon 94 Dunlop William B Mainrange Pty Ltd Sandgate Pensioners and Eales John Marker Consulting Superannuants League Inc Eggar RC & JG McDonald Keen Group Pty Ltd Sandstrom Christian Eski Cleaning Services McEwan Don & Gloria Sarri Bros T/as Sarcon Building Services Evans C B McGuigan Margaret Scientific Pest Management Flecker P O McLaren David & Loraine Shepherd Alan Formula Interiors McLeod & Partners Pty Ltd Shorncliffe Investments Foster Ruth Menzies Scott Silva Mandy Functional Business Innovations Mermaid Beach Bowls Club Inc Sim Alice Garnsey John Micalizzi Tony Sinclair Knight Merz Gore-Jones Megan Mike O’Regan & Associates Sneyd A H Grand Slam Sports Equipment Mitchel & Partners (Qld) Pty Ltd Sound Reasoning Grimmer Ken Mt Coolum Charity Golf Day St Patricks College Sports Support Grundy David Murray Margaret Group Haba Dive Nathanson Leslie & Janet Stanton Gayle Hair Culture by Raylene National Seniors - Bardon Steele Hair Dynamics National Seniors Association - Stoney Heather M Hair Techniques by Jane Calamvale Strathlea Pty Ltd Hallett Keith & Maureen National Seniors Association - Hervey Stuart M E Hancock A B Bay Branch Sunnybank Masonic Lodge No 264 Hanson Darren National Seniors Association - Uglq Hargreave Malcom Nambour Sunshine Coast Deep Sea Fishing Club Harper Jan National Seniors Association - Supersport Images (Aust) Pty Ltd Harris B Stanthorpe Surface Coating Assoc Harwood R S National Servicemen’s Assoc Surman AJ Havecoat Contractors Caboolture & District Branch Swan Tim Hawken B New Caledonia Grazing Co Tarong Energy Corporation Limited Hayman Keith & Jenny Nexus East Pty Ltd The Coffee Club Hengstberger Helen Norfolk Jet Holidays Pty ltd The Hair Architect Hill Kevin NRMA Insurance Australia Limited The Smile Workz Hoey Moreen Open Door Consulting Thiess Honeywell Limited Optus Business Direct Thompson M A K Hot Tomato 102.9FM Order of the Eastern Star - Coolangatta Toowoomba Golf Club Women Hudson Lynne Chapter Members Hunter Anna PA Lucas & Co Toowoomba State High School iExec Pty Ltd Parsons Karen Turner G

109 W T Partnership Bratchford B Donnan David Wassman R C Breitenbach Tom & Joan Doo Ellie Watpac Aust Pty Ltd Brisbane Ionian Club Doulman Tony Webb K Brodribb T R Downtown Toyota Westera John Brooks E L Dr Alison Bruce Medical Pty Ltd WHD Lawyers Bruce Stephen Dunn B Williams Madeline Bruggy W A Dwyer Mary Wisemantel T/A Professional Client Bryant Rosalie Eastern Suburbs Leagues Club Limited Services Bukala H J Edmeades Robert & Alison Xi Eta Chapter, Beta Sigma Phi Burgess Roy J Elliott Betty Zinns Ailsa Byrne Bill Evans and Hearn Zonta Club Of Blackall Range C.B. Nurcombe Engineering Pty Ltd Fadden Joan Friends ($200-$499) Caboolture Shire Council Fancee Fruit A Klinge & Co Campbell Ann Farley William Aarts Maria Canning-Debelle Pty Ltd Faulks J Abel Kay Cards Bridge Centre Fawcett William Abtourk Vic No 39 Pty Ltd Carlyon Carol Ferguson Mal & Leanne Action fire Pty Ltd B & B Carr Peter Filipino Australian Care Trust Inc Adermann Joan Carseldine Mary L Finn P Advanced National Services Carter Rod & Loma Fischle Joan AHI Jensen Vicki J Catholic Womens League - Banyo Fitzgerald WJ & N Aland R W Centenary Hire Flanders Ken Alcorn N Childs Robyn Fleming Geoffrey Aldersgate Residents Association Chinchilla Rotary Club Flynn Robin Allanna Plumbing Services Choong Yvonne Followmont Transport Pty Ltd Allen Lindsay H Clark WB Foo Paul Angela’s Silver Scissors Clarke IWN Fookes A J Anne Everingham Jewellery Clarke Lorraine Foote G M & B M ANZ Banking Group Clarke Dowling Francis B M Armstrong Allison Clendinnen FJ Freeman I B Armstrong Y C Clive Berghofer Group Fry G C Arthur Geoff & Jenny Cloherty Lorna Furnival Colin & Isobel Aslan Corporate Services P/L Cock W J Gac Maria Atkinson Grant Cockburn Keith & Julie Gac Miroslaw Australian Fire Supplies & Fabrication Cockburn William & Linda Gallagher Marjorie Pty Limited Collinson RA Galluzzo Sam AW Edwards Pty Limited Colvin M Ganley Maree Azuno Developments Comerford J Garson C W Babcock & Brown Community Friendship Centre Gaskell Norm Baden Powell Guild of Queensland Inc Compton Gardens Craft Group Gauld Iain Valley Sub Branch Comsure Insurance Brokers Geisler K A Baird Don & Norma Condon Mike Gibbs I & D Ball Pam Conroy Barney & Jean Gibson Margaret Bank of Queensland Consolidated Rutile Ltd Gill J & M Bannister John Cooper Esme Girdis Group of Companies Barnett J G & M C Cormie Rod & Ailsa Globenet Travel Baronio Evelyn Cornerstone Properties Ltd Go Ford Solution Bartlett Dominica Corocorz For Hair Goangra Pastoral Company Pty Ltd Basei Gino & Nina Cosgrove A Goodwin AH & AD Baseline Consulting Courtice & Neilsen Solictiors Granna Pty Limited Battersby B Cousens Ian & Karen Grant Peter Beardmore H A & J M Crombie Mildred Graycog Pty Ltd T/A Diesel Express Bechly Coral Crushers Leagues Club Green Ricki D Becket Yvonne de Bie V Greenup RB & MC Belonogoff M De Watteville Richard Gregor DJ & JL Berkley Group Financial Consultants Deacons Guest Florence J Berry Elwyn Dean Ash Constructions Pty Ltd Gustafson Rohan Berry Keith Desmarchelier Marc Guy AJ Bevan E F DeSouza Caji Gynther Margaret Bird Valma Dillon John Haald Engineering Bowman P Distinctive Print Hacker J B & J L F Box Beryl D Divola Dani Hair on Hamilton

110 Hallis People Skills Lockwood John & Robbyn O’Connor Patricia Hansen Kerri Lok A Ord Minnett Harbison Ian Long Alan Orpheus Consulting Group Hardinge Gaynor Lord Robert Orrcon Operations Pty Ltd Harrison Brent & Lynne Lynch Janey O’Shannassy Hazel Harvey H L Mackay Mary-Ellen Palm Beach SLSC Hawes Richard Macpherson Brett Paradise Point & District Senior Citizens Hay Vince Major League Corporate Marketing Association Inc Healthy Lifestyle Club Mann John Parmac Property Pty Ltd Heck Patricia Mari Noutsatos Pty Ltd Parsons Brinckerhoff Heilbronn Kerry J Marsh Pty Ltd Paula’s Hairstylists Helen’s European Cuisine Marshall Janice Peake John Hemming Alex Masci C & C G Pearson Edwin Herron Todd White Massey John Peter Brookes Property Marketing Herron Todd White Sunshine Coast Mayhew Owen Phelan Grant Hill David Maynard OAM G Picnolay Pty Ltd Hobbs Graham McArthur Amanda PJ Slaughter Advisory Services Hockings Vic McConnel D & A Porsche Centre Brisbane Hogan Brothers Pty Ltd McConsulting Poulsen G P & D M Hughes RE McCutchan Arthur Powell Alan N Humes Erica McDonald Christine Prendergast Colin & Kay Hurd Shirley McDonald’s Helensvale & McDonald’s Price H D & A Hyde R E Coomera Prien Des Ibrox Park Nursery Mckay Robyn Pro Shop Ilett G B McKenzie Colin & Shirley Probuild Industries Developments Pty International Management Group of Mcnamee Graham Ltd America PL McTiernan John Probus Club Of Bribie Island Isothermal Mercer R & B Probus Club Of Redlands Ladies J W lock Pty Ltd Mickan RC Project Control International Pty Ltd JA Evans & Co Mitchelton Everton Park Branch - Pukall Kieter & Kathy Jackson DS & LE National Seniors Association QCWA - Maroochydore Branch James Bob Mogg R & J QLD Cricketers James L Williams Pty Ltd Mondo Architects QM Properties Janda Furniture Moorooka Legacy Care Group Quality Connect Pty Ltd Jeffrey J W Morton James Queensland Chamber of Commerce & Jellinbah Mining Pty Ltd Motor Trades Assoc of QLD Industry Jenkinson NA & PE Munro D & M Queensland Hire Jennifers Hair, Nail & Beauty Murra Wolka Creations Pty Ltd Queensland Rail Jobling W J Murray Judith Queensland Stairs John Finlay Engineering Pty Ltd Murray Kay RA Cartmill Pty Ltd Johnson Lesley National Homes Pty Ltd Rains C & MJ Johnston Ross National Seniors Association - Ray White Real Estate Clayfield Jones GL & LJ Chermside E L Rayner Rod Joyce Kevin & Nora National Seniors Association - Redford Jenny Jurd J W Maryborough Branch Reid Margaret Kambu Medical Centre Ipswich National Seniors Association - Reid Sally Kawana Ladies Bowling Club Tewantin-Noosa Branch Reilly Elma Kaye Bill & Jackie National Seniors Association - Victoria Reilly Philippa Kentish Edith Point Branch Reliance Door Service Kinross Gardens Café Nelson G R E Retired Officers Club - Gold Coast Kirby Lilian Nemeth Phyllis Richardson Kerry Kouzoukas Barbara M Neumann John & Gabi Riddel G Lagana Santo Ngalla Pty Ltd Riverside Newsagency Lancaster Valerie Nicholls J Robbins Betty Lasseters Online Nicklin James Roberts Helen Learmonth J H Nicol Robinson Hallets Lawyers Robertson Jenny Leppitsch Justin Norman Disney & Young Robertson Norma L’estrange Sarah Norris H Robertson Peter Lewis Joyce Nundah Fellowship Rollason BM & DR Lewis Ray Nundah State School Rollings Noel & Bobbie Little Joyce E Ocean Cuts Rooney Franca Livingstones Australia O’Connor NJ Ross G M

111 Ross Keith Thomas A A Ross Kym Thomson Ian & Dorothy Rotary Club Of Mt Gravatt Inc Thorpe Glen Rowland Throp E Ryan Brendan Ticketek Pty Ltd Salmon Marlene Tobler George Sandgate Golf Club Associates Townsend Ian & Ira Santos Transmax Pty Ltd Scanlan GJ Trezise Marcia Schmidt Brett Trinder Bob Schulte M Twighlight Bill Schultz J U3A University Of The Third Age Schultz J M Maryborough Schuster R Unwin Maureen Sciaccas Lawyers & Consultants Van Werkum L Scott Elizabeth Vance V Seeleither Dawn Vandeleur P & M E Selwood R M Vanlu Nominees Serafin O Vietnam Veterans Assoc of Aust Shabrokh F Gympie Sub Branch Shear Image VMR International Pty Ltd Shear Pleasure Wanless Ron & Judy Sheldon College Wanless Susan Shields J & R Watling K Shinners R Watson Shortt Julian Weatherstone J Simmonds Lumber PL Webb Leann Smallcombe Sandra Webber BR & JC Smith B P & B L Websters Prestige Cars Smith Gloria Wenck W N Smith Katherine Wesfarmers Curragh Pty Ltd Solley Edris Westinghouse Rail Systems Aust Southern Cross Ford Whitbread R St Andrew’s Uniting Church Women’s Whitby Don & Beth Association White N L & P R St Andrew’s Women’s Association White Patrick St Lukes Chapter No 100 Order Of The Whitehouse T R & J A Eastern Star Whiting Peter & Cliona Stapleton Kevin Whybird Des Star Cut Salon Williams Rod Stergou George Willis Michael Stevens Col Wilson Diane Stewart D C Wilson Kaye Stewart Edward Wilson Parking Stormonth Margaret Wright D B Street Julie Wright Gordon & Dawn Suncorp - Metway Retired Officers’ Wyborn George Assoc Yarrabee Coal Company Pty Ltd Sutton John Your Risk Protection Specialists Tattersall’s Club Taylor Byrne Valuers Tempo Services Teske Barry & Denise The Bachmann Group The Brisbane Ionian Club Inc The Coffee Club / Arbait Pty Ltd The Hair Base The Mad Chinaman Restaurant The Sunnybank Thin Thinkers Thiess Thiess Thiess

112 Staff 2005-2006

Director P Crooks BSc(Hons) Thuy Le BAppSc M F Good BSc(Med) MBBS(Hons) S Cross BSc(Hons) MSc DipEd GradDipBiotech PhD MD DSc FASM J Davis BSc(Hons) PhD M Linn MBBS PhD FAFPHM FRACP(HON) J Duraiswamy MSc BVSc PhD (to T Pirayesh BSc (to Feb 06) FAIM Jan 06) W Schroder BSc(Hons) PhD Deputy Director K Harej RN A C Green AC MBBS MSc PhD Malaria and Scabies L Heslop BBiomedSc (to May D J Kemp FAA BSc(Hons) PhD Secretary and Chief Operating Officer 06) K Anderson CBLT M J Staley MSc GMQ MBA V Lutzky MSS PhD MAACB MACS FAIM S Beckham BSc MAICD M Martinez DipAssSc K Fischer PhD L Morrison CBLT Assistant Directors MF Ho BSc(Hons) A Nehring BNurs BSc(Hons) (to S Smith BSc(Hons) A W Boyd BMedSc(Hons) MBBS Sep 05) PhD FRACP A Topping BSc(Hons) (to Feb 06) D Tscharke BSc(Hons) PhD (to K Trenholme BSc MSc PhD The University of Queensland May 06) M F Lavin BSc(Hons) PhD Malaria Biology Y Woo BSc (Hons) PhD (to The University of Queensland D L Gardiner BAppSc PhD Jan 06) Executive Secretary to Director Molecular Genetics EBV Molecular Biology J Black P Upcroft BSc(Hons) PhD T B Sculley BSc(Hons) PhD Administrative Support L Dunn BSc(Hons) PhD M Buck DipMedTech T Checkley J Upcroft BSc(Hons) PhD I S Misko BSc(Hons) PhD Communications Officer Molecular Immunology Helminth Biology J O’Keefe BAppSc DipBusComm M F Good BSc(Med) MBBS(Hons) A C Loukas BSc(Hons) PhD PhD MD DSc FASM INFECTIOUS DISEASES AND FAFPHM FRACP(HON) IMMUNOLOGY DIVISION S Gaze BSc MSc PhD J Mulvenna BComm BSc(Hons) Division Chair : J McCarthy V Anderson BSc(Hons) PhD Bacterial Pathogenesis M Batzloff BSc(Hons) PhD M Pearson BSc MSc PhD K S Sriprakash BPharm MPharm PhD L Beattie BAppSc(Hons) (to Jan D Pickering BAppSc 06) M Binks BSc M Smout BSc(Hons) J Dyer BSc(Hons) (to Mar 06) C Denham BSc(Hons) (to Feb 06) D Smyth BSc(Hons) PhD J Hartas BAppSc D McMillan BSc(Hons) PhD M Tran BSc PhD N Huang BAgSc DipHortSc J Shera BSc(Hons) GradDipClinBioChem MAppSc MAppSc Bone Marrow Transplantation HIV Molecular Virology C Keighley MBBS G Hill BHB MBChB FRCPA D A Harrich BSc PhD FRACP MD X Liu BMed MMedSc A Apolloni BSc PhD G Magor BSc(Hons) T Banovic MD MMedSc C Harrich RN BSc(Nurs) V McPhun BSc MSc H Bofinger BAppSc(Hons) D Warrilow BSc(Hons) PhD C Olive BSc(Hons) PhD P Bunn N Willemsen BAppSc(Hons) M Pandey BSc MSc PhD A Burman BSc PhD Immunology and Infection A Pinzon- MD PhD A Don BSc(Hons) C R Engwerda BAgrSc PhD Charry R Kuns BSc(Hons) F Amante BSc(Hons) PhD M Wykes BSc(Hons) PhD K MacDonald BSc(Hons) MSc PhD K Clark BSc(Hons) (to Dec 05) H Xu BMed MMed PhD N Odorico BSc(Hons) A Haque BA(Hons) PhD Molecular Parasitology V Rowe TechCertAnimalLabSc K McSweeney BSc(Hons) AdvCertAppSc D P McManus BSc(Hons) PhD DSc A Stanley BSc(Hons) PhD M Duke AssocDipFarmMngmt Cellular Immunology Y Zhou BMed DipAppSc G Gobert BSc(Hons) PhD S R Burrows BSc PhD Immunoregulation M Jones BSc(Hons) PhD M Bell BSc(Hons) A Kelso BSc(Hons) PhD Y Li MD PhD R Brennan BSc(Hons) A Baz BChem PhD J Burrows BSc GradDipTeach L Zhang BMSc MMSc PhD (to K Buttigieg BBioTech Feb 06) S Silins BSc(Hons) PhD P Groves BAppSc W Zhang BSc PhD Clinical Tropical Medicine N Kienzle BSc PhD Mosquito Control J S McCarthy MBBS FRACP MD S Olver BSc(Hons) P Ryan BSc(Hons) PhD Royal Brisbane and Women’s Hospital Immunovirology P Fraley K Andrews BSc(Hons) PhD A Suhrbier BA(Hons) PhD T Hurst BSc(Hons) PhD N Lee BBiotech(Hons) I Anraku BSc(Hons) PhD J Jeffery BSc (Hons) BA L Melville BSc BA G Darnell BAppSc MAppSc PhD B H Kay AM FAA BSc(Hons) C Pasay BS MSc PhD GradDipBiotech PhD EBV Biology J Gardner BAppSc D J Moss BSc PhD D Hoang-Le BSc(Hons) K Marshall M Corban BBiol MBiol E Lambley BSc(Hons) L Perkins BSc(Hons) PhD

113 L Packer BSc(Hons) A Zournazi BSc MAppSc Protein Discovery Centre J Palmer RN Radiation Biology and Oncology J Gorman BSc PhD S Pavey BAppSc(Hons) PhD M F Lavin BSc(Hons) PhD B Hamilton BSc(Hons) PhD P Schultz The University of Queensland M Headlam BSc PhD M Stark BAppSc(Hons) O Becherel PhD T Wallis BSc(Hons) PhD G Walker BSc MScQual PhD G Birrell CBT MMedSc PhD Tumour Immunology GradDipClinBiochem P Chen BSc MSc PhD R Khanna BSc MSc PhD S Walsh (to May 06) A Farrell NCEA CertAppBiol G Connolly BSc(Hons) Leukaemia Foundation M Gatei BSc PhD L Cooper BAppSc A W Boyd BMedSc(Hons) MBBS N Guven BSc MSc PhD T Crough BSc(Hons) (to Jun 06) PhD FRACP A Kijas BBiotech PhD U Dua BSc MBiotech The University of Queensland S Koecher BEng M Gandhi MBChB MRCP MRC J Carter BAppSc(Hons) S Kozlov MSc PhD Path PhD K Chen BSc(Med) J Luff CVetNurs/AnCare C Gastparini BBiomedSc(Hons) (to J Cox GradDipBiotech C Peng MMed PhD May 06) BAppSc (to Mar 06) N Rundle MSc(Hons) PhD (to M Rist BSc(Hons) PhD B Douglas MSc(Hons) (to Nov 05) Nov 05) C Smith BSc(Hons) PhD R Stirling BSc(Hons) J Tellam BSc MSc PhD S Duffy BSc(Hons) PhD M Trabi BSc(Hons) PhD R Tyagi BSc PhD (to Jan 06) N Herath BSc(Hons) PhD R Woods BSc(Hons) PhD S Walker BAppSc J Lickliter MBBS PhD RBWH Gastroenterology N Webb BSc J McCarron BSc B A Leggett MBBS(Hons) MD GradDipClinBioChem J Reeder DMLT MMedSc (to FRACP Dec 05) CANCER AND CELL BIOLOGY Royal Brisbane Women’s Hospital DIVISION F Smith BAppSc C Bond BSc (Hons) Division Chair: KK Khanna M Spanevello BAppSc(Hons) PhD J Chia BBiotech(Hons) Cancer Genetics B Stringer BMedSc MBBS PhD S Cozzi BAppSc(Hons) G Trench BSc(Hons) PhD C Stylianou BSc(Hons) PhD E Pelzer BA BAppSc J Arnold BSc(Hons) PhD L Wilkinson BSc R Price CertVetNurse J Beesley BSc(Hons) PhD T Yeadon BSc(Hons) PhD LabAnimalTechCert (to X Chen BMed Membrane Transport Jul 05) S Healey BSc DipEd BAppSc N BSc MSc PhD J Robinson BSc(Hons) PhD Subramaniam H Holland BHlthSc(Hons) BA K Spring BSc PhD S Johnatty MSc PhD L Summerville BSc V Whitehall BSc(Hons) PhD J Kerr BSc(Hons) GradDipClinBiochem Signal Transduction S Manu BSc MMicroBio D Wallace BSc(Hons) PhD K K Khanna BSc MSc PhD A Marsh BSc(Hons) Molecular Cancer Epidemiology E Bolderson BSc(Hons) PhD N Waddell BSc(Hons) PhD A B Spurdle BSc MSc PhD K Hobson BSc(Hons) Cancer Immunotherapy S Arnold BSc(Hons) S Khan DipEd Mphil MSc BSc C W Schmidt BSc(Hons) PhD M Barker BAppSc MSc PhD K Ellem AO BSc(Med) MBBS G Birney BSc (Hons) L Papp BSc(Hons) PhD D Buchanan BSc(Hons) D Richard BSc(Hons) PhD X Huang BMed PhD R Byrnes BSc M Shariff BSc (Hons) C Lanagan BBiomedSc(Hons) K Ferguson S Tsvetanov MSc PhD N Martinez BSc(Hons) PhD L Jackson BSc (to May 06) A Urquhart BSc(Hons) PhD L O’Connor AssocDegAppSc L Jaskowski ADCLT D Young BSc(Hons) PhD (to Cell Therapy P Lovelock BSc(Hons) PhD Dec 05) A J Nicol MBBS FRACP FRCPA D McKeone AssDip LabTechniques POPULATION STUDIES AND HUMAN PhD (to Dec 05) M Newman (to Nov 05) GENETICS DIVISION The University of Queensland M Walsh BSc Division Chair G Anderson Dendritic Cells and Cancer J Young GradDipBiotech Cancer and Population Studies MAppSc PhD J A Lopez MD A C Green MBBS MSc PhD Human Genetics Molecular Psychiatry B Alexander RN BNursing N K Hayward BSc MScQual PhD C Lendon BSc(Hons) PhD D Ayers BInfoTech L Aoude BA BEngineer A Pritchard BMedSc(Hons) J Bain (to Jul 05) M Auret BSc(Hons) PhD QCF Transgenics C Baxter BA V Bonazzi PhD G F Kay BSc(Hons) PhD S Brown RN BA R Duncan BAppSc(Hons) S Greco BSc R Cicero BA K Loffler BHlthSc BSc(Hons) PhD A Mould BSc(Hons) PhD M Connard BSc(Hons) (to May 06) D Nancarrow BSc MscQual PhD I Tonks BSc(Hons) PhD T Corish RN

114 H Croy BSc BNursing (to Jul J Van Vliet BSc(Hons) PhD A MacKenzie BA (to Feb 06) 05) N Vickaryous BSc MSc PhD C Madigan BNursing BHlthSc (to M Davis MPH MD Feb 06) J Doecke BSc(Hons) E Mallon M Dunks RN (to Dec 05) Genetic Epidemiology L Matthews BA(Psych)(Hons) (to R Dutton (to Sep 05) N G Martin FASSA BSc(Hons) PhD Jan 06) L Green RN L Anderson BA(Hons) K McAloney BCommerce M Hughes BS MMedSc L Barnes RN (to Sep 05) S McCoombe K Ibiebele BScClinDiet MPHSocSc P Barton L McDonald GradDipPsych (to Feb PhD A Baxter BAppSc 06) L Jackman BSc(BusAdmin) M Baylart (to Feb 06) R McLaughlin BA(Hons) (to Feb 06) D Lincoln BSc(Hons) MBiostats H Beeby BSc(Hons) J McPhee AssocDip (to Jan 06) A Birley BSc MSc PhD CommunityRec (to V Logan S Brimstone BA(Hons) MBus MEd Feb 06) C Loos BAppSc J Brodie A McRae BSc(Hons) PhD T Luong AssocDipArts/ K Bunch BPsych(Hons) S Medland BA(Psych)(Hons) (to Photography S Burgis BPsych(Hons) Feb 06) M Malt BBus EN M Caffrey L Nunn DipTeaching A Mapfumo (to Oct 05) A Casal D Nyholt BSc PhD K Martin RN BHlthAdmin H Clarke W O’Connell (to Sep 05) J Mayhew RN T Coates BA GradDipEarlyChild M Okello BA P/GDipEd P/ A McMurtrie RN BNurs (to Dec 05) GDipSocPlan&Develop E Minehan RN J Cochrane BBus (to May 06) S Moore RN BHlthSc MPH L Connelly D Park P Moser N Cross BA(Hons) H Park GradDipRehab S Mott BSc RN (to Dec 05) T De Dassel BSc(Hons) C Pink C Nagle BAppSc PhD M De Nooyer BPsych(Hons) C Pretsel S O’Brien BNurs MPH P Dickson BSc(Hons) (to Oct 05) F Price BA S O’Keeffe BAppSc RN D Duffy MBBS PhD I Putnoki C Olsen BSc(Hons) PhD H Egan DipBusMngmt C Redfern BA(Psych)(Hons) S Perry DipAppScNurs BAppSc A Eldridge RN M Reilly (to Mar 06) Nurs MEnvirCommHlth R Eyers MA (to Mar 06) D Reynolds (to Apr 06) BEnvirHlthSc (to Jun M Ferguson BA(Psych)(Hons) 06) J Rosa (to Nov 05) M Ferreira PhD L Ryan BSc(Hons) K Quinn (to Dec 05) M Furlong BA(Hons) MCP L Saeck BA GradDipHlthProm J Ramsden RDT RDP (to Sep 05) N Gillespie BA(Hons) MHlthSc (to Nov 05) H Rangappa MBBS MPH S Gordon BEng(Hons) PhD V Sellin B Ranieri M Grace RN P Shertock A Richards AssDipBus (to Mar 06) M Grimmer BSc(Psych)(Hons) L Simms BSc(Hons) D Roffe RN MSc(OccPsych) D Smyth T Sadkowski BIT BSc T Gunasekera BSc(Biotech)(Hons) A Somerville BA J Scott DipSc MSc N Hansell BSc(Hons) PhD K Sorensen H Shirley DipNurs BSc A Hawkins BSc(Hons) PhD (to D Statham BA(Hons) MCP V Siskind BSc PhD Aug 05) V Stringer BA (to Nov 05) M Steele RN D Healey AssocDipSocSc (to L Sullivan BA A Taylor Aug 05) J Symmons BBus L Terry RN BHlthSc MHlthPlan D Hickey AssocDipArts H Taylor MHlthLaw (to Jan 06) J Higgins BHlthSc V Thomas (to Feb 06) J Thomas BHlthSc (to Sep 05) F Husband J Tindale GradDipInternational P Valery BMed MPH M James BSc(Hons) MSc PhD Law BA RN (to Nov F Walker RN (to Sep 05) S James CertInfoTech A Toivanen BPsych(Hons) A Ward RN AssocDipAppSc S Treloar BSocSc MSc MSocWk P Webb MA PhD K Jordan BSc(Hons) (to Oct 05) PhD S Webb BNursing L Kelpie RN (to Sep 05) P Visscher BSc MSc PhD J White RN K King BSc MSc L Walters-Hill (to Mar 06) D Whiteman BMedSc MBBS(Hons) C Laizans PhD M Lee-Smith BAppSc(Psych) (to Mar K Watson Epigenetics 06) C Wheat BBus(HIM) (to Jan 06) E Whitelaw BSc(Hons) PhD M Luciano BPsych(Hons) PhD K White AdvCertArts S Chong BAppSc(Hons) Phd S MacGregor BSc MSc Phd N Whiteman BA

115 J Whitfield BSc(Hons) MSc PhD S Crooks BSc T Jones BSc(Hons) (to Dec 05) FRC Path FRACB GradDipClinMicrobiol K Kennedy BPsych(Hons) (to Dec L Winkler C D’Amato BSc (to Jul 05) 05) J Wood A Dowling BSc (to Feb 06) S Stein BAppSc N Wray BSc(Hons) MSc Phd M Downey BSc(Hons) (to Dec 06) Indigenous Health Research Program M Wright BSc(Hons) PhD T Dumenil BAppSc J Stirling DipTeach O Zheng A Henders BSc(Hons) MPrimHlthCare G Zhu MPH BSc A Higgins BSc (to Apr 06) V Harrhy BSc Hepatic Fibrosis L Le BSc(Hons) MSc Cooperative Research Centre for G A Ramm BSc(Hons) PhD P Lind BSc(Hons) PhD Vaccine Technology M Bertrand- MSc PhD L McNeill GradDipGeneticCouns A Kelso BSc(Hons) PhD Philippe BBiomedSc S Johnston BBus MSc R Bing R Mayne BSc (to Jun 06) L Leong BComm T Pereira BSc(Hons) PhD J Mountford BSc(Hons) (to Feb 06) M Quince DipBus L Ramm BSc J Palmer BSc BBiochem(Hons) Australian Centre for International R Ruddell BSc(Hons) PhD (to May 06) and Tropical Health (Joint with the C Xu BMed MMed PhD (to University of Queensland) S Thomas BSc Jun 06) S Thompson BSc B H Kay BSc(Hons) PhD Iron Metabolism Z Zhao MDentSc PhD P Fraley G J Anderson BSc(Hons) MSc PhD THERAPEUTIC DEVELOPMENT AND Army Malaria Institute T Amos CLINICAL RESEARCH DIVISION Q Cheng MBBS MSc PhD D Darshan MBBS MAppSc Phd Divisional Chair: DJ Moss M Chavchich BSc MSc (to Sep 05) J Dixon RN BA(Hons) Therapeutic Development (Q-GEN) M Gatton BSc(Hons) PhD J Dodemaide BSc A W Boyd BMedSc(Hons) MBBS K Gresty BSc(Hons) D Frazer BAppSc(Hons) PhD PhD FRACP D Krause BSc(Hons) PhD J Ghazali BNursing The University of Queensland S McLeod- ADCLT P Hawthorne BSc(Hons A McLean BAppSc(Biotech)(Hons) Robertson GradCertJournalism M Bleasdale BSc(Hons) J Peters BAppSc E Hay BSc(Hons) N Bleasdale BTechMngmt CORPORATE DIVISION K Hyde (to Jan 06) T Bodetti BAppSc(Hons) PhD (to Secretary and Chief Operating Officer C McDonald BSc May 06) M J Staley MSc GMQ MBA K Millard BSc(Hons) K Bouyer BAppSc MAACB MACS FAIM T Murphy BSc MSc B Butcher MAIDC M Pollard (to Mar 06) G Butterworth Assistant Secretary L Powell AC FTSE MBBS MD S Chilcott BSc N Fox PhD D Univ(Griff) J Condren BSc GradDipFood Executive Secretary to Sec/CEO FRCP FRACP DrugAnalysis B Wanrooy D Raffelt J Crowley RN Administrative Support V Shaw A Day BAppSc L Devey (to Sep 05) T Steele BSc(Hons) J Heise- BBiotech(Hons) (to C Green S Wilkins BSc(Hons) Seabrook May 06) D Gunn Melanoma Genomics S Hodgson T Laing BA P G Parsons BSc(Hons) PhD A Jordan BAppSc R Meaclem G Boyle BSc(Hons) PhD P Kearns BAppSc(Hons) PhD M Paul (to Aug 05) L Crowther BSc(Hons) (to Feb 06) M Lin MSc I Pritchard B Ferguson L Liu BMed MSc G Sriprakash J Johns BSc(Hons) M McIntyre AssocDipAppSc V Torres A Martyn BSc(Hons) M O’Hara Finance S Mason BAppSc(Hons) S Parimi MBiotech (to Dec 05) Chief Financial Officer S Ogbourne BSc(Hons) PhD (to K Potter LabTech M Cornell BBus Dec 05) N Quirk Accountant J Pedley BSc S Sekuloski BSc(Hons) PhD C Baldwin BEcon Molecular Epidemiology M Sheridan BSc Grants Officers G BAgrSc(Hons) PhD J Talbot BBiotech(Hons) L Casey BSc GDTh Montgomery J Uksanovic- DipVetFoodSc F Khaya BA MAPublicPolicy A Ali BAppSc Barnzak DipLabTech Payroll Officer L Bardsley BAppSc K Windle BBiotech M Weaver AdvDipBus(Acct) M Campbell BAppSc Z Yameen BSc PhD Assistant Payroll Officer A Caracella BSc Translation Research P Donnelly B Castellano BSc (to Dec 05) G Beadle MBBS FRACP FRACR Accounts (to Dec 05)

116 C McNally A O’Regan Cert Companion Development and Marketing K Moran Animal Services Director L Sanderson DipAppSc (to Dec 05) J Sutton (to Apr 06) M Lagana BBus(PR) M Stromberg Media AssocDipSocSc Human Resources L Jones General Manager HR Executive Glassware C Borthwick BBusComm RN (to N Green BBus(HRM) MBA G Cuthbert BNurs Jun 06) HR Officer V Matthews Office Manager L Lane L Thompson H Carroll HR Assistant S Watkins T Reddacliff (to Sep 05) M Anderson CertBus Store Senior Development and Marketing Business Development S Wood Officer Executive M Eaton M Elliott T Mynott BAgrSc PhD A Girle Development and Marketing Officer Assistants T Kent S Millman DipMktg BBusMktg D Cann BSc M McDade Events Manager J Fox BSc PhD Building and Security E Waites R Osborne (to Aug 05) Manager Bequest Officers Regulatory Affairs A Stockman HND (Elec Eng) HTC M Gray RN Executive (Plant) B Hein A Mitchell BSc(Hons) PhD Workshop J Stockman Administrative Officers M Bugden TradeCert(Refrig) Media Relations Officer J Chow BA BSc MPH J-P Fahrner CKennel/CatPrac F Beltran BBus M Griffiths RN BPsych A McKee AssocDipElectEngineer Personal Assistant to Director N Fielding Cert Workplace G Madders ElectricMechanic/Fitter D Krha Training DipAppSc B Meyers Parasitology Network Officer BSc(Hons) (to Apr 06) D Patrick AssocDipElecEngineer C Johnson BBus(PR) D O’Brien RN R Tyrrell EngFitter VISITING SCIENTISTS Scientific Services Safety Infectious Diseases and Immunology Division Manager Safety Manager JA Cooper BSc MSc PhD H Leonard BSc MSc PhD P Bartley BMedSc MBBS GCertMgt Safety Officers M Green BBiomedSc Sequencing and Synthesis G Lawrence MBBS FRACP MD C Hirunpet- BSc MSc PhD charat M Edmundson BSc MSc FAFPHM P Collins BSc(Hons) T Murphy BSc MSc L Hugo BSc(Hons) PhD Flow Cytometry Information Technology C Hyland BSc MSc PhD G Chojnowski BAppSc Chief Information Technology Officer S Jiang BSc MSc P Hall BSc C Ward ADAB MACS A Khromykh BSc PhD Histotechnology GradDipCommComp A Lenarczyk BSc(Hons) PhD SH Park DipClinPath Computing Services Y Liu BA (to Dec 05) J Mackenzie BSc(Hons) PhD FASM Animal Services M Feodoroff BInf FACTM (to Feb 06) S Cassidy CLabAnCare D James L Mateo BSc MSc (to Apr 06) N Felder S Jaremczuk BBiolSc MCP CAN R Moqbel BSc MSc PhD (to May C Groennou D Johnstone DipInfoTech 06) C Kerwick BVSc MACVS (Animal P Kaim BAppSc T Ngo (to Jul 05) Welfare) M Kersting M Pender MBBS FRACP PhD MD R Lee BBus X Lin BEng MEng PhD G Raso MSc Phd M McInnes CertAnimalCare A Nutley- BAppSc E Skevos Govaerts D Shanks BSc MD MPH T Skinner- BSc(Hons) PhD M Vandeleur L Ward BInfoTech Adams S Whittam CLabAnTech Library T Spielmann MSc PhD C Dickfos CerLabCare J Ho AssDipAppSc F Teuscher PhD R Caperon G Ulett BBioSc(Hons) PhD S Greene Cert Companion Graphic Support Animal Services (to L Wen BM MSc (to mar 06) H Matthews BA CertPhotography Jun 06) G Williams BSc(Hons) MSc PhD I Anderson BInfoTech(Hons) (to A Hale Apr 06) J Wilks GradDipLegalPractice S James Cert Companion LLB(Hons) PhD Animal Services Cert S Sculley (to Aug 05) BA(Hons) Childrens Services M Woods MD MPH (to Jan 06)

117 Cancer and Cell Biology Division P Hall MBBS FRCPA FC G Brooke BSc(Hons) PhD A Heath BA PhD M Bryant MBBS M Kedda BSc(Hons) PhD M Burger BSc(Hons) PhD L Kelly MBBS FRACR (to Dec R Buttenshaw CertChem 05) J Catto MB ChB FRCS Phd P Lewindon MBBS MRCP FRACP R Clark BSc(Hons) M Lynskey BSc(Hons) MSc PhD C Clarke BA(Hons) PhD G MacDonald MBBS FRACP A Cook BSc(Hons) D Mackey M Cummings MBBS FRCPA PhD P Madden BS MS PhD FIAC E Nelson BA MD L Da Silva MD S BSc M Fabbro BSc(Hons) PhD Nighswander- C Filippich BAppSc Rempel J Fleming PhD G Radford- BAMedSc MBBCh PhD F Gardiner MBBS FRCS FRACS Smith MD D Reed BSc PhD D Gotley MBBS FRACS MD PhD J Smith BSc PhD (to Dec 05) R Sturm BSc(Hons) PhD M Hamilton MBChB MRCP MRCGP R Todd BA PhD H Handoko BSc MSc PhD J Van der Pols BSc MSc DipScComm A Jones BSc MResBiotech (to PhD Oct 05) P Welburn (to Dec 05) P Keith BSc MPhil J Wicks BSc(Hons) MA BEcon S Lakhani BSc(Hons) MBBS (to Dec 05) MRCP MD FRCP I Wood BSc BE(Hons) Phd J Larsen BSc(Hons) Therapeutic Development and Clinical P Masci BSc MBiochem Research N Matigan BSc(Hons) A Bosman BSc B Mowry MBBS BA(Hons) B Dumevska DipHlthSc FRANZP MD J Harrison BAgSc S Parry BSc(Hons) MSc L Kravets BSc O Ramuz T Peura MSc BSc Phd K Roper BSc MPhil P Simpson BSc PhD H Smith BSc A Sofronis BSc(Hons) MSc (to Aug 05) L St Pierre BAppSc(Hons) Phd A Sutherland BSc(Hons) PhD (to Dec 05) F Tomlinson MDFRACS PhDMBBS(Hons) CH Vo (to Jul 05) D Walker BMedSc MBBS(Hons) PhD M White Population Studies and Human Genetics Division K Andreasyan BDS MDS MPH (to Aug 05) R Alati GradDip BD(Hons) MAppSc PhD J Aylward BSc MSc PhD C Bain BSc MBBS MPH MS M Beaton BSc(Hons) MD T Blackson BA MA PhD W Chen BMed MDermatology Z Clavarino BA(Hons) PhD L Fletcher BSc(Hons) PhD

118 Research Students at QIMR as at 30 June 2006

QIMR QIMR PhD Scholars PhD Scholars Supervisor Supervisor C Anderson BSc(Hons) MSc N Martin R Laherty MBBS M Lavin B Andrew BSocSc(Hons) N Martin M Lai BSc(Hons) C Schmidt B Appleyard BSc(Hons) MPH McCarthy K Landers BAppSc(Hons) M Lavin S Apte BSc(Hons) A Kelso E Lau BSc(Hons) A Boyd A Ashe BSc (Hons) E Whitelaw K Lee BSc(Hons) P Ryan J Balen BSc(Hons) D McManus K Lim MBBS BDS S Lakhani T Barnes VET MB D McManus K Loh BAppSc MBiotech B Leggett BA(Hons) F Lose BSc(Hons) A Spurdle T Bell BSc(Hons) A Green L Major BAppSc (Hons) A Suhrbier B Benyamin BSc(Hons) MAgriculture N Martin K Mallitt BSc (Hons) E Whitelaw T Bladen BAppSc(Hons) H Leonard K Markey BEng(Chem)(Hons) G Hill J Brown BAppSc(Hons) M Lavin T Maxwell BAppSc(Hons) J Lopez T Bruxner BSc (Hons) E Whitelaw L Merredith BSc (Hons) D Harrich A Burgess MSc(Hons) T Sculley M Merritt BSc(Hons) A Green M Burke BBiomedSc McManus L Micallef BSc(Hons) P Parsons D Chin MBBCh FRCSI P Parsons R Middleberg BSc(Hons) N Martin T Chuah BMedSc MBBS M Lavin S Mijajlovic BSc GradDipIT P Parsons W Chung BSc(Hons) D Kemp J Miles BSc(Hons) S Burrows B Cornes BA BSc(Hons) N Martin L Moertel BBiomedSc(Hons) D McManus M Coulthard MBBS FRACP FJFICM A Boyd D Morgan BSc (Hons) E Whitelaw W Coventry BAgrEcon GradDipSocSc N Martin K Morley BSc(Hons) N Martin BA(Hons)(Psych) M Neller BAppSc(Hons) C Schmidt B Datu BSc MPH A Loukas N Oates BSc (Hons) E Whitelaw K Dave MSc BSc J Gorman J Pagan BSc(Hons) K Khanna M Davies BAppSc(Hons) K Sriprakash BSc MMedSc N Pandeya A Green B Day BSc(Hons) A Boyd GradDipAppSc BSc M Dixon BSc(Hons) D Gardiner Y Panpisutchai BSc MSc M Good T Don BSc(Hons) A Loukas L Randall BSc(Hons) C Engwerda R Dunne BSc(Hons) P Upcroft N Ranjit BBiotech(Hons) A Loukas S Earl BBiotech(Hons) M Lavin P Rattanasena MSc A Suhrbier M Ellis BSc(Hons) MSc D McManus M Reiter BSc(Hons) C Schmidt J Evans BSc(Hons) MBBS(Hons) A Green N Richmond BAppSc(Hons) A Green L Fernandez BAppSc (Hons) J McCarthy D Roberts BSc(Hons) QRI M Georgousakis BSc(Hons) K Sriprakash J Ross BAppSc(Hons) P Upcroft A Glanfield BSc(Hons) D McManus T Russell BSc(Hons) B Kay A Guerney BSc MEnt B Kay S Sadeghi BSc(Hons) A Green E Hacker BSc(Hons) N Hayward K Savage BBiomedSc(Hons) K Khanna D Hall BSc(Hons) MBBS P Parsons S Shekar BSc(Hons) N Martin L Hall BTechBiomedSc(Hons) A Green D Sivakumaran BSc(Hons) D Harrich J Hancock BAppSc(Hons) M Lavin K Smith MBBS MBChB A Green J Hansen BSc/BBusMgt BSc(Hons) N Martin M Smout BSc(Hons) A Loukas E Holliday BSc(Hons) N Martin A Suraweera BSc(Hons) M Lavin C Jekimovs BAppSc(Hons) K Khanna A Sykes BAppSc(Hons) J McCarthy M Jones BSc(Hons) K Khanna M Ting BSc(Hons) A Boyd J Jonnalagadda BSc MSc K Khanna T Tran BSc(Hons) J McCarthy MBBS(Hons) GradDip A Twist MCommNut A Green S Jordan A Green Epidem M Wainwright BA(Hons)(Psych) N Martin J Kelly BSc(Hons) K Khanna N Wayte BSc (Hons) G Trench M Kerr BHlthSc N Martin N Whitelaw BSc (Hons) E Whitelaw F Kolahdooz DipPubHlth A Green E Williams BSc(Hons) M Lavin T Knox BSc(Hons) B Kay C Willis BSc MSc D Kemp M Kerr BHlthSc(Hons) N Martin J Wright BAppSc(Hons) J Upcroft S Kopp BVetSc J McCarthy K Wynn BAppSc (Hons) R Khanna Y Yang BMed MMed D McManus

119 QIMR MAppEpl Scholar Supervisor V Clements BAppSc A Green MD Scholar BMedSc MBBS(Hons) E Morris G Hill MRCP MPhil Scholars P McBride BMedSc MBBS A Green M Smith BSc MBBS D Moss MSc Scholars A Lewis BSc(Hons) G Trench M Sheel BSc(Biotech) M Good Honours Scholars M Burgess BAppSc M Good C Lane BAppSc D Kemp E Leddy BAppSc N Subramaniam J Loo BA (Psych) N Martin A Martin BSc N Martin J Monkman BSc M Lavin C Peatey BSc D Gardiner N Raffelt BSc D Gardiner P Shah BAppSc G Anderson Bpsych T Thornell N Martin BA (Psych) BAppSc Scholars L Whop A Green

120 Our Location

Compilation and Design Jann O’Keefe

Staff photographs Heather Matthews Madeleine Kersting

Printing IPG Print Queensland Institute of Medical Research

2005 - 2006

The Bancroft Centre 300 Herston Road Herston QLD 4006 Australia

Postal Address Post Offi ce Royal Brisbane Hospital QLD 4029 Australia

(+61) 7 3362 0222 P (+61) 7 3362 0111 F

www.qimr.edu.au W [email protected] E